0001090872-20-000004.txt : 20200303 0001090872-20-000004.hdr.sgml : 20200303 20200303161023 ACCESSION NUMBER: 0001090872-20-000004 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 107 CONFORMED PERIOD OF REPORT: 20200131 FILED AS OF DATE: 20200303 DATE AS OF CHANGE: 20200303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGILENT TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001090872 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 770518772 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15405 FILM NUMBER: 20682275 BUSINESS ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD CITY: SANTA CLARA STATE: CA ZIP: 95051 BUSINESS PHONE: (408) 345-8886 MAIL ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD, MS 1A-LC STREET 2: P.O. BOX 58059 CITY: SANTA CLARA STATE: CA ZIP: 95052-8059 FORMER COMPANY: FORMER CONFORMED NAME: AGILENT TECHNOLOGIES INC DATE OF NAME CHANGE: 19990816 FORMER COMPANY: FORMER CONFORMED NAME: HP MEASUREMENT INC DATE OF NAME CHANGE: 19990716 10-Q 1 a-01312020x10q.htm 10-Q Document
0.660.440.150.151300000033000000false--10-31Q120200001090872falseLarge Accelerated FilerfalseP8YP13YP3YP5Y400000000.010.012000000000200000000030900000031000000000000000400000030000000100000090000000200000000.010.0112500000012500000000P0Y12M0D0.850 0001090872 2019-11-01 2020-01-31 0001090872 2020-02-27 0001090872 2018-11-01 2019-01-31 0001090872 us-gaap:ProductMember 2018-11-01 2019-01-31 0001090872 us-gaap:ServiceOtherMember 2018-11-01 2019-01-31 0001090872 us-gaap:ProductMember 2019-11-01 2020-01-31 0001090872 us-gaap:ServiceOtherMember 2019-11-01 2020-01-31 0001090872 2020-01-31 0001090872 2019-10-31 0001090872 2018-10-31 0001090872 2019-01-31 0001090872 us-gaap:NoncontrollingInterestMember 2020-01-31 0001090872 us-gaap:RetainedEarningsMember 2019-11-01 2020-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2019-11-01 2020-01-31 0001090872 us-gaap:RetainedEarningsMember 2020-01-31 0001090872 us-gaap:ParentMember 2019-11-01 2020-01-31 0001090872 us-gaap:ParentMember 2019-10-31 0001090872 us-gaap:CommonStockMember 2020-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001090872 us-gaap:TreasuryStockMember 2019-11-01 2020-01-31 0001090872 us-gaap:TreasuryStockMember 2019-10-31 0001090872 us-gaap:ParentMember 2020-01-31 0001090872 us-gaap:CommonStockMember 2019-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001090872 us-gaap:CommonStockMember 2019-11-01 2020-01-31 0001090872 us-gaap:TreasuryStockMember 2020-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-31 0001090872 us-gaap:RetainedEarningsMember 2019-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2019-10-31 0001090872 us-gaap:ParentMember 2018-10-31 0001090872 us-gaap:TreasuryStockMember 2018-10-31 0001090872 us-gaap:CommonStockMember 2019-01-31 0001090872 us-gaap:ParentMember 2018-11-01 2019-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0001090872 us-gaap:TreasuryStockMember 2018-11-01 2019-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-31 0001090872 us-gaap:TreasuryStockMember 2019-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-01 2019-01-31 0001090872 us-gaap:RetainedEarningsMember 2018-10-31 0001090872 us-gaap:CommonStockMember 2018-11-01 2019-01-31 0001090872 us-gaap:RetainedEarningsMember 2018-11-01 2019-01-31 0001090872 us-gaap:ParentMember 2019-01-31 0001090872 us-gaap:CommonStockMember 2018-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2018-11-01 2019-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001090872 us-gaap:RetainedEarningsMember 2019-01-31 0001090872 us-gaap:NoncontrollingInterestMember 2018-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2018-11-01 2019-01-31 0001090872 us-gaap:NoncontrollingInterestMember 2019-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0001090872 2019-11-01 0001090872 us-gaap:AccountingStandardsUpdate201602Member 2019-11-01 0001090872 a:BioTekMember 2019-08-22 2019-08-23 0001090872 a:BioTekMember 2020-01-31 0001090872 a:ACEABiosciencesInc.Member 2018-11-14 2018-11-14 0001090872 a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-23 0001090872 a:BioTekMember us-gaap:TrademarksAndTradeNamesMember 2019-08-23 0001090872 a:BioTekMember 2019-08-23 0001090872 a:BioTekMember us-gaap:OrderOrProductionBacklogMember 2019-08-23 0001090872 a:BioTekMember us-gaap:TrademarksAndTradeNamesMember 2019-08-22 2019-08-23 0001090872 a:BioTekMember us-gaap:OrderOrProductionBacklogMember 2019-08-22 2019-08-23 0001090872 a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-23 0001090872 srt:MinimumMember a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-22 2019-08-23 0001090872 srt:MinimumMember a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-22 2019-08-23 0001090872 srt:MaximumMember a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-22 2019-08-23 0001090872 srt:MaximumMember a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-22 2019-08-23 0001090872 a:DiagnosticsandClinicalMarketMember 2018-11-01 2019-01-31 0001090872 a:EnvironmentalandForensicsMarketMember 2018-11-01 2019-01-31 0001090872 a:PharmaceuticalandBiopharmaceuticalMarketMember 2019-11-01 2020-01-31 0001090872 a:DiagnosticsandClinicalMarketMember 2019-11-01 2020-01-31 0001090872 a:InstrumentationMember 2019-11-01 2020-01-31 0001090872 a:NonInstrumentationandOtherMember 2019-11-01 2020-01-31 0001090872 a:InstrumentationMember 2018-11-01 2019-01-31 0001090872 a:EnvironmentalandForensicsMarketMember 2019-11-01 2020-01-31 0001090872 a:ChemicalandEnergyMarketMember 2019-11-01 2020-01-31 0001090872 a:AcademiaandGovernmentMarketMember 2018-11-01 2019-01-31 0001090872 a:FoodMarketMember 2019-11-01 2020-01-31 0001090872 a:PharmaceuticalandBiopharmaceuticalMarketMember 2018-11-01 2019-01-31 0001090872 a:AcademiaandGovernmentMarketMember 2019-11-01 2020-01-31 0001090872 a:FoodMarketMember 2018-11-01 2019-01-31 0001090872 a:NonInstrumentationandOtherMember 2018-11-01 2019-01-31 0001090872 a:ChemicalandEnergyMarketMember 2018-11-01 2019-01-31 0001090872 srt:AsiaPacificMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-01-31 0001090872 a:AgilentCrossLabMember 2019-11-01 2020-01-31 0001090872 srt:AmericasMember a:AgilentCrossLabMember 2018-11-01 2019-01-31 0001090872 srt:AsiaPacificMember 2018-11-01 2019-01-31 0001090872 a:DiagnosticsAndGenomicsMember 2019-11-01 2020-01-31 0001090872 a:DiagnosticsAndGenomicsMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember 2018-11-01 2019-01-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-01-31 0001090872 srt:AsiaPacificMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-01-31 0001090872 srt:AmericasMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-01-31 0001090872 srt:AmericasMember a:AgilentCrossLabMember 2019-11-01 2020-01-31 0001090872 srt:AsiaPacificMember 2019-11-01 2020-01-31 0001090872 srt:EuropeMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-01-31 0001090872 srt:EuropeMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-01-31 0001090872 srt:AsiaPacificMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-01-31 0001090872 srt:AsiaPacificMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-01-31 0001090872 srt:EuropeMember 2019-11-01 2020-01-31 0001090872 srt:AsiaPacificMember a:AgilentCrossLabMember 2018-11-01 2019-01-31 0001090872 srt:AmericasMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-01-31 0001090872 srt:AsiaPacificMember a:AgilentCrossLabMember 2019-11-01 2020-01-31 0001090872 a:AgilentCrossLabMember 2018-11-01 2019-01-31 0001090872 srt:AmericasMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-01-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember a:AgilentCrossLabMember 2018-11-01 2019-01-31 0001090872 srt:AmericasMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember a:AgilentCrossLabMember 2019-11-01 2020-01-31 0001090872 srt:AmericasMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-01-31 0001090872 srt:AmericasMember 2019-11-01 2020-01-31 0001090872 us-gaap:PublicUtilitiesInventoryTypeDomain 2019-11-01 2020-01-31 0001090872 us-gaap:CostOfSalesMember 2018-11-01 2019-01-31 0001090872 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-11-01 2020-01-31 0001090872 us-gaap:ResearchAndDevelopmentExpenseMember 2019-11-01 2020-01-31 0001090872 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-11-01 2019-01-31 0001090872 us-gaap:ResearchAndDevelopmentExpenseMember 2018-11-01 2019-01-31 0001090872 us-gaap:CostOfSalesMember 2019-11-01 2020-01-31 0001090872 a:LtppMember 2018-11-01 2019-01-31 0001090872 a:LtppMember 2019-11-01 2020-01-31 0001090872 a:LTPPRSUMember 2019-11-01 2020-01-31 0001090872 a:LTPPRSUMember 2018-11-01 2019-01-31 0001090872 us-gaap:PublicUtilitiesInventoryTypeDomain 2018-11-01 2019-10-31 0001090872 us-gaap:OtherCurrentLiabilitiesMember 2020-01-31 0001090872 us-gaap:OtherNoncurrentAssetsMember 2020-01-31 0001090872 us-gaap:OtherNoncurrentLiabilitiesMember 2020-01-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2019-10-31 0001090872 a:AgilentCrossLabMember 2020-01-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2020-01-31 0001090872 a:DiagnosticsAndGenomicsMember 2020-01-31 0001090872 a:DiagnosticsAndGenomicsMember 2019-10-31 0001090872 a:AgilentCrossLabMember 2019-10-31 0001090872 us-gaap:InProcessResearchAndDevelopmentMember 2019-10-31 0001090872 us-gaap:TrademarksMember 2019-10-31 0001090872 a:ThirdPartyTechnologyandLicensesMember 2019-10-31 0001090872 us-gaap:CustomerRelationshipsMember 2019-10-31 0001090872 us-gaap:DevelopedTechnologyRightsMember 2020-01-31 0001090872 us-gaap:OrderOrProductionBacklogMember 2019-10-31 0001090872 us-gaap:InProcessResearchAndDevelopmentMember 2020-01-31 0001090872 a:TotalAmortizableIntangibleAssetsMember 2019-10-31 0001090872 us-gaap:CustomerRelationshipsMember 2020-01-31 0001090872 us-gaap:OrderOrProductionBacklogMember 2020-01-31 0001090872 us-gaap:DevelopedTechnologyRightsMember 2019-10-31 0001090872 us-gaap:TrademarksMember 2020-01-31 0001090872 a:ThirdPartyTechnologyandLicensesMember 2020-01-31 0001090872 a:TotalAmortizableIntangibleAssetsMember 2020-01-31 0001090872 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0001090872 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0001090872 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0001090872 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-01-31 0001090872 currency:GBP us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:KRW us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:KRW us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:JPY us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:XXX us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:XXX us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:JPY us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:GBP us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:CNY us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:GBP us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SGD us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-31 0001090872 currency:JPY us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SGD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-01-31 0001090872 currency:XXX us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-31 0001090872 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-01-31 0001090872 currency:CAD us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SEK us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:CNY us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SGD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-31 0001090872 currency:KRW us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:CAD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-01-31 0001090872 currency:CNY us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:CAD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SEK us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SEK us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 a:SeniorNotes2022Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 a:SeniorNotes2026Member us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 a:SeniorNotes2029Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 a:SeniorNotes2026Member us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-02-01 0001090872 a:SeniorNotes2022Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2012-07-01 0001090872 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-01-31 0001090872 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 a:SeniorNotes2029Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-08-16 0001090872 a:SeniorNotes2026Member us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-14 2016-09-15 0001090872 us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-11-01 2020-01-31 0001090872 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-01-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-10-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-01-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-11-01 2019-01-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-11-01 2020-01-31 0001090872 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-11-01 2019-01-31 0001090872 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-11-01 2019-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-11-01 2020-01-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-01-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-01-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-01-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-01-31 0001090872 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-11-01 2019-01-31 0001090872 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-11-01 2020-01-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-31 0001090872 us-gaap:RevolvingCreditFacilityMember 2020-01-31 0001090872 us-gaap:RevolvingCreditFacilityMember 2019-11-01 2020-01-31 0001090872 2019-10-21 0001090872 us-gaap:RevolvingCreditFacilityMember 2019-03-13 2019-03-13 0001090872 us-gaap:RevolvingCreditFacilityMember 2019-03-13 0001090872 a:SeniorNotes2029Member 2020-01-31 0001090872 a:SeniorNotes2026Member 2020-01-31 0001090872 a:SeniorNotes2026Member 2019-10-31 0001090872 a:SeniorNotes2022Member 2020-01-31 0001090872 a:SeniorNotes2023Member 2020-01-31 0001090872 a:SeniorNotes2022Member 2019-10-31 0001090872 a:SeniorNotes2023Member 2019-10-31 0001090872 a:SeniorNotes2029Member 2019-10-31 0001090872 a:A2019RepurchaseProgramMember 2018-11-01 2019-01-31 0001090872 a:A2019RepurchaseProgramMember 2019-11-01 2020-01-31 0001090872 a:A2015RepurchaseProgramMember 2018-11-01 2019-01-31 0001090872 a:A2019RepurchaseProgramMember 2020-01-31 0001090872 a:A2019RepurchaseProgramMember 2018-11-19 0001090872 us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedTranslationAdjustmentMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2019-10-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2020-01-31 0001090872 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2019-10-31 0001090872 us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-10-31 0001090872 us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2020-01-31 0001090872 us-gaap:AccumulatedTranslationAdjustmentMember 2019-10-31 0001090872 a:SegmentTotalMember 2018-11-01 2019-01-31 0001090872 a:SegmentTotalMember 2019-11-01 2020-01-31 0001090872 a:SegmentTotalMember 2020-01-31 0001090872 a:SegmentTotalMember 2019-10-31 0001090872 us-gaap:SubsequentEventMember 2020-02-06 2020-02-06 xbrli:pure a:contracts xbrli:shares iso4217:USD iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
 
(MARK ONE) 
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 
For the quarterly period ended January 31, 2020 
OR 
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 
For transition period from              to        
 Commission File Number: 001-15405
 AGILENT TECHNOLOGIES, INC.
(Exact Name of registrant as specified in its charter)
 
Delaware
 
 
 
77-0518772
 
(State or other jurisdiction of incorporation or organization)
 
(IRS Employer Identification No.)
 
5301 Stevens Creek Blvd.,
Santa Clara, California 95051
(Address of principal executive offices)

Registrant’s telephone number, including area code: (800) 227-9770  

Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
 
Trading Symbol
 
Name of each Exchange on which registered
Common Stock, $0.01 par value
 
 
A
 
 
 
New York Stock Exchange
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒  No  ☐
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒  No  ☐  
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
 
Accelerated filer
☐
 
Non-accelerated filer
☐
 
Smaller reporting company
☐
 
 
 
 
Emerging growth company
☐
 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐    
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  ☐ No  ☒ 

As of  February 27, 2020, the registrant had 309,651,359 shares of common stock, $0.01 par value per share, outstanding.


AGILENT TECHNOLOGIES, INC.
TABLE OF CONTENTS
 
 
 
 
Page
Number
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2

PART I
— FINANCIAL INFORMATION
 
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
 
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(in millions, except per share amounts)
(Unaudited)
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
Net revenue:
 

 
 

Products
$
1,023

 
$
980

Services and other
334

 
304

Total net revenue
1,357

 
1,284

Costs and expenses:
 

 
 

Cost of products
454

 
414

Cost of services and other
180

 
163

Total costs
634

 
577

Research and development
104

 
102

Selling, general and administrative
404

 
355

Total costs and expenses
1,142

 
1,034

Income from operations
215

 
250

Interest income
3

 
10

Interest expense
(20
)
 
(18
)
Other income (expense), net
21

 
6

Income before taxes
219

 
248

Provision (benefit) for income taxes
22

 
(256
)
Net income
$
197

 
$
504

 
 
 
 
Net income per share:
 

 
 

Basic
$
0.64

 
$
1.58

Diluted
$
0.63

 
$
1.57

 
 
 
 
Weighted average shares used in computing net income per share:
 

 
 

Basic
310

 
318

Diluted
313

 
322

 
The accompanying notes are an integral part of these condensed consolidated financial statements.


3

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)
(in millions)
(Unaudited)

 
Three Months Ended
 
January 31,
 
2020
 
2019
 
 
 
 
Net income
$
197

 
$
504

Other comprehensive income (loss):
 
 
 
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $0 and $(2)
1

 
(4
)
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0 and $(1)
—

 
(4
)
Foreign currency translation, net of tax expense (benefit) of $0 and $(9)
(11
)
 
38

Net defined benefit pension cost and post retirement plan costs:
 
 
 
Change in actuarial net loss, net of tax expense of $3 and $4
6

 
6

Change in net prior service benefit, net of tax expense of $1 and $0
(3
)
 
(2
)
Other comprehensive income (loss)
(7
)
 
34

Total comprehensive income
$
190

 
$
538



The accompanying notes are an integral part of these condensed consolidated financial statements.


4

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(in millions, except par value and share amounts)
(Unaudited)
 
January 31,
2020
 
October 31,
2019
ASSETS
 

 
 

Current assets:
 

 
 

Cash and cash equivalents
$
1,226

 
$
1,382

Accounts receivable, net
966

 
930

Inventory
706

 
679

Other current assets
204

 
198

Total current assets
3,102

 
3,189

Property, plant and equipment, net
844

 
850

Goodwill
3,589

 
3,593

Other intangible assets, net
1,059

 
1,107

Long-term investments
118

 
102

Other assets
789

 
611

Total assets
$
9,501

 
$
9,452

LIABILITIES AND EQUITY
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
329

 
$
354

Employee compensation and benefits
253

 
334

Deferred revenue
379

 
336

Short-term debt
675

 
616

Other accrued liabilities
256

 
440

Total current liabilities
1,892

 
2,080

Long-term debt
1,787

 
1,791

Retirement and post-retirement benefits
354

 
360

Other long-term liabilities
620

 
473

Total liabilities
4,653

 
4,704

Commitments and contingencies (Note 14)


 


Total equity:
 

 
 

Stockholders’ equity:
 

 
 

Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding
—

 
—

Common stock; $0.01 par value; 2 billion shares authorized; 310 million shares at January 31, 2020 and 309 million shares at October 31, 2019 issued
3

 
3

Additional paid-in-capital
5,293

 
5,277

Retained earnings (accumulated deficit)
73

 
(18
)
Accumulated other comprehensive loss
(521
)
 
(514
)
Total stockholders' equity
4,848

 
4,748

Total liabilities and equity
$
9,501

 
$
9,452


 
The accompanying notes are an integral part of these condensed consolidated financial statements.

5

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(in millions)
(Unaudited)
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
 

 
 

Net income
$
197

 
$
504

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
 

 
 

Depreciation and amortization
79

 
54

Share-based compensation
27

 
24

Deferred taxes
10

 
(281
)
Excess and obsolete inventory related charges
4

 
4

Unrealized gain on equity securities
(16
)
 
—

Other non-cash expense, net
2

 
3

Changes in assets and liabilities:
 

 
 

Accounts receivable
(40
)
 
(22
)
Inventory
(32
)
 
(12
)
Accounts payable
(15
)
 
(16
)
Employee compensation and benefits
(80
)
 
(71
)
Other assets and liabilities
(195
)
 
26

Net cash provided (used in) by operating activities
(59
)
 
213

 
 
 
 
Cash flows from investing activities:
 

 
 

Investments in property, plant and equipment
(34
)
 
(39
)
Payment to acquire fair value investments
(1
)
 
(2
)
Payment in exchange for convertible note
—

 
(1
)
Acquisitions of businesses and intangible assets, net of cash acquired
—

 
(248
)
Net cash used in investing activities
(35
)
 
(290
)
 
 
 
 
Cash flows from financing activities:
 

 
 

Issuance of common stock under employee stock plans
32

 
22

Payment of taxes related to net share settlement of equity awards
(33
)
 
(13
)
Payment of dividends
(56
)
 
(52
)
Purchase of non-controlling interest
—

 
(4
)
Proceeds from revolving credit facility
432

 
—

Repayment of revolving credit facility
(372
)
 
—

Repayment of finance lease
(4
)
 
—

Treasury stock repurchases
(60
)
 
(75
)
Net cash used in financing activities
(61
)
 
(122
)
 
 
 
 
Effect of exchange rate movements
(1
)
 
9

 
 
 
 
Net decrease in cash, cash equivalents and restricted cash
(156
)
 
(190
)
 
 
 
 
Cash, cash equivalents and restricted cash at beginning of period
1,388

 
2,254

Cash, cash equivalents and restricted cash at end of period
$
1,232

 
$
2,064

 
 
 
 
Supplemental cash flow information:
 
 
 
Income tax paid, net
$
241

 
$
21

Interest payments
$
17

 
$
25

Non-cash changes in investments in property, plant and equipment - increase (decrease)
$
(9
)
 
$
(13
)
 
The accompanying notes are an integral part of these condensed consolidated financial statements.

6

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF EQUITY
(in millions, except number of shares in thousands)
(Unaudited)
 
Common Stock
 
Treasury Stock
 
 
 
Accumulated
Other
Comprehensive
Income/(Loss)
 
 
 
 
 
 
Three Months Ended January 31, 2020
Number
of
Shares
 
Par
Value
 
Additional
Paid-in
Capital
 
Number
of
Shares
 
Treasury
Stock at
Cost
 
Retained
Earnings
(Accumulated Deficit)
 
Total Stockholders' Equity
 
Non-
Controlling
Interest
 
Total
Equity
Balance as of October 31, 2019
309,071

 
$
3

 
$
5,277

 
—

 
$
—

 
$
(18
)
 
$
(514
)
 
$
4,748

 
$
—

 
$
4,748

Components of comprehensive income, net of tax:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income
—

 
—

 
—

 
—

 
—

 
197

 
—

 
197

 
—

 
197

Other comprehensive income (loss)
—

 
—

 
—

 
—

 
—

 
—

 
(7
)
 
(7
)
 
—

 
(7
)
Total comprehensive income
 

 
 

 
 

 
 

 
 

 
 

 
 

 
190

 
 
 
190

Cash dividends declared ($0.18 per common share)
—

 
—

 
—

 
—

 
—

 
(56
)
 
—

 
(56
)
 
—

 
(56
)
Share-based awards issued, net of tax of $33
1,703

 
—

 
(1
)
 
—

 
—

 
—

 
—

 
(1
)
 
—

 
(1
)
Repurchase of common stock
—

 
—

 
—

 
(726
)
 
(60
)
 
—

 
—

 
(60
)
 
—

 
(60
)
Retirement of treasury stock
(726
)
 
—

 
(10
)
 
726

 
60

 
(50
)
 
—

 
—

 
—

 
—

Share-based compensation
—

 
—

 
27

 
—

 
—

 
—

 
—

 
27

 
—

 
27

Balance as of January 31, 2020
310,048

 
$
3

 
$
5,293

 
—

 
$
—

 
$
73

 
$
(521
)
 
$
4,848

 
$
—

 
$
4,848


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Common Stock
 
Treasury Stock
 
 
 
Accumulated
Other
Comprehensive
Income/(Loss)
 
 
 
 
 
 
Three Months Ended January 31, 2019
Number
of
Shares
 
Par
Value
 
Additional
Paid-in
Capital
 
Number
of
Shares
 
Treasury
Stock at
Cost
 
Retained
Earnings
(Accumulated Deficit)
 
Total Stockholders' Equity
 
Non-
Controlling
Interest
 
Total
Equity
Balance as of October 31, 2018
317,715

 
$
3

 
$
5,308

 
—

 
$
—

 
$
(336
)
 
$
(408
)
 
$
4,567

 
$
4

 
$
4,571

Effects of adoption of new accounting standards
—

 
—

 
—

 
—

 
—

 
33

 
(7
)
 
26

 
—

 
26

Components of comprehensive income, net of tax:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income
—

 
—

 
—

 
—

 
—

 
504

 
—

 
504

 
—

 
504

Other comprehensive income
—

 
—

 
—

 
—

 
—

 
—

 
34

 
34

 
—

 
34

Total comprehensive income
 

 
 

 
 

 
 

 
 

 
 

 
 

 
538

 
 
 
538

Purchase of non-controlling interest
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(4
)
 
(4
)
Cash dividends declared ($0.164 per common share)             
—

 
—

 
—

 
—

 
—

 
(52
)
 
—

 
(52
)
 
—

 
(52
)
Share-based awards issued, net of tax of $13
946

 
—

 
8

 
—

 
—

 
—

 
—

 
8

 
—

 
8

Repurchase of common stock
—

 
—

 
—

 
(1,128
)
 
(75
)
 
—

 
—

 
(75
)
 
—

 
(75
)
Retirement of treasury stock
(1,128
)
 
—

 
(16
)
 
1,128

 
75

 
(59
)
 
—

 
—

 
—

 
—

Share-based compensation
—

 
—

 
24

 
—

 
—

 
—

 
—

 
24

 
—

 
24

Balance as of January 31, 2019
317,533

 
$
3

 
$
5,324

 
—

 
$
—

 
$
90

 
$
(381
)
 
$
5,036

 
$
—

 
$
5,036


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.

7

AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)


1.
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.

Basis of Presentation. We have prepared the accompanying financial data for the three months ended January 31, 2020 and 2019 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2019 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2019.

In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of January 31, 2020 and October 31, 2019, condensed consolidated statement of comprehensive income (loss) for the three months ended January 31, 2020 and 2019, condensed consolidated statement of operations for the three months ended January 31, 2020 and 2019, condensed consolidated statement of cash flows for the three months ended January 31, 2020 and 2019 and condensed consolidated statement of equity for the three months ended January 31, 2020 and 2019.

Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement benefit plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes,.

Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $90 million and $62 million as of January 31, 2020 and October 31, 2019, respectively. The change in the fair value over carrying value in the three months ended January 31, 2020 is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 11, "Fair Value Measurements" for additional information on the fair value of financial instruments.


8
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows:
 
January 31,
 
October 31
 
2020
 
2019
 
(in millions)
Cash and cash equivalents
$
1,226

 
$
1,382

Restricted cash included in other assets
6

 
6

Total cash, cash equivalents and restricted cash
$
1,232

 
$
1,388



Leases. We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") and lease liabilities on the condensed consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates we have used a number of factors including the parent credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.

A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.

   See also Note 2, "New Accounting Pronouncements" and Note 9, "Leases" for additional information about the company’s leases.

 2. NEW ACCOUNTING PRONOUNCEMENTS

Accounting Pronouncements Not Yet Adopted

There were no changes to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2019 except for the following:

In December 2019, the Financial Accounting Standards Board ("FASB") issued new guidance to simplify the accounting for income taxes. This guidance eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences.The new guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We are evaluating the impact of this guidance on our consolidated financial statements and disclosures.

Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to record most leases on the balance sheet as lease liabilities, initially measured at the present value of future lease payments, with a corresponding right-of-use asset. The accounting applied by a lessor is largely unchanged from that applied under the prior

9
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







accounting standard.
On November 1, 2019, we adopted the new accounting guidance using the modified retrospective method, by applying the transition approach, for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning November 1, 2019 are presented under the new accounting standard, while prior period amounts have not been restated. The standard had a significant impact on the condensed consolidated balance sheet as of January 31, 2020, but did not have a significant impact on the condensed consolidated statement of operations or condensed consolidated statement of cash flows for the three months ended January 31, 2020. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of new accounting standard, we elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. We also elected to exclude leases with a term of 12 months or less in the ROU assets and lease liabilities. The adoption of this standard had no impact on our results of operations, cash flows and retained earnings.
Adoption of the new guidance impacted the condensed consolidated balance sheet as follows:

 
October 31, 2019
 
Impact of Adopting
 
November 1, 2019
 
As Reported
 
Lease Guidance
 
As Adopted
 
(in millions)
Other assets
$
611

 
$
192

 
$
803

Other accrued liabilities
$
440

 
$
48

 
$
488

Other long-term liabilities
$
473

 
$
144

 
$
617



Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

3.     ACQUISITIONS

Acquisition of BioTek and ACEA

On August 23, 2019 we completed the acquisition of privately-owned Lionheart Technologies LLC ("BioTek"), a leader in the design, manufacture and distribution of innovative life science instrumentation for $1.17 billion, under the merger agreement. As a result of the acquisition, BioTek has become a wholly-owned subsidiary of Agilent. Accordingly, the results of BioTek are included in Agilent's condensed consolidated financial statements from the acquisition date. The acquisition of BioTek and its portfolio is another step to expand our position in the cell analysis market.

The consideration paid was $1.17 billion. Agilent funded the acquisition using existing cash of $470 million and debt of $700 million.

The BioTek acquisition was accounted for in accordance with the authoritative accounting guidance. The acquired assets and assumed liabilities were recorded by Agilent at their estimated fair values. Agilent determined the estimated fair values with the assistance of appraisals or valuations performed by third party specialists, discounted cash flow analyses, and estimates made by management. We expect to realize revenue synergies, leverage and expand the existing sales channels and product development resources, and utilize the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of BioTek’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction.
 
Goodwill acquired was allocated to our operating segments and reporting units as a part of the purchase price allocation. All goodwill was allocated to the life sciences and applied markets reporting unit.

Agilent’s acquisition of BioTek is treated as an asset purchase for tax purposes. The tax basis of the acquired assets equals the fair market value on acquisition date.

10
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):
Cash and cash equivalents
 
 
$
10

 
Accounts receivable
 
 
28

 
Inventories
 
 
21

 
Other current assets
 
 
2

 
Property, plant and equipment
 
 
8

 
Intangible assets
 
 
641

 
Goodwill
 
 
483

 
Total assets acquired
 
1,193
 

Accounts payable
 
 
(4
)
 
Deferred revenue
 
 
(5
)
 
Employee compensation and benefits
 
 
(7
)
 
Other accrued liabilities
 
 
(2
)
 
Long-term debt
 
 
(4
)
 
Net assets acquired
 
 
$
1,171

 


The fair value of cash and cash equivalents, accounts receivable, other current assets, accounts payable and other accrued liabilities were generally determined using historical carrying values given the short-term nature of these assets and liabilities.
 
The fair values for acquired intangible assets and deferred revenue were determined with the input from third party valuation specialists.
 
The fair values of certain other assets, inventory, property, plant and equipment, investments, long-term debt, and certain other long-term liabilities were determined internally using historical carrying values and estimates made by management.
 
Valuations of intangible assets acquired
 
The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):

 
Fair Value
 
Estimated
Useful Life
Developed product technology
 
$
387

 
 
5-13 years
Customer relationships
 
202

 
 
3-8 years
Backlog
 
5

 
 
2 months
Tradenames and trademarks
 
43

 
 
10 years
Total intangible assets subject to amortization
 
637

 
 
 
In-process research and development
 
4

 
 
 
Total intangible assets
 
$
641

 
 
 


As noted above, the intangible assets, including in-process research and development, were valued with input from valuation specialists. Agilent used variations of the income approach in determining the fair value of intangible assets acquired in the BioTek acquisition. Specifically, the developed product technology and in-process research and development were valued using the multi-period excess earnings method under the income approach by discounting forecasted cash flows directly related to the products expecting to result from the projects, net of returns on contributory assets. The company utilized the incremental cash flow method for determining the fair value of the customer relationships acquired, and the relief from royalty method to determine the fair value of the tradename. Order backlog was valued on a direct cash flow basis.

The primary in-process research and development project acquired relates to a next version of a product which will be released later in 2020. Total costs to complete for all BioTek in-process research and development were estimated at approximately $2 million as of the close date.

Acquisition and integration costs directly related to the BioTek acquisition totaled $4 million for the three months ended

11
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







January 31, 2020 and were recorded in selling, general and administrative expenses.

On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for $250 million. The financial results of ACEA have been included in our financial results from the acquisition date.
 
The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's condensed consolidated statements of operations as of the beginning of fiscal 2019 (in millions, except per share amounts):

 
Three Months Ended January 31,
 
2019
Net revenue
$
1,326

Net income
$
474

Net income per share — basic
$
1.49

Net income per share — diluted
$
1.47



The unaudited proforma financial information assumes that the companies were combined as of November 1, 2017 and include business combination accounting effects from the acquisition including amortization charges from acquired intangible assets, the impact on cost of sales due to the respective estimated fair value adjustments to inventory, changes to interest income for cash used in the acquisition, interest expense and currency losses associated with debt paid in connection with the acquisition and acquisition related transaction costs and tax related effects. The proforma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2018.
 
The unaudited proforma financial information for the three months ended January 31, 2019 combines the historical results of Agilent (which includes ACEA after the acquisition date), the first two weeks of the quarter for ACEA and BioTek for the three months ended January 31, 2019.
 
4. REVENUE


The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
 
Three Months Ended January 31,
 
2020
 
2019
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
(in millions)
 
 
 
 
 
 
 
 
Revenue by Region
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Americas
$
209

 
$
118

 
$
167

 
$
494

 
$
168

 
$
109

 
$
156

 
$
433

Europe
167

 
92

 
133

 
392

 
164

 
91

 
128

 
383

Asia Pacific
262

 
39

 
170

 
471

 
275

 
35

 
158

 
468

Total
$
638

 
$
249

 
$
470

 
$
1,357

 
$
607

 
$
235

 
$
442

 
$
1,284

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


12
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)








The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Revenue by End Markets
 
 
 
Pharmaceutical and Biopharmaceutical
$
423

 
$
391

Chemical and Energy
312

 
308

Diagnostics and Clinical
194

 
187

Food
130

 
129

Academia and Government
141

 
116

Environmental and Forensics
157

 
153

Total
$
1,357

 
$
1,284

 
 
 
 
Revenue by Type
 
 
 
Instrumentation
$
593

 
$
567

Non-instrumentation and other
764

 
717

Total
$
1,357

 
$
1,284



Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.

Contract Balances

Contract Assets

Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheet.

The balance of contract assets as of January 31, 2020 and October 31, 2019 were $131 million and $110 million, respectively. The increase in unbilled receivables during the three months ended January 31, 2020 is a result of recognition of revenue upon the transfer of the control to the customer. In some instances, transfer of control is prior to invoicing the customers and excluding amounts transferred to trade receivables during the period amounted to $21 million.


13
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







Contract Liabilities

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2020:

 
 
Contract
Liabilities
 
 
(in millions)
 
 
 
Ending balance as of October 31, 2019
 
$
386

Net revenue deferred in the period
 
180

Revenue recognized that was included in the contract liability balance at the beginning of the period
 
(142
)
Change in deferrals from customer cash advances, net of revenue recognized
 
9

Currency translation and other adjustments
 
(1
)
Ending balance as of January 31, 2020
 
$
432


During the three months ended January 31, 2019 revenue recognized that was included in the contract liability balance at October 31, 2018 was $125 million.

Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Contract Costs

Incremental costs of obtaining a contract with a customer are recognized as an asset if it expects the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the three months ended January 31, 2020 and are included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.

Transaction Price Allocated to the Remaining Performance Obligations

We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.
 
The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of January 31, 2020, was $210 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, and software maintenance contracts and revenue associated with lease arrangements.

5.     SHARE-BASED COMPENSATION
 
Agilent accounts for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, employee stock purchases made under our employee stock purchase plan (“ESPP”) and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values.

Participants in the LTPP are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the

14
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award, for the company's executive officers and other key employees. Participants in this program are also entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets over the three-year period are met. The performance target for grants made beginning 2017 and later were based on Earnings Per Share ("EPS"). The performance targets for the LTPP-EPS grants for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period.

The final LTPP award may vary from zero to 200 percent of the target award. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant.
 
The impact on our results for share-based compensation was as follows:
 

Three Months Ended

January 31,
 
2020

2019
 
(in millions)
Cost of products and services
$
6


$
5

Research and development
3


2

Selling, general and administrative
18


17

Total share-based compensation expense
$
27

 
$
24

 
At January 31, 2020 and October 31, 2019, there was no share-based compensation capitalized within inventory.
                                               
The following assumptions were used to estimate the fair value of awards granted.
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
LTPP:
 
 
 
Volatility of Agilent shares
23%
 
22%
Volatility of selected peer-company shares
15%-44%
 
15%-66%
Pair-wise correlation with selected peers
29%
 
30%
 
 
 
 
Post-vest holding restriction discount for all executive awards
5.3%
 
5.0%
 
Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulations model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock.  For the volatility of our LTPP (TSR) grants, we used our own historical stock price volatility.  

The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value.

The estimated fair value of restricted stock units and LTPP (EPS) awards is determined based on the market price of Agilent’s common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period.

All awards granted to our senior management employees have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulations model and an expected dividend yield to compute the discount.


15
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







6.     INCOME TAXES

For the three months ended January 31, 2020, the company's income tax expense was $22 million with an effective tax rate of 10.0 percent. For the three months ended January 31, 2020, our effective tax rate and the resulting provision for income taxes were significantly impacted by a discrete benefit of $13 million related to the excess tax benefits from stock-based compensation.

For the three months ended January 31, 2019, the company's income tax benefit was $256 million with an effective tax rate of (103.2) percent. For the three months ended January 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by a discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore. The income taxes for the three months ended January 31, 2019 also includes the excess tax benefits of $4 million from stock-based compensation.

In the U.S., tax years remain open back to the year 2016 for federal income tax purposes and the year 2015 for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009.

It is reasonably possible there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits. The company will continue to assess the impact of the further guidance from federal and state tax authorities on its business and consolidated financial statements. Any future adjustments will be recognized as discrete income tax expense or benefit in the period the adjustments are determined.

7. NET INCOME PER SHARE
 
The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Numerator:
 

 
 

Net income
$
197

 
$
504

Denominator:
 
 
 
Basic weighted-average shares
310

 
318

Potential common shares— stock options and other employee stock plans
3

 
4

Diluted weighted-average shares
313

 
322


 
The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards.

We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive.  

For the three months ended January 31, 2020 and 2019, the impact of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share was not material.


16
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







8. INVENTORY
 
 
January 31,
2020
 
October 31,
2019
 
(in millions)
Finished goods
$
423

 
$
416

Purchased parts and fabricated assemblies
283

 
263

Inventory
$
706

 
$
679



9. LEASES

As a lessee, we have various non- cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms was well as payments for common area maintenance. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years.
Prior to the adoption of the new lease accounting standard, future minimum lease payments as of October 31, 2019 and previously disclosed in the company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2019 under non- cancelable leases with initial terms exceeding twelve months were as follows:
 
Operating Leases
 
(in millions)
2020
$
52

2021
41

2022
29

2023
21

2024
14

2025 and thereafter
56

Total future minimum lease payments
$
213



The components of lease cost for operating leases were as follows:
 
Three Months Ended
 
January 31, 2020
 
(in millions)
 
 
Operating lease cost
$
15

Variable lease cost (a)
4

Sublease income
(4
)
      Total lease cost
$
15

(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.


17
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







Supplemental cash flow information related to leases was as follows:
 
Three Months Ended
 
January 31, 2020
 
(in millions)
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flow from operating leases
$
15

Non-cash right of use assets obtained in exchange for operating lease obligations
$
14



Supplemental balance sheet information related to leases was as follows:

 
 
 
Three Months Ended
 
Financial Statement Line Item
 
January 31, 2020
 
 
 
(in millions, except lease term and discount rate)
Assets:
 
 
 
Operating lease:
 
 
 
Right of use asset
Other assets
 
$
191

 
 
 
 
Liabilities:
 
 
 
Current
 
 
 
Operating lease liabilities
Other accrued liabilities
 
$
51

Long-Term
 
 
 
Operating lease liabilities
Other long-term liabilities
 
$
141

 
 
 
 
Weighted average remaining lease term in years
 
 
 
Operating leases
 
 
8.25 years

Weighted average discount rate
 
 
 
Operating leases
 
 
2.1
%

Future minimum rents payable as of January 31, 2020 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the condensed consolidated balance sheet as follows:
 
 
Operating Leases
 
 
(in millions)
2020
 
$
41

2021
 
45

2022
 
33

2023
 
22

2024
 
14

2025 and thereafter
 
57

Total undiscounted future minimum lease payments
 
$
212

Less: amount of lease payments representing interest
 
(20
)
Present value of future minimum lease payments
 
$
192

Less: current liabilities
 
(51
)
Long-term lease liabilities
 
$
141

 
 
 


As of January 31, 2020, we had no additional significant operating or finance leases that had not yet commenced.

As a lessor, we have contracts for equipment leased to customers in connection with our diagnostics business which include both operating-type lease and sales-type lease arrangements. We account for the non-lease component under the revenue recognition rules and the lease component under the leasing guidance. Equipment lease revenue for operating lease agreements is recognized as visualization kits and reagents are shipped over the life of the lease and the cost of customer leased equipment is recorded within property, plant and equipment, net in the consolidated condensed balance sheet and depreciated over the equipment’s estimated

18
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







useful life. For arrangements that have been classified as sales-type leases revenue is recognized when the transfer of control of the underlying leased asset has occurred and the net investment the lease recorded which is calculated at the present value of the remaining lease payments due from the lessee.

Revenue allocated to the lease income for both finance/sales-type lease and operating lease rental arrangements represents less than one percent of total net revenue in the three months ended January 31, 2020.

As of January 31, 2020, the original cost and net book value of operating leased assets was $49 million and $16 million, respectively. As of January 31, 2020, lease receivables related to sales-type leases were $38 million.

10. GOODWILL AND OTHER INTANGIBLE ASSETS
 
The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2020:
 
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
(in millions)
Goodwill as of October 31, 2019
$
1,438

 
$
1,594

 
$
561

 
$
3,593

Foreign currency translation impact
—

 
(2
)
 
(2
)
 
(4
)
Goodwill as of January 31, 2020
$
1,438

 
$
1,592

 
$
559

 
$
3,589


The components of other intangible assets as of January 31, 2020 and October 31, 2019 are shown in the table below:
 
 
Purchased Other Intangible Assets
 
Gross
Carrying
Amount
 
Accumulated
Amortization
and Impairments
 
Net Book
Value
 
(in millions)
As of October 31, 2019
 

 
 

 
 

Purchased technology
$
1,413

 
$
763

 
$
650

Backlog
5

 
5

 
—

Trademark/Tradename
196

 
102

 
94

Customer relationships
329

 
87

 
242

Third-party technology and licenses
28

 
22

 
6

Total amortizable intangible assets
1,971

 
979

 
992

In-Process R&D
115

 
—

 
115

Total
$
2,086

 
$
979

 
$
1,107

As of January 31, 2020
 

 
 

 
 

Purchased technology
$
1,412

 
$
787

 
$
625

Backlog
5

 
5

 
—

Trademark/Tradename
196

 
106

 
90

Customer relationships
329

 
105

 
224

Third-party technology and licenses
28

 
23

 
5

Total amortizable intangible assets
1,970

 
1,026

 
944

In-Process R&D
115

 
—

 
115

Total
$
2,085

 
$
1,026

 
$
1,059


During the three months ended January 31, 2020, there were no additions to goodwill and there were no additions to other intangible assets. During the three months ended January 31, 2020, the impact of foreign currency translation on other intangible assets was not material.

In general, for United States federal tax purposes, goodwill from asset purchases is deductible, however any goodwill created as part of a stock acquisition is not deductible. 


19
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. There were no indicators of impairments of indefinite-lived intangible assets or goodwill during the three months ended January 31, 2020 and 2019, respectively.

Amortization expense of intangible assets was $48 million and $29 million for the three months ended January 31, 2020 and 2019, respectively.

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2020 and for each of the five succeeding fiscal years and thereafter is estimated below:
Estimated future amortization expense:
 
(in millions)
 
Remainder of 2020
$
138

2021
$
172

2022
$
150

2023
$
107

2024
$
86

2025
$
68

Thereafter
$
223


 
11. FAIR VALUE MEASUREMENTS
 
The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.

Fair Value Hierarchy

The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:

Level 1- applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2- applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.

Level 3- applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.


20
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)








Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
 
Financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2020 were as follows:
 
 
 
 
Fair Value Measurement at January 31, 2020 Using
 
January 31,
2020
 
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
 
Significant
 Other
 Observable
 Inputs
 (Level 2)
 
Significant
 Unobservable
 Inputs
 (Level 3)
 
(in millions)
Assets:
 

 
 

 
 

 
 

Short-term
 

 
 

 
 

 
 

Cash equivalents (money market funds)
$
602

 
$
602

 
$
—

 
$
—

Derivative instruments (foreign exchange contracts)
6

 
—

 
6

 
—

Long-term
 
 
 
 
 
 
 
Trading securities
29

 
29

 
—

 
—

Other investments
25

 
—

 
25

 
—

Total assets measured at fair value
$
662

 
$
631

 
$
31

 
$
—

Liabilities:
 

 
 

 
 

 
 

Short-term
 
 
 
 
 
 
 
Derivative instruments (foreign exchange contracts)
$
6

 
$
—

 
$
6

 
$
—

Long-term
 
 
 
 
 
 
 
Deferred compensation liability
29

 
—

 
29

 
—

Total liabilities measured at fair value
$
35

 
$
—

 
$
35

 
$
—


Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows:
 
 
 
 
Fair Value Measurement at October 31, 2019 Using
 
October 31,
2019
 
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
 
Significant
 Other
 Observable
 Inputs
 (Level 2)
 
Significant
 Unobservable
 Inputs
 (Level 3)
 
(in millions)
Assets:
 

 
 

 
 

 
 

Short-term
 

 
 

 
 

 
 

Cash equivalents (money market funds)
$
784

 
$
784

 
$
—

 
$
—

Derivative instruments (foreign exchange contracts)
12

 
—

 
12

 
—

Long-term
 
 
 
 
 
 
 
Trading securities
30

 
30

 
—

 
—

Other investments
25

 
—

 
25

 
—

Total assets measured at fair value
$
851

 
$
814

 
$
37

 
$
—

Liabilities:
 

 
 

 
 

 
 

Short-term
 
 
 
 
 
 
 
Derivative instruments (foreign exchange contracts)
$
6

 
$
—

 
$
6

 
$
—

Long-term
 
 
 
 
 
 
 
Deferred compensation liability
30

 
—

 
30

 
—

Total liabilities measured at fair value
$
36

 
$
—

 
$
36

 
$
—


 
Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. It has been classified as level 2

21
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself.

Trading securities, which is comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive loss within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income.

Impairment of Investments. There were no impairments of investments for the three months ended January 31, 2020 and 2019.
 
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

For the three months ended January 31, 2020 and 2019, there were no impairments of long-lived assets held and used or long-lived assets held for sale. For the three months ended January 31, 2020 and 2019, there were no impairment of non-marketable securities. For the three months ended January 31, 2020 and 2019, an unrealized gain of $16 million and zero, respectively, were included in net income as adjustments to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. As of January 31, 2020 and October 31, 2019, the carrying amount of non-marketable equity securities without readily determinable fair values was $63 million and $47 million, respectively.

Fair values for the non-marketable securities included in long-term investments on the condensed consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when it occurs.

12. DERIVATIVES
 
We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts, purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates.
 
Cash Flow Hedges
 
We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of January 31, 2020 changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the three months ended January 31, 2020 and 2019 ineffectiveness and gains and losses recognized in other income (expense) due to de-designation of cash flow hedge contracts were not significant.

In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at January 31, 2020 was $1 million.


22
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million and we recognized this as a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at January 31, 2020 was $6 million.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at January 31, 2020 was $6 million.

Net Investment Hedges

We enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) and are assessed for effectiveness against the underlying exposure every reporting period.  If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period.

Other Hedges
 
Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
 
Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors.  We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.

A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.

The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of January 31, 2020, was $3 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of January 31, 2020.


23
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







There were 267 foreign exchange forward contracts open as of January 31, 2020 and designated as cash flow hedges. There were 172 foreign exchange forward contracts open as of January 31, 2020 not designated as hedging instruments. There was 1 foreign exchange forward contracts open as of January 31, 2020 and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of January 31, 2020 were as follows:
 
 
 
Derivatives 
Designated as
Cash Flow Hedges
 
Derivatives
Designated as
Net Investment Hedges
 
Derivatives
Not Designated as 
Hedging Instruments
 
 
Forward
Contracts USD
 
Forward
Contracts USD
 
Forward
Contracts USD
Currency
 
Buy/(Sell)
 
Buy/(Sell)
 
Buy/(Sell)
 
 
(in millions)
Euro
 
$
(63
)
 
$
(55
)
 
$
64

British Pound
 
(43
)
 
—

 
(4
)
Canadian Dollar
 
(39
)
 
—

 
26

Japanese Yen
 
(83
)
 
—

 
(10
)
Korean Won
 
(62
)
 
—

 
(36
)
Singapore Dollar
 
15

 
—

 
26

Chinese Yuan Renminbi
 
(71
)
 
—

 
(40
)
Swedish Krona
 
—

 
—

 
(8
)
Other
 
4

 
—

 
(9
)
Totals
 
$
(342
)
 
$
(55
)
 
$
9

 
Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of January 31, 2020 and October 31, 2019 were as follows:

Fair Values of Derivative Instruments
Asset Derivatives
 
Liability Derivatives
 
 
Fair Value
 
 
 
Fair Value
Balance Sheet Location
 
January 31,
2020
 
October 31, 2019
 
Balance Sheet Location
 
January 31,
2020
 
October 31,
2019
(in millions)
Derivatives designated as hedging instruments:
 
 

 
 

 
 
 
 

 
 

Cash flow hedges
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
 
 
 
 
 
 
 
 
 
 
Other current assets
 
$
3

 
$
3

 
Other accrued liabilities
 
$
2

 
$
2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 

 
 

 
 
 
 

 
 

Foreign exchange contracts
 
 

 
 

 
 
 
 

 
 

Other current assets
 
$
3

 
$
9

 
Other accrued liabilities
 
$
4

 
$
4

Total derivatives
 
$
6

 
$
12

 
 
 
$
6

 
$
6



24
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows

 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Derivatives designated as hedging instruments:
 

 
 

Cash Flow Hedges
 
 
 
Foreign exchange contracts:
 
 
 
Gain (loss) recognized in accumulated other comprehensive income
$
1

 
$
(6
)
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales
$
—

 
$
5

Gain (loss) on time value of forward contracts recorded in cost of sales
$
—

 
$
1

 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
Gain (loss) recognized in other income (expense)
$
(2
)
 
$
(3
)

At January 31, 2020, the estimated amount of existing net gain that is expected to be reclassified from accumulated other comprehensive loss to cost of sales within the next twelve months is $4 million.

13. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS

Components of net periodic costs. For the three months ended January 31, 2020 and 2019, our net pension and post retirement benefit costs were comprised of the following:
 
 
Three Months Ended January 31,
 
U.S.
Pension Plans
 
Non-U.S.
Pension Plans
 
U.S. Post Retirement
Benefit Plans
 
2020
 
2019
 
2020
 
2019
 
2020
 
2019
 
(in millions)
Service cost—benefits earned during the period
$
—

 
$
—

 
$
7

 
$
6

 
$
—

 
$
—

Interest cost on benefit obligation
4

 
5

 
2

 
3

 
1

 
—

Expected return on plan assets
(8
)
 
(7
)
 
(12
)
 
(11
)
 
(1
)
 
(1
)
Amortization:
 
 
 
 
 
 
 
 
 
 
 
Actuarial losses
1

 
—

 
12

 
9

 
1

 
1

Prior service credits
—

 
—

 
—

 
—

 
(2
)
 
(2
)
Total net plan costs
$
(3
)
 
$
(2
)
 
$
9

 
$
7

 
$
(1
)
 
$
(2
)

 
 
 
 
 
 
 
 
 
 
 
 

The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.

We made no contributions to our U.S. defined benefit plans during the three months ended January 31, 2020. We contributed $5 million to our non-U.S. defined benefit plans during the three months ended January 31, 2020.

We made no contributions to our U.S. defined benefit plans during the three months ended January 31, 2019. We contributed $6 million to our non-U.S. defined benefit plans during the three months ended January 31, 2019.

We do not expect to contribute to our U.S. defined benefit plans during the remainder of 2020 and we expect to contribute $19 million to our non-U.S. defined benefit plans during the remainder of 2020.


25
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







14. WARRANTIES AND CONTINGENCIES
 
Warranties
 
We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product.
 
A summary of the standard warranty accrual activity is shown in the table below:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Beginning balance as of November 1,
$
32

 
$
35

Accruals for warranties including change in estimate
12

 
13

Settlements made during the period
(14
)
 
(16
)
Ending balance as of January 31,
$
30


$
32

 
 
 
 
Accruals for warranties due within one year
$
30

 
$
32

 
Bank Guarantees

Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $40 million as of January 31, 2020 and October 31, 2019. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss.

Contingencies
 
We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable and reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

15. SHORT-TERM DEBT
 
Credit Facilities
 
On March 13, 2019, Agilent entered into a credit agreement with a group of financial institutions which provided for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. For the three months ended January 31, 2020, we borrowed $432 million and repaid $372 million under the credit facility. As of January 31, 2020, the company had borrowings of $175 million outstanding under the credit facility. We were in compliance with the covenants for the credit facility during the three months ended January 31, 2020. On August 7, 2019, we entered into an amendment to the credit agreement, which provided for a $500 million short-term loan facility that was used in full to complete the BioTek acquisition and which is outstanding at January 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental loan facilities as of January 31, 2020.


26
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







16. LONG-TERM DEBT
 
Senior Notes
 
The following table summarizes the company’s long-term senior notes:
 
 
January 31, 2020
 
October 31, 2019
 
Amortized
Principal
 
Amortized
Principal
 
 
2022 Senior Notes
$
399

 
$
399

2023 Senior Notes
597

 
597

2026 Senior Notes
298

 
298

2029 Senior Notes
493

 
492

Total
$
1,787

 
$
1,786


All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. There have been no changes to the principal, maturity, interest rates and interest payment terms of the Agilent senior notes, detailed in the table above, in the three months ended January 31, 2020 as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2019.

17. STOCKHOLDERS' EQUITY
 
Stock Repurchase Program
 
On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the three months ended January 31, 2020, we repurchased and retired approximately 725,827 shares for $60 million under this authorization. During the three months ended January 31, 2019, we repurchased and retired approximately 1.1 million shares for $75 million under this authorization. As of January 31, 2020, we had remaining authorization to repurchase up to $967 million of our common stock under this program.

 
Cash Dividends on Shares of Common Stock
 
During the three months ended January 31, 2020, we paid cash dividends of $0.180 per common share or $56 million on the company's common stock. During the three months ended January 31, 2019, we paid cash dividends of $0.164 per common share or $52 million on the company's common stock.



27
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions):
 
 
 
 
Net defined benefit pension cost and post retirement plan costs
 
 
 
 
Three Months Ended January 31, 2020
 
Foreign currency translation
 
Prior service credits
 
Actuarial Losses
 
Unrealized gains (losses) on derivatives
 
Total
 
 
(in millions)
As of October 31, 2019
 
$
(204
)
 
$
131

 
$
(437
)
 
$
(4
)
 
$
(514
)
 
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
 
(11
)
 
—

 
(5
)
 
1

 
(15
)

 
 
 
 
 
 
 
 
 
 
Amounts reclassified out of accumulated other comprehensive income (loss)
 
—

 
(2
)
 
14

 
—

 
12


 
 
 
 
 
 
 
 
 
 
Tax expense
 
—

 
(1
)
 
(3
)
 
—

 
(4
)

 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss)
 
(11
)
 
(3
)
 
6

 
1

 
(7
)

 
 
 
 
 
 
 
 
 
 
As of January 31, 2020
 
$
(215
)
 
$
128

 
$
(431
)
 
$
(3
)
 
$
(521
)
 
 
 
 
 
 
 
 
 
 
 


Reclassifications out of accumulated other comprehensive income (loss) for the three months ended January 31, 2020 and 2019 were as follows (in millions):
Details about accumulated other
comprehensive income (loss) components
 
Amounts Reclassified from
other comprehensive income (loss)
 
Affected line item in
statement of operations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
January 31,
 
 
 
 
2020

2019
 
 
 
 



 
 
Unrealized gain (loss) on derivatives
 
$
—


$
5

 
Cost of products
 
 
—


5

 
Total before income tax
 
 
—


(1
)
 
Provision for income tax
 
 
—


4

 
Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
 



 
 
 
 



 
 
Actuarial net loss
 
(14
)

(10
)
 
 
Prior service benefit
 
2


2

 
 
 
 
(12
)

(8
)
 
Total before income tax
 
 
6


4

 
Benefit for income tax
 
 
(6
)

(4
)
 
Total net of income tax
 
 



 
 
Total reclassifications for the period
 
$
(6
)

$
—

 
 


Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss).

Reclassifications out of accumulated other comprehensive income (loss) of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost together with curtailments and settlements (see Note 13, "Retirement Plans and Post Retirement Pension Plans").

28
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)








18. SEGMENT INFORMATION
 
Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments.
A description of our three reportable segments is as follows:

Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.

Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples.  Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.

A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of

29
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







acquisition-related intangible assets, transformational initiatives expenses, acquisition and integration costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations and in-sourcing or outsourcing of activities.

The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.

The profitability of each of the segments is measured after excluding transformational initiatives, acquisition and integration costs, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below:
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Net Revenue:
 
 
 
Life Sciences and Applied Markets
$
638

 
$
607

Diagnostics and Genomics
249

 
235

Agilent CrossLab
470

 
442

Total net revenue
$
1,357

 
$
1,284

 
 
 
 
Segment Income From Operations:


 


Life Sciences and Applied Markets
$
158

 
$
159

Diagnostics and Genomics
34

 
33

Agilent CrossLab
119

 
105

Total segment income from operations
$
311

 
$
297



The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Total reportable segments’ income from operations
$
311

 
$
297

Transformational initiatives
(13
)
 
(5
)
Amortization of intangible assets related to business combinations
(48
)
 
(28
)
Acquisition and integration costs
(13
)
 
(10
)
NASD site costs
—

 
(2
)
Other(1)
(22
)
 
(2
)
Interest income
3

 
10

Interest expense
(20
)
 
(18
)
Other income (expense), net
21

 
6

Income before taxes, as reported
$
219

 
$
248


(1) The other category primarily includes legal costs related to our pursuing our claim against a third party in addition to other miscellaneous adjustments and settlements.


30
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)







The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  
 
January 31,
2020
 
October 31,
2019
 
(in millions)
Segment Assets:
 
 
 
Life Sciences and Applied Markets
$
3,187

 
$
3,202

Diagnostics and Genomics
2,612

 
2,620

Agilent CrossLab
1,360

 
1,331

Total segment assets
$
7,159

 
$
7,153


 
19. SUBSEQUENT EVENT


In February 2020, the company reached a settlement agreement with Twist Bioscience Corporation ("Twist") under which Twist has agreed to pay us $22.5 million to settle our intellectual property claim against Twist. The settlement agreement provides a license to Twist for discrete aspects of Agilent’s oligo-synthesis technology and successfully resolves all outstanding litigation between all parties.





31

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (UNAUDITED)
 
The following discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included elsewhere in this Form 10-Q and our Annual Report on Form 10-K. This report contains forward-looking statements including, without limitation, statements regarding growth opportunities, including for revenue and our end markets, strength and drivers of the markets we sell into, sales funnels, our strategic direction, new product and service introductions and the position of our current products and services, market demand for and adoption of our products, the ability of our products and solutions to address customer needs and meet industry requirements, our focus on differentiating our product solutions, improving our customers’ experience and growing our earnings, future financial results, our operating margin, mix, our investments, including in manufacturing infrastructure, research and development and expanding and improving our applications and solutions portfolios, expanding our position in developing countries and emerging markets, our focus on balanced capital allocation, our contributions to our pension and other defined benefit plans, impairment of goodwill and other intangible assets, the effect of the U.S. and other tariffs, the impact of foreign currency movements, our hedging programs and other actions to offset the effects of tariffs and foreign currency movements, our future effective tax rate, tax valuation allowance and unrecognized tax benefits, the impact of local government regulations on our ability to pay vendors or conduct operations, our ability to satisfy our liquidity requirements, including through cash generated from operations, the potential impact of adopting new accounting pronouncements, indemnification, source and supply of materials used in our products, our sales, our purchase commitments, our capital expenditures, the integration and effects of our acquisitions and other transactions, the effects of the public health crisis in China and worldwide and our stock repurchase program and dividends that involve risks and uncertainties. Our actual results could differ materially from the results contemplated by these forward-looking statements due to various factors, including those discussed in Part II Item 1A and elsewhere in this Form 10-Q.

Basis of Presentation
 
The financial information presented in this Form 10-Q is not audited and is not necessarily indicative of our future consolidated financial position, results of operations, comprehensive income (loss) or cash flows. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal periods.
 
Executive Summary
 
Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Net revenue of $1,357 million for the three months ended January 31, 2020 increased 6 percent when compared to the same period last year. In January 2020, net revenue was negatively impacted due to the public health crisis in China and the extension of the Lunar New Year resulting in fewer selling days in the month. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of less than 1 percentage point when compared to the same period last year. Revenue generated by our life sciences and applied markets business for the three months ended January 31, 2020 increased 5 percent when compared to the same period last year. Revenue from our recent acquisitions contributed approximately 8 percentage points to our life sciences and applied markets business revenue growth in the three months ended January 31, 2020. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of less than 1 percentage point when compared to the same period last year. Revenue generated by our diagnostics and genomics business for the three months ended January 31, 2020 increased 6 percent when compared to the same period last year. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of 1 percentage point when compared to the same period last year. Revenue generated by our Agilent CrossLab business in the three months ended January 31, 2020 increased 6 percent when compared to the same period last year. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of 1 percentage point when compared to the same periods last year.

Net income for the three months ended January 31, 2020 was $197 million compared to net income of $504 million for the corresponding period last year. Net income for the three months ended January 31, 2019 was impacted by a discrete tax benefit of $299 million related to the extension of the company’s tax incentive in Singapore. In the three months ended January 31, 2020, cash used in operations was $59 million which includes an one-time tax outflow of $226 million related to a transfer of intangibles compared to cash generated from operations of $213 million in the same period last year.


32

For the three months ended January 31, 2020 and 2019, cash dividends of $56 million and $52 million, respectively, were paid on the company's outstanding common stock.

On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the three months ended January 31, 2020, we repurchased and retired approximately 725,827 shares for $60 million under this authorization. During the three months ended January 31, 2019, we repurchased and retired approximately 1.1 million shares for $75 million under this authorization. As of January 31, 2020, we had remaining authorization to repurchase up to $967 million of our common stock under this program.

Looking forward, we continue to focus on differentiating product solutions, improving our customers' experience, continued growth and earnings expansion. Based on current information, we expect the recent public health crisis that started in China and has grown worldwide will reduce business results in the first half of fiscal year 2020, but despite the short-term uncertainty caused by this health crisis, we remain optimistic about our long-term growth opportunities. In addition, we remain focused on a balanced capital allocation through our dividend and share repurchase programs. We expect foreign currency to negatively impact revenue for 2020 but we also anticipate the contribution from our acquisitions in fiscal year 2019 to partially offset the currency impact.

Critical Accounting Policies and Estimates
 
Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. The preparation of condensed consolidated financial statements in conformity with GAAP in the U.S. requires management to make estimates, judgments and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, share-based compensation, retirement and post-retirement benefit plan assumptions, goodwill and purchased intangible assets and accounting for income taxes. There have been no significant changes to our critical accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2019. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates.

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made and if different estimates that reasonably could have been used or changes in the accounting estimate that are reasonably likely to occur could materially change the financial statements.

Adoption of New Pronouncements
 
See Note 2, “New Accounting Pronouncements,” to the condensed consolidated financial statements for a description of new accounting pronouncements.
 
Foreign Currency
 
Our revenues, costs and expenses, and monetary assets and liabilities and equity are exposed to changes in foreign currency exchange rates as a result of our global operating and financing activities. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of less than 1 percentage point when compared to the same period last year. When movements in foreign currency exchange rates have a negative impact on revenue it will also have a positive impact by reducing our costs and expenses. We calculate the impact of foreign currency exchange rates movements by applying the actual foreign currency exchange rates in effect during the last month of each quarter of the current year to both the applicable current and prior year periods. We hedge revenues, expenses and balance sheet exposures that are not denominated in the functional currencies of our subsidiaries on a short term and anticipated basis. We do experience some fluctuations within individual lines of the condensed consolidated statement of operations and balance sheet because our hedging program is not designed to offset the currency movements in each category of revenues, expenses, monetary assets and liabilities. Our hedging program is designed to hedge currency movements on a relatively short-term basis (up to a rolling twelve-month period). We may also hedge equity balances denominated in foreign currency on a long term basis.To the extent that we are required to pay for all, or portions, of an

33

acquisition price in foreign currencies, we may enter into foreign exchange contracts to reduce the risk that currency movements will impact the U.S. dollar cost of the transaction.
 
Results from Operations

Net Revenue
  
 
Three Months Ended

Year over Year Change
 
January 31,

Three
 
2020

2019

Months
 
(in millions)
 
 
Net revenue:
 
 
 
 
 
Products
$
1,023

 
$
980

 
4%
Services and other
334

 
304

 
10%
Total net revenue
$
1,357


$
1,284


6%
 
Net revenue of $1,357 million for the three months ended January 31, 2020 increased 6 percent when compared to the same period last year. Revenue from our acquisitions in fiscal year 2019 contributed approximately 4 percentage points to our revenue growth in the three months ended January 31, 2020. In January 2020, net revenue was negatively impacted due to the public health crisis in China and the extension of the Lunar New Year resulting in fewer selling days in the month. Foreign currency movements for the three months ended January 31, 2020 had an unfavorable impact on revenue of less than 1 percentage point when compared to the same period last year.

Revenue from products increased 4 percent for the three months ended January 31, 2020 when compared to the same period last year. The growth in product revenue was driven by increased sales within our cell analysis business, mainly due to contributions from our recent acquisitions. Excluding recent acquisitions, life science and applied markets revenue from products decreased approximately 2 percent.

Services and other revenue increased 10 percent for the three months ended January 31, 2020 when compared to the same period last year. Services and other revenue consists of revenue generated from our three business segments; Agilent CrossLab, diagnostics and genomics and our life science and applied markets business. Some of the prominent services in the Agilent CrossLab business include repair and maintenance on multi-vendor instruments, compliance services and installation services. Services in the diagnostics and genomics business include consulting services related to the companion diagnostics and nucleic acid businesses. Services in the life science and applied markets business include repair and maintenance and installation services.

For the three months ended January 31, 2020, the service revenue from the Agilent CrossLab business increased 8 percent with a less than 1 percentage point unfavorable currency impact on revenue when compared to the same period last year. The growth in the service revenue from the Agilent CrossLab business was driven by strong growth in the Asia Pacific region. From a service portfolio perspective, the growth came from a wide range of service offerings.

For the three months ended January 31, 2020, the service revenue from the diagnostics and genomics business increased 5 percent when compared to the same period last year. The increase in diagnostics and genomics service revenue reflects growth in the pathology and companion diagnostics service businesses.

For the three months ended January 31, 2020, the service revenue from the life sciences and applied markets business increased significantly when compared to the same period last year. The increase in life sciences and applied markets service revenue is primarily due to the additional service revenue within the cell analysis business due to our recent acquisitions.



34

Net Revenue By Segment

 
 
Three Months Ended
 
Year over Year Change
 
 
January 31,
 
Three
 
 
2020
 
2019
 
Months
 
 
(in millions)
 
 
Net revenue by segment:
 
 
 
 
 
 
Life sciences and applied markets
 
$
638

 
$
607

 
5%
Diagnostics and genomics
 
249

 
235

 
6%
Agilent CrossLab
 
470

 
442

 
6%
Total net revenue
 
$
1,357

 
$
1,284

 
6%

Revenue in the life sciences and applied markets business for the three months ended January 31, 2020, increased 5 percent when compared to the same period last year. However, our instrumentation revenue has decreased mainly due to current subdued demand. Revenue from our recent acquisitions contributed approximately 8 percentage points to our revenue growth in the three months ended January 31, 2020. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of less than 1 percentage point when compared to the same period last year. For the three months ended January 31, 2020, revenue growth within the academia and government, diagnostics and clinical and pharmaceutical markets was strong which was partially offset by declines in revenue from the food market when compared to the same period last year.

Revenue in the diagnostics and genomics business for the three months ended January 31, 2020, increased 6 percent when compared to the same period last year. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of 1 percentage point when compared to the same period last year. For the three months ended January 31, 2020, revenue growth within the diagnostics and clinical market and the pharmaceutical market continued to be strong led by performance from our pathology, biomolecular analysis and our nucleic acid solutions businesses.

Revenue generated by Agilent CrossLab in the three months ended January 31, 2020, increased 6 percent when compared to the same period last year. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of 1 percentage point when compared to the same period last year. For the three months ended January 31, 2020, revenue growth was strong across all key end markets. Revenue growth was driven broadly by our entire services and consumables portfolio.

Operating Results
 
 

Three Months Ended

Year over Year Change
 

January 31,

Three
 

2020

2019

Months
(in millions, except margin data)
 
 
 
 
 
 
Total gross margin

53.3
%

55.1
%

(2) ppts
Research and development

$
104


$
102


1%
Selling, general and administrative

$
404


$
355


14%
Operating margin
 
15.9
%
 
19.5
%
 
(4) ppts
 
Total gross margin for the three months ended January 31, 2020 decreased 2 percentage points when compared to the same period last year. Gross margin for the three months ended January 31, 2020 reflects unfavorable product mix, higher intangible amortization expense and higher fixed costs related to the new manufacturing facility in Frederick, Colorado, partially offset by favorable currency impact.

Research and development expenses for the three months ended January 31, 2020 increased 1 percent when compared to the same period last year. Research and development expenses for the three months ended January 31, 2020 increased due to higher wages and additional expenses related to recent acquisitions partially offset by operational savings and favorable currency impact.
 
Selling, general and administrative expenses for the three months ended January 31, 2020 increased 14 percent when compared to the same period last year. The increase in selling, general and administrative expenses for the three months ended

35

January 31, 2020 was due to higher wages, higher intangible amortization expense, higher acquisition and integration costs, higher transformation initiative expenses and higher legal costs in connection with our claim against a third party.

Total operating margin for the three months ended January 31, 2020 decreased 4 percentage points when compared to the same period last year. Operating margin for the three months ended January 31, 2020 was impacted by higher wages, higher acquisition-related expenses, higher transformation initiatives and increased legal costs associated with our claim against a third party.

At January 31, 2020, our headcount was approximately 16,300 as compared to approximately 15,300 at January 31, 2019.

Other income (expense), net

In the three months ended January 31, 2020 and 2019, other income (expense), net, includes $3 million of income in both periods related to the provision of site service costs to, and lease income from Keysight Technologies, Inc. The costs associated with these services are reported within income from operations. Also included in other income (expense), net for the three months ended January 31, 2020 is a gain on the fair value of an equity investment of approximately $16 million.
 
Income Taxes
 
For the three months ended January 31, 2020, the company's income tax expense was $22 million with an effective tax rate of 10.0 percent. For the three months ended January 31, 2020, our effective tax rate and the resulting provision for income taxes were significantly impacted by a discrete benefit of $13 million related to the excess tax benefits from stock-based compensation.

For the three months ended January 31, 2019, the company's income tax benefit was $256 million with an effective tax rate of (103.2) percent. For the three months ended January 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by a discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore. The income taxes for the three months ended January 31, 2019 also includes the excess tax benefits of $4 million from stock-based compensation.

In the U.S., tax years remain open back to the year 2016 for federal income tax purposes and the year 2015 for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009.

It is reasonably possible there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits. The company will continue to assess the impact of the further guidance from federal and state tax authorities on its business and consolidated financial statements. Any future adjustments will be recognized as discrete income tax expense or benefit in the period the adjustments are determined.

Segment Overview

We continue to have three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business.

Life Sciences and Applied Markets

Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.


36


Net Revenue

 
 
Three Months Ended
 
Year over Year Change
 
 
January 31,
 
Three
 
 
2020
 
2019
 
Months
 
 
(in millions)
 
 
 
 
 
 
 
 
 
Net revenue
 
$
638

 
$
607

 
5%

Life sciences and applied markets business revenue for the three months ended January 31, 2020 increased 5 percent when compared to the same period last year. Overall, foreign currency movements for the three months ended January 31, 2020 had an unfavorable impact of less than 1 percentage point on revenue when compared to the same period last year. Revenue from our acquisitions in fiscal year 2019 contributed approximately 8 percentage points to our revenue growth in the three months ended January 31, 2020. Geographically, revenue increased 23 percent in the Americas with a 1 percentage point unfavorable currency impact, increased 2 percent in Europe with a 1 percentage point unfavorable currency impact and decreased 4 percent in Asia Pacific with no currency impact for the three months ended January 31, 2020 compared to the same period last year. Excluding recent acquisitions and currency impact, revenue decreased 2 percent during the three months ended January 31, 2020. Weaker sales in liquid chromatography, gas chromatography and vacuum were partially offset by increased revenue in liquid chromatography mass spectrometry, informatics and cell analysis products when compared to the same period last year.

For the three months ended January 31, 2020, revenue results by end markets were mixed with the pharmaceutical, academia and government, diagnostics and clinical and environmental markets delivering strong revenue growth partially offset by weakness in the food and forensics markets. Revenue growth in the pharmaceutical, academia and government and diagnostics and clinical markets was entirely driven by strong performance of our cell analysis products, which includes products from the Lionheart Technologies LLC ("BioTek") acquisition.

Looking forward, despite short term uncertainties, we are optimistic about our long-term growth opportunities in the life sciences and applied markets as our broad portfolio of products and solutions are well suited to address customer needs. We anticipate strong growth from our new product introductions and recent acquisitions as we continue to invest in expanding and improving our applications and solutions portfolio. While we anticipate volatility in our markets, we expect continued growth across most end markets in the long term.

Operating Results


Three Months Ended

Year over Year Change


January 31,

Three


2020

2019

Months
(in millions, except margin data)
 
 
 
 
 
 
Gross margin

60.2
%
 
62.1
%
 
(2) ppts
Research and development

$
55

 
$
56

 
(2)%
Selling, general and administrative

$
171

 
$
162

 
5%
Operating margin
 
24.8
%
 
26.1
%
 
(1) ppt

Gross margin for products and services for the three months ended January 31, 2020, decreased 2 percentage points when compared to the same period last year. Gross margin for the three months ended January 31, 2020 was impacted by the increased impact of pricing pressures and lower volume partially offset by favorable currency impact.

Research and development expenses for the three months ended January 31, 2020, decreased 2 percent when compared to the same period last year. Research and development for the three months ended January 31, 2020 was impacted by operational savings and favorable currency impact partially offset by additional expenses related to our recent acquisitions as well as higher wages and benefits.

Selling, general and administrative expenses for the three months ended January 31, 2020, increased 5 percent when compared to the same period last year. Selling, general and administrative expenses for the three months ended January 31, 2020 was impacted by higher wages and benefits and additional expenses related to our recent acquisitions partially offset by operational savings and a favorable currency impact.

37


Operating margin for products and services for the three months ended January 31, 2020 decreased 1 percentage point when compared to the same period last year. The decrease in operating margin was due to additional expenses related to our recent acquisitions and unfavorable product mix partially offset by modest revenue growth.

Income from Operations

Income from operations for the three months ended January 31, 2020, decreased $1 million on a corresponding revenue increase of $31 million.

Diagnostics and Genomics

Our diagnostics and genomics business includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses.

Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples.  Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.

Net Revenue

 
 
Three Months Ended
 
Year over Year Change
 
 
January 31,
 
Three
 
 
2020
 
2019
 
Months
 
 
(in millions)
 
 
 
 
 
 
 
 
 
Net revenue
 
$
249

 
$
235

 
6%

Diagnostics and genomics business revenue for the three months ended January 31, 2020 increased 6 percent when compared to the same period last year. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of 1 percentage point when compared to the same period last year. Geographically, revenue increased 9 percent in the Americas with no currency impact, increased 1 percent in Europe with a 2 percentage point unfavorable currency impact and increased 11 percent in Asia Pacific with no currency impact for the three months ended January 31, 2020 compared to the same period last year. For the three months ended January 31, 2020, the growth in Americas was driven by strong performance in the nucleic acid solutions, companion diagnostics and reagent partnership businesses. The performance in Europe was driven by the biomolecular analysis and reagent partnership businesses. Asia Pacific growth was mainly driven by the pathology and biomolecular analysis businesses.
 
For the three months ended January 31, 2020, revenue growth in the diagnostics and genomics business was led by strong revenue performance in our nucleic acid solutions and reagent partnership businesses. The diagnostics and clinical research end markets remain strong and growing driven by an aging population and lifestyle developments such as poor diet and physical inactivity.

38


Looking forward, we are optimistic about our growth opportunities in our end markets and continue to invest in expanding and improving our applications and solutions portfolio. We remain positive about our growth in our end markets, as our product portfolio around OMNIS, PD-L1 assays and SureFISH, continue to gain strength with our customers in clinical oncology applications and our next generation sequencing target enrichment solutions continue to be adopted. Market demand in the nucleic acid solutions business related to therapeutic oligo programs continues to be strong and, with our newly opened nucleic acid solutions production facility in Frederick, we are well positioned to serve more of the market demand. We will continue to invest in research and development and seek to expand our position in developing countries and emerging markets.

Operating Results

 
 
Three Months Ended
 
Year over Year Change
 
 
January 31,
 
Three
 
 
2020
 
2019
 
Months
(in millions, except margin data)
 
 
 
 
 
 
Gross margin
 
51.7
%
 
54.0
%
 
(2) ppts
Research and development
 
$
32

 
$
31

 
3%
Selling, general and administrative
 
$
63

 
$
63

 
—
Operating margin
 
13.5
%
 
14.0
%
 
(1) ppt

Gross margin for products and services for the three months ended January 31, 2020, decreased 2 percentage points when compared to the same period last year. Gross margin in the three months ended January 31, 2020 was impacted by higher fixed costs related to the new manufacturing facility in Frederick, Colorado.

Research and development expenses for the three months ended January 31, 2020, increased 3 percent when compared to the same period last year. Research and development for the three months ended January 31, 2020 was impacted by increased spending around the development of clinical applications and solutions and higher wages and benefits.

Selling, general and administrative expenses for the three months ended January 31, 2020, was flat when compared to the same period last year. Selling general and administrative expenses for the three months ended January 31, 2020 was impacted by higher wages and benefits offset by savings in discretionary spending.

Operating margin for products and services for the three months ended January 31, 2020 decreased 1 percentage point when compared to the same period last year. The decrease in operating margin for the three months ended January 31, 2020 was mainly due to higher wages and benefits and the gross margin deterioration more than offsetting gains from higher revenue.

Income from Operations

Income from operations for the three months ended January 31, 2020 increased $1 million on a corresponding revenue increase of $14 million.
 
Agilent CrossLab

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.



39

Net Revenue

 
 
Three Months Ended
 
Year over Year Change
 
 
January 31,
 
Three
 
 
2020
 
2019
 
Months
 
 
(in millions)
 
 
 
 
 
 
 
 
 
Net revenue
 
$
470

 
$
442

 
6%

Agilent CrossLab business revenue for the three months ended January 31, 2020 increased 6 percent when compared to the same period last year. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of 1 percentage point when compared to the same period last year. Geographically, revenue increased 6 percent in the Americas with no currency impact, increased 4 percent in Europe with a 1 percentage point unfavorable currency impact and increased 8 percent in Asia Pacific with a 1 percentage point unfavorable currency impact for the three months ended January 31, 2020 compared to the same period last year. During the three months ended January 31, 2020, revenue growth was driven by strong revenue growth in the overall service portfolio, while the consumables portfolio had moderate revenue growth.

For the three months ended January 31, 2020, the Agilent CrossLab business saw the strongest growth coming from the food market, as well as strong growth from our largest market segment, the pharmaceutical market. The other major market segments all saw moderate growth for the three months ended January 31, 2020 when compared to the same period last year.

Looking forward, we anticipate strength in key end markets will continue to drive our revenue growth in the near term. The Agilent CrossLab portfolio of products and services capabilities are well positioned to succeed in changing market conditions in our key end markets. Geographically, the business is well diversified across all regions to swiftly take advantage of local market opportunities and to help hedge against market volatility in any one region. Despite the short-term logistical hurdle against delivering service caused by the health crisis closing off access to certain customer sites in a few countries, we remain optimistic about the long-term growth opportunities of the global service business. Other factors for near term revenue growth include continued expansion of digital capabilities and leveraging of our deep understanding of customer workflows.


Operating Results

 
 
Three Months Ended
 
Year over Year Change
 
 
January 31,
 
Three
 
 
2020
 
2019
 
Months
(in millions, except margin data)
 
 
 
 
 
 
Gross margin
 
51.8
%
 
51.3
%
 
1 ppt
Research and development
 
$
15

 
$
15

 
—
Selling, general and administrative
 
$
109

 
$
107

 
2%
Operating margin
 
25.4
%
 
23.9
%
 
2 ppts

Gross margin for products and services for the three months ended January 31, 2020 increased 1 percentage point when compared to the same period last year. This margin increase was a result of the higher sales volume partially offset by higher tariffs on service parts and consumables and by an unfavorable product mix impact in the consumables business.

Research and development expenses for the three months ended January 31, 2020 was relatively flat when compared to the same period last year.

Selling, general and administrative expenses for the three months ended January 31, 2020 increased 2 percent when compared to the same period last year. The increase was primarily due to higher orders driving higher selling costs, as well as higher wages and benefits.

Operating margin for products and services for the three months ended January 31, 2020 increased 2 percentage points when compared to the same period last year. The improvement was driven by strong growth in revenues combined with a slower growth in operating expenses.

40


Income from Operations

Income from operations for the three months ended January 31, 2020 increased $14 million on a corresponding revenue increase of $28 million.

FINANCIAL CONDITION
 
Liquidity and Capital Resources
 
Our financial position as of January 31, 2020 consisted of cash and cash equivalents of $1,226 million as compared to $1,382 million as of October 31, 2019.

As of January 31, 2020, $1,164 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries and can be repatriated to the U.S. as local working capital and other regulatory conditions permit. We utilize a variety of funding strategies to ensure that our worldwide cash is available in the locations in which it is needed.

We believe our cash and cash equivalents, cash generated from operations, and ability to access capital markets and credit lines will satisfy, for at least the next twelve months, our liquidity requirements, both globally and domestically, including the following: working capital needs, capital expenditures, business acquisitions, stock repurchases, cash dividends, contractual obligations, commitments, principal and interest payments on debt, and other liquidity requirements associated with our operations.
 
Net Cash Provided by Operating Activities
 
Net cash outflow from operating activities was $59 million for the three months ended January 31, 2020 compared to cash inflow of $213 million for the same period in 2019. In the three months ended January 31, 2020 and 2019, we paid approximately $79 million under our variable and incentive pay programs in both periods. Net cash paid for income taxes was approximately $241 million which included a one-time payment of $226 million related to the transfer of intellectual property compared to income taxes paid of $21 million in the prior year. For the three months ended January 31, 2020, deferred tax cash inflows was $10 million compared to cash outflows of $281 million in the prior year. Deferred tax outflows in 2019 included $266 million related to the extension of the company's tax incentive in Singapore. For the three months ended January 31, 2020, there was an unrealized gain on the fair value of an equity investment of $16 million. For the three months ended January 31, 2020, other assets and liabilities had cash outflow of $195 million compared to cash inflow of $26 million for the same period in 2019. Cash outflow in the three months ended January 31, 2020 was largely the result of increased income tax payments, interest payments on senior notes and changes in deferred revenue. Cash inflow for the three months ended January 31, 2019 in other assets and liabilities was related to changes in non-U.S. transaction tax receivables and deferred revenue.
 
In the three months ended January 31, 2020, accounts receivable used cash of $40 million compared to cash used of $22 million for the same period in 2019.  Days’ sales outstanding as of January 31, 2020 and 2019 was 64 days and 58 days, respectively. Accounts payable used cash of $15 million for the three months ended January 31, 2020 compared to cash used of $16 million in the same period in 2019. Cash used for inventory was $32 million for the three months ended January 31, 2020 compared to cash used of $12 million for the same period in 2019. Inventory days on-hand was 100 days as of January 31, 2020 compared to 102 days as of January 31, 2019.

We contributed approximately $5 million to our defined benefit plans in both the three months ended January 31, 2020 and 2019. Our annual contributions are highly dependent on the relative performance of our assets versus our projected liabilities, among other factors. We expect to contribute approximately $19 million to our defined benefit plans during the remainder of 2020.
 
Net Cash Used in Investing Activities
 
Net cash used in investing activities was $35 million for the three months ended January 31, 2020 as compared to net cash used in investing activities of $290 million in the same period of 2019. Investments in property, plant and equipment were $34 million for the three months ended January 31, 2020 compared to $39 million in the same period of 2019. We expect that total capital expenditures for the current year will be approximately $180 million. In the three months ended January 31, 2019, we invested $248 million in our acquisition of ACEA.


41

Net Cash Used in Financing Activities
 
Net cash used in financing activities for the three months ended January 31, 2020 was $61 million compared to net cash used in financing activities of $122 million for the same period of 2019.
 
Treasury Stock Repurchases

On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the three months ended January 31, 2020, we repurchased and retired approximately 725,827 shares for $60 million under this authorization. During the three months ended January 31, 2019, we repurchased and retired approximately 1.1 million shares for $75 million under this authorization. As of January 31, 2020, we had remaining authorization to repurchase up to $967 million of our common stock under this program.

Dividends

During the three months ended January 31, 2020 and 2019, we paid cash dividends of $0.180 per common share or $56 million and $0.164 per common share or $52 million, respectively, on the company's common stock.

Credit Facilities and Short Term Debt
 
Credit Facilities. On March 13, 2019, Agilent entered into a credit agreement with a group of financial institutions which provided for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. For the three months ended January 31, 2020, we borrowed $432 million and repaid $372 million under the credit facility. As of January 31, 2020, the company had borrowings of $175 million outstanding under the credit facility. We were in compliance with the covenants for the credit facility during the three months ended January 31, 2020. On August 7, 2019, we entered into an amendment to the credit agreement, which provided for a $500 million short-term loan facility that was used in full to complete the BioTek acquisition and which is outstanding at January 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental loan facilities as of January 31, 2020.

Long-term debt

There have been no other changes to the principal, maturity, interest rates and interest payment terms of the Agilent outstanding senior notes in the three months ended January 31, 2020 as compared to the senior notes as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2019.

Other

There were no other substantial changes from our Annual Report on Form 10-K for the fiscal year ended October 31, 2019 to our contractual commitments in the first three months of fiscal 2020. We have contractual commitments for non-cancelable operating leases see Note 9, "Leases" for more information. We have no other material non-cancelable guarantees or commitments.

Other long-term liabilities as of January 31, 2020 and October 31, 2019 include $333 million and $328 million, respectively, related to long-term income tax liabilities. Of these amounts, $204 million and $199 million related to uncertain tax positions of continuing operations as of January 31, 2020 and October 31, 2019, respectively. We are unable to accurately predict when these amounts will be realized or released. However, it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitations or a tax audit settlement. The remaining $129 million in other long-term liabilities relates to the one-time transition tax payable.


42

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
We are exposed to foreign currency exchange rate risks inherent in our sales commitments, anticipated sales, and assets and liabilities and equity denominated in currencies other than the functional currency of our subsidiaries. We hedge future cash flows denominated in currencies other than the functional currency using sales forecasts up to twelve months in advance. Our exposure to exchange rate risks is mainlymanaged on an enterprise-wide basis. This strategy utilizes derivative financial instruments, including option and forward contracts, to hedge certain foreign currency exposures with the intent of offsetting gains and losses that occur on the underlying exposures with gains and losses on the derivative contracts hedging them. We may also hedge equity balances denominated in foreign currency on a long term basis. We do not currently and do not intend to utilize derivative financial instruments for speculative trading purposes. To the extent that we are required to pay for all, or portions, of an acquisition price in foreign currencies, we may enter into foreign exchange contracts to reduce the risk that currency movements will impact the cost of the transaction.
 
Our operations generate non-functional currency cash flows such as revenues, third party vendor payments and inter-company payments. In anticipation of these foreign currency cash flows and in view of volatility of the currency market, we enter into such foreign exchange contracts as are described above to manage our currency risk. Approximately 50 percent and 49 percent of our revenue was generated in U.S. dollars during the three months ended January 31, 2020 and 2019, respectively. The overall unfavorable effects of changes in foreign currency exchange rates, principally as a result of the strength of the U.S. dollar, has decreased revenue by less than 1 percentage point in the three months ended January 31, 2020. We calculate the impact of foreign currency exchange rates movements by applying the actual foreign currency exchange rates in effect during the last month of each quarter of the current year to both the applicable current and prior year periods.
 
We performed a sensitivity analysis assuming a hypothetical 10 percent adverse movement in foreign exchange rates to the hedging contracts and the underlying exposures described above. As of January 31, 2020, the analysis indicated that these hypothetical market movements would not have a material effect on our condensed consolidated financial position, results of operations, statement of comprehensive income or cash flows.
 
We are also exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments. We have issued long-term debt in U.S. dollars or foreign currencies at fixed interest rates based on the market conditions at the time of financing. We believe that the fair value of our fixed rate debt changes when the underlying market rates of interest change, and we may use interest rate swaps to modify such market risk.

We performed a sensitivity analysis assuming a hypothetical 10 percent adverse movement in interest rates relating to the underlying fair value of our fixed rate debt. As of January 31, 2020, the sensitivity analyses indicated that a hypothetical 10 percent adverse movement in interest rates would result in an immaterial impact to the fair value of our fixed interest rate debt.

ITEM 4. CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures
 
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by the Securities Exchange Act of 1934 (the "Exchange Act") Rule 13a-15(b) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective at ensuring that information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding such required disclosure to the SEC.


Changes in Internal Control over Financial Reporting
 
There were no changes in our internal control over financial reporting during the quarter ended January 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



43



PART II — OTHER INFORMATION
 
ITEM 1. LEGAL PROCEEDINGS
 
We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable or reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

ITEM 1A.  RISK FACTORS
 
Risks, Uncertainties and Other Factors That May Affect Future Results

Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated.

Visibility into our markets is limited. Our quarterly sales and operating results are highly dependent on the volume and timing of orders received during the fiscal quarter, which are difficult to forecast and may be cancelled by our customers. In addition, our revenue and earnings forecasts for future fiscal quarters are often based on the expected seasonality of our markets. However, the markets we serve do not always experience the seasonality that we expect as customer spending policies and budget allocations, particularly for capital items, may change. Any decline in our customers' markets or in general economic conditions would likely result in a reduction in demand for our products and services. Also, if our customers' markets decline, we may not be able to collect on outstanding amounts due to us. Such declines could harm our consolidated financial position, results of operations, cash flows and stock price, and could limit our profitability. Also, in such an environment, pricing pressures could intensify. Since a significant portion of our operating expenses is relatively fixed in nature due to sales, research and development and manufacturing costs, if we were unable to respond quickly enough these pricing pressures could further reduce our operating margins.

If we do not introduce successful new products and services in a timely manner to address increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards, our products and services may become obsolete, and our operating results may suffer.

We generally sell our products in industries that are characterized by increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards. Without the timely introduction of new products, services and enhancements, our products and services may become technologically obsolete over time, in which case our revenue and operating results could suffer. The success of our new products and services will depend on several factors, including our ability to:

•
properly identify customer needs and predict future needs;
•
innovate and develop new technologies, services and applications;
•
appropriately allocate our research and development spending to products and services with higher growth prospects;
•
successfully commercialize new technologies in a timely manner;
•
manufacture and deliver new products in sufficient volumes and on time;
•
differentiate our offerings from our competitors' offerings;
•
price our products competitively;
•
anticipate our competitors' development of new products, services or technological innovations; and
•
control product quality in our manufacturing process.


44

In addition, if we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest in research and development of products and services that do not lead to significant revenue, which would adversely affect our profitability. Even if we successfully innovate and develop new and enhanced products and services, we may incur substantial costs in doing so, and our operating results may suffer. In addition, promising new products may fail to reach the market or realize only limited commercial success because of real or perceived concerns of our customers. Furthermore, as we collaborate with pharmaceutical customers to develop drugs such as companion diagnostics assays or provide drug components like active pharmaceutical ingredients, we face risks that those drug programs may be cancelled upon clinical trial failures.

General economic conditions may adversely affect our operating results and financial condition.

Our business is sensitive to negative changes in general economic conditions, both inside and outside the United States. Slower global economic growth and uncertainty in the markets in which we operate may adversely impact our business resulting in:

•
reduced demand for our products, delays in the shipment of orders, or increases in order cancellations;
•
increased risk of excess and obsolete inventories;
•
increased price pressure for our products and services; and
•
greater risk of impairment to the value, and a detriment to the liquidity, of our investment portfolio.

Failure to adjust our purchases due to changing market conditions or failure to accurately estimate our customers' demand could adversely affect our income.

Our income could be harmed if we are unable to adjust our purchases to reflect market fluctuations, including those caused by the seasonal nature of the markets in which we operate. The sale of our products and services are dependent, to a large degree, on customers whose industries are subject to seasonal trends in the demand for their products. During a market upturn, we may not be able to purchase sufficient supplies or components to meet increasing product demand, which could materially affect our results. In the past, we have experienced a shortage of parts for some of our products. In addition, some of the parts that require custom design are not readily available from alternate suppliers due to their unique design or the length of time necessary for design work. Should a supplier cease manufacturing such a component, we would be forced to reengineer our product. In addition to discontinuing parts, suppliers may also extend lead times, limit supplies or increase prices due to capacity constraints or other factors. In order to secure components for the production of products, we may continue to enter into non-cancelable purchase commitments with vendors, or at times make advance payments to suppliers, which could impact our ability to adjust our inventory to declining market demands. If demand for our products is less than we expect, we may experience additional excess and obsolete inventories and be forced to incur additional expenses.

Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies.

Our customers include pharmaceutical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities, available resources, mergers and consolidations, institutional and governmental budgetary policies and spending priorities, and product and economic cycles, have a significant effect on the capital spending policies of these entities. Fluctuations in the research and development budgets at these organizations could have a significant effect on the demand for our products and services. Research and development budgets fluctuate due to changes in available resources, consolidation, spending priorities, general economic conditions and institutional and governmental budgetary policies. The timing and amount of revenue from customers that rely on government funding or research may vary significantly due to factors that can be difficult to forecast, including changes in spending authorizations and budgetary priorities for our products and services. If demand for our products and services is adversely affected, our revenue and operating results would suffer.


45

Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations.

Because we sell our products worldwide, our business is subject to risks associated with doing business internationally. We anticipate that revenue from international operations will continue to represent a majority of our total revenue. International revenue and costs are subject to the risk that fluctuations in foreign currency exchange rates could adversely affect our financial results when translated into U.S. dollars for financial reporting purposes. Foreign currency movements for the three months ended January 31, 2020 had an overall unfavorable impact on revenue of less than 1 percentage point when compared to the same period last year. When movements in foreign currency exchange rates have a negative impact on revenue, they will also have a positive impact by reducing our costs and expenses. In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:

•
interruption to transportation flows for delivery of parts to us and finished goods to our customers;
•
changes in a specific country's or region's political, economic or other conditions;
•
changes in diplomatic and trade relationships, such as the United Kingdom's exit from the European Union, including new tariffs, trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers;
•
tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs enacted and proposed by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods;
•
negative consequences from changes in or differing interpretations of laws and regulations, including those related to tax and import/export;
•
difficulty in staffing and managing widespread operations;
•
differing labor regulations;
•
differing protection of intellectual property;
•
unexpected changes in regulatory requirements;
•
geopolitical uncertainty or turmoil, terrorism and war; and
•
impact of public health crises, including pandemics and epidemics, such as COVID-19 on the global economy.

We sell our products into many countries and we also source many components and materials for our products from and manufacture our products in various countries. Future tariffs and tariffs already implemented could have negative impact on our business, results of operations and financial condition. It may be time-consuming and expensive for us to alter our business operations in order to adapt to any such change. Further, additional tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition.

Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivables and tax functions are centralized at locations in India and Malaysia. If conditions change in those countries, it may adversely affect operations, including impairing our ability to pay our suppliers and collect our receivables. Our results of operations, as well as our liquidity, may be adversely affected and possible delays may occur in reporting financial results.

In addition, although the majority of our products are priced and paid for in U.S. dollars, a significant amount of certain types of expenses, such as payroll, utilities, tax, and marketing expenses, are paid in local currencies. Our hedging programs reduce, but do not always entirely eliminate, within any given twelve-month period, the impact of currency exchange rate movements, and therefore fluctuations in exchange rates, including those caused by currency controls, could impact our business, operating results and financial condition by resulting in lower revenue or increased expenses. For expenses beyond that twelve-month period, our hedging strategy does not mitigate our exposure. In addition, our currency hedging programs involve third party financial institutions as counterparties. The weakening or failure of financial institution counterparties may adversely affect our hedging programs and our financial condition through, among other things, a reduction in available counterparties, increasingly unfavorable terms, and the failure of the counterparties to perform under hedging contracts.


46

Our strategic initiatives to adjust our cost structure could have long-term adverse effects on our business and we may not realize the operational or financial benefits from such actions.

We have implemented multiple strategic initiatives across our businesses to adjust our cost structure, and we may engage in similar activities in the future. These strategic initiatives and our regular ongoing cost reduction activities may distract management, could slow improvements in our products and services and limit our ability to increase production quickly if demand for our products increases. In addition, delays in implementing our strategic initiatives, unexpected costs or failure to meet targeted improvements may diminish the operational and financial benefits we realize from such actions. Any of the above circumstances could have an adverse effect on our business and operating results and financial condition.

Our business will suffer if we are not able to retain and hire key personnel.

Our future success depends partly on the continued service of our key research, engineering, sales, marketing, manufacturing, executive and administrative personnel. If we fail to retain and hire a sufficient number of these personnel, we will not be able to maintain or expand our business. The markets in which we operate are very dynamic, and our businesses continue to respond with reorganizations, workforce reductions and site closures. We believe our pay levels are very competitive within the regions that we operate. However, there is intense competition for certain highly technical specialties in geographic areas where we continue to recruit, and it may become more difficult to hire and retain our key employees.

Our acquisitions, strategic investments and alliances, joint ventures, exiting of businesses and divestitures may result in financial results that are different than expected.

In the normal course of business, we frequently engage in discussions with third parties relating to possible acquisitions, strategic investments and alliances, joint ventures and divestitures, and generally expect to complete several transactions per year. In addition, we may decide to exit a particular business within our product portfolio. As a result of such transactions, our financial results may differ from our own or the investment community's expectations in a given fiscal quarter, or over the long term. We may have difficulty developing, manufacturing and marketing the products of a newly acquired company in a way that enhances the performance of our combined businesses or product lines. Acquired businesses may also expose us to new risks and new markets and we may have difficulty addressing these risks in a cost effective and timely manner. Transactions such as acquisitions have resulted, and may in the future result in, unexpected significant costs and expenses. In the future, we may be required to record charges to earnings during the period if we determine there is an impairment of goodwill or intangible assets, up to the full amount of the value of the assets, or, in the case of strategic investments and alliances, consolidate results, including losses, of third parties or write down investment values or loans and convertible notes related to the strategic investment.

Integrating the operations of acquired businesses within Agilent could be a difficult, costly and time-consuming process that involves a number of risks. Acquisitions and strategic investments and alliances may require us to integrate and collaborate with a different company culture, management team, business model, business infrastructure and sales and distribution methodology and assimilate and retain geographically dispersed, decentralized operations and personnel. Depending on the size and complexity of an acquisition, our successful integration of the entity depends on a variety of factors, including introducing new products and meeting revenue targets as expected, the retention of key employees and key customers, increased exposure to certain governmental regulations and compliance requirements and increased costs and use of resources. Further, the integration of acquired businesses is likely to result in our systems and internal controls becoming increasingly complex and more difficult to manage. Any difficulties in the assimilation of acquired businesses into our control system could harm our operating results or cause us to fail to meet our financial reporting obligations.

Even if we are able to successfully integrate acquired businesses within Agilent, we may not be able to realize the revenue and other synergies and growth that we anticipated from the acquisition in the time frame that we expected, and the costs of achieving these benefits may be higher than what we expected. As a result, the acquisition and integration of acquired businesses may not contribute to our earnings as expected, we may not achieve our operating margin targets when expected, or at all, and we may not achieve the other anticipated strategic and financial benefits of such transactions.

A successful divestiture depends on various factors, including our ability to effectively transfer liabilities, contracts, facilities and employees to the purchaser, identify and separate the intellectual property to be divested from the intellectual property that we wish to keep and reduce fixed costs previously associated with the divested assets or business. In addition, if customers of the divested business do not receive the same level of service from the new owners, this may adversely affect our other businesses to the extent that these customers also purchase other Agilent products. In exiting a business, we may still retain liabilities associated with the support and warranty of those businesses and other indemnification obligations. All of these efforts require varying levels of management resources, which may divert our attention from other business operations. If we do not realize the expected benefits

47

or synergies of such transactions, our consolidated financial position, results of operations, cash flows and stock price could be negatively impacted.

If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an adverse effect on our stock price.

Effective internal controls are necessary for us to provide reliable and accurate financial statements and to effectively prevent fraud. We devote significant resources and time to comply with the internal control over financial reporting requirements of the Sarbanes Oxley Act of 2002 and continue to enhance our controls. However, we cannot be certain that we will be able to prevent future significant deficiencies or material weaknesses. Inadequate internal controls could cause investors to lose confidence in our reported financial information, which could have a negative effect on investor confidence in our financial statements, the trading price of our stock and our access to capital.

Our customers and we are subject to various governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.

Our customers and we are subject to various significant international, federal, state and local regulations, including but not limited to regulations in the areas of health and safety, packaging, product content, employment, labor and immigration, import/export controls, trade restrictions and anti-competition. In addition, as a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal, sensitive and/or patient health data in the course of our business. The EU's General Data Protection Regulation ("GDPR"), which became effective in May 2018, applies to all of our activities related to products and services that we offer to EU customers and workers. The GDPR established new requirements regarding the handling of personal data and includes significant penalties for non-compliance (including possible fines of up to 4 percent of total company revenue). Other governmental authorities around the world have passed or are considering similar types of legislative and regulatory proposals concerning data protection. Each of these privacy, security and data protection laws and regulations could impose significant limitations and increase our cost of providing our products and services where we process end user personal data and could harm our results of operations and expose us to significant fines, penalties and other damages.

We must also comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental officials, anti-competition regulations and sanctions imposed by the U.S. Office of Foreign Assets Control and other similar laws and regulations. Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct and on our ability to offer our products in one or more countries, and could also materially affect our brand, our ability to attract and retain employees, our international operations, our business and our operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, or agents will not violate our policies.

These regulations are complex, change frequently and have tended to become more stringent over time. We may be required to incur significant expenses to comply with these regulations or to remedy any violations of these regulations. Any failure by us to comply with applicable government regulations could also result in the cessation of our operations or portions of our operations, product recalls or impositions of fines and restrictions on our ability to carry on or expand our operations. In addition, because many of our products are regulated or sold into regulated industries, we must comply with additional regulations in marketing our products. We develop, configure and market our products to meet customer needs created by these regulations. Any significant change in these regulations could reduce demand for our products, force us to modify our products to comply with new regulations or increase our costs of producing these products. If demand for our products is adversely affected or our costs increase, our operating results and business would suffer.

Our products and operations are also often subject to the rules of industrial standards bodies, like the International Standards Organization, as well as regulation by other agencies such as the FDA. We also must comply with work safety rules. If we fail to adequately address any of these regulations, our businesses could be harmed.


48

We are subject to extensive regulation by the FDA and certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.

A number of our products are subject to regulation by the FDA and certain similar foreign regulatory agencies. In addition, a number of our products may in the future be subject to regulation by the FDA and certain similar foreign regulatory agencies. These regulations govern a wide variety of product-related activities, from quality management, design and development to labeling, manufacturing, promotion, sales and distribution. If we or any of our suppliers or distributors fail to comply with FDA and other applicable regulatory requirements or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity affecting both us and our customers; investigations or notices of non-compliance, fines, injunctions, and civil penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our products. Any such FDA or other regulatory agency actions could disrupt our business and operations, lead to significant remedial costs and have a material adverse impact on our financial position and results of operations. In addition, the global regulatory environment has become increasingly stringent. For example, the EU has adopted the EU In Vitro Diagnostic Regulation (the “EU IVDR”), which imposes stricter requirements for the marketing and sale of medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance. Manufacturers will have until May 2022 to meet the EU IVDR requirements for in vitro diagnostic medical devices currently on the market. Failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.

Some of our products are subject to particularly complex regulations such as regulations of toxic substances and failure to comply with such regulations could harm our business.

Some of our products and related consumables are used in conjunction with chemicals whose manufacture, processing, distribution and notification requirements are regulated by the U.S. Environmental Protection Agency (“EPA”) under the Toxic Substances Control Act, and by regulatory bodies in other countries under similar laws. The Toxic Substances Control Act regulations govern, among other things, the testing, manufacture, processing and distribution of chemicals, the testing of regulated chemicals for their effects on human health and safety and the import and export of chemicals. The Toxic Substances Control Act prohibits persons from manufacturing any chemical in the United States that has not been reviewed by the EPA for its effect on health and safety, and placed on an EPA inventory of chemical substances. We must ensure conformance of the manufacturing, processing, distribution of and notification about these chemicals to these laws and adapt to regulatory requirements in all applicable countries as these requirements change. If we fail to comply with the notification, record-keeping and other requirements in the manufacture or distribution of our products, then we could be subject to civil penalties, criminal prosecution and, in some cases, prohibition from distributing or marketing our products until the products or component substances are brought into compliance.

Our business may suffer if we fail to comply with government contracting laws and regulations.

We derive a portion of our revenue from direct and indirect sales to U.S., state, local, and foreign governments and their respective agencies. Such contracts are subject to various procurement laws and regulations and contract provisions relating to their formation, administration and performance. Failure to comply with these laws, regulations or provisions in our government contracts could result in the imposition of various civil and criminal penalties, termination of contracts, forfeiture of profits, suspension of payments, increased pricing pressure or suspension from future government contracting. If our government contracts are terminated, if we are suspended from government work, or if our ability to compete for new contracts is adversely affected, our business could suffer.


49

Our reputation, ability to do business and financial statements may be harmed by improper conduct by any of our employees, agents or business partners.

We cannot provide assurance that our internal controls and compliance systems will always protect us from acts committed by employees, agents or business partners of ours (or of businesses we acquire or partner with) that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, money laundering and data privacy. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the United States and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable as a successor for violations committed by companies in which we invest or that we acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards of conduct could occur that could have a material effect on our business, reputation and financial statements.

Our retirement and post retirement pension plans are subject to financial market risks that could adversely affect our future results of operations and cash flows.

We have significant retirement and post retirement pension plan assets and obligations. The performance of the financial markets and interest rates impact our plan expenses and funding obligations. Significant decreases in market interest rates, decreases in the fair value of plan assets and investment losses on plan assets will increase our funding obligations, and adversely impact our results of operations and cash flows.

The impact of consolidation and acquisitions of competitors is difficult to predict and may harm our business.

The life sciences industry is intensely competitive and has been subject to increasing consolidation. Consolidation in our industries could result in existing competitors increasing their market share through business combinations and result in stronger competitors, which could have a material adverse effect on our business, financial condition and results of operations. We may not be able to compete successfully in increasingly consolidated industries and cannot predict with certainty how industry consolidation will affect our competitors or us.

If we are unable to successfully manage the consolidation and streamlining of our manufacturing operations, we may not achieve desired efficiencies and our ability to deliver products to our customers could be disrupted.

Although we utilize manufacturing facilities throughout the world, we have consolidated, and may further consolidate, our manufacturing operations to certain of our plants to achieve efficiencies and gross margin improvements. Additionally, we typically consolidate the production of products from our acquisitions into our supply chain and manufacturing processes, which are technically complex and require expertise to operate. If we are unable to establish processes to efficiently and effectively produce high quality products in the consolidated locations, we may not achieve the anticipated synergies and production may be disrupted, which could adversely affect our business and operating results.

Our operating results may suffer if our manufacturing capacity does not match the demand for our products.

Because we cannot immediately adapt our production capacity and related cost structures to rapidly changing market conditions, when demand does not meet our expectations, our manufacturing capacity may exceed our production requirements. If during an economic downturn we had excess manufacturing capacity, then our fixed costs associated with excess manufacturing capacity would adversely affect our gross margins and operating results. If, during a general market upturn or an upturn in one of our segments, we cannot increase our manufacturing capacity to meet product demand, we may not be able to fulfill orders in a timely manner which could lead to order cancellations, contract breaches or indemnification obligations. This inability could materially and adversely limit our ability to improve our results.


50

Dependence on contract manufacturing and outsourcing other portions of our supply chain, including logistics and third-party package delivery services, may adversely affect our ability to bring products to market and damage our reputation. Dependence on outsourced information technology and other administrative functions may impair our ability to operate effectively.

As part of our efforts to streamline operations and to manage costs, we outsource aspects of our manufacturing processes and other functions and continue to evaluate additional outsourcing. If our contract manufacturers or other outsourcers fail to perform their obligations in a timely manner or at satisfactory quality levels, our ability to bring products to market and our reputation could suffer. For example, during a market upturn, our contract manufacturers may be unable to meet our demand requirements, which may preclude us from fulfilling our customers' orders on a timely basis. The ability of these manufacturers to perform is largely outside of our control. If one or more of the third-party package delivery providers experiences a significant disruption in services or institutes a significant price increase, we may have to seek alternative providers, our costs could increase and the delivery of our products could be prevented or delayed. Additionally, changing or replacing our contract manufacturers, logistics providers or other outsourcers could cause disruptions or delays. In addition, we outsource significant portions of our information technology ("IT") and other administrative functions. Since IT is critical to our operations, any failure to perform on the part of our IT providers could impair our ability to operate effectively. In addition to the risks outlined above, problems with manufacturing or IT outsourcing could result in lower revenue and unexecuted efficiencies, and impact our results of operations and our stock price.

Environmental contamination from past and ongoing operations could subject us to substantial liabilities.

Certain properties we have previously owned or leased are undergoing remediation for subsurface contamination.  Although we are indemnified for liability relating to the required remediation at some of those properties, we may be subject to liability if these indemnification obligations are not fulfilled.  In other cases, we have agreed to indemnify the current owners of certain properties for liabilities related to contamination, including companies with which we have previously been affiliated such as HP, Inc., Hewlett-Packard Enterprise (formerly Hewlett-Packard Company) and Varian Medical Systems, Inc.  Further, other properties we have previously owned or leased at which we have operated in the past, or for which we have otherwise contractually assumed, or provided indemnities for, certain actual or contingent environmental liabilities may or do require remediation. While we are not aware of any material liabilities associated with any potential environmental contamination at any of those properties or facilities, we may be exposed to material liability if environmental contamination at material levels is found to exist. In addition, in connection with the acquisition of certain companies, we have assumed other costs and potential or contingent liabilities for environmental matters.  Any significant costs or liabilities could have an adverse effect on results of operations.

Our current and historical manufacturing processes and operations involve, or have involved, the use of certain substances regulated under various foreign, federal, state and local environment protection and health and safety laws and regulations. As a result, we may become subject to liabilities for environmental contamination and these liabilities may be substantial. Although our policy is to apply strict standards for environmental protection and health and safety at our sites inside and outside the United States, we may not be aware of all conditions that could subject us to liability. Further, in the event that any future climate change legislation would require that stricter standards be imposed by domestic or international environmental regulatory authorities, we may be required to make certain changes and adaptations to our manufacturing processes. Failure to comply with these environmental protection and health and safety laws and regulations could result in civil, criminal, regulatory, administrative or contractual sanction, including fines, penalties or suspensions. If we have any violations of, or incur liabilities pursuant to these laws or regulations, our financial condition and operating results could be adversely affected.

Third parties may claim that we are infringing their intellectual property and we could suffer significant litigation or licensing expenses or be prevented from selling products or services.

From time to time, third parties may claim that one or more of our products or services infringe their intellectual property rights. We analyze and take action in response to such claims on a case by case basis. Any dispute or litigation regarding patents or other intellectual property could be costly and time-consuming due to the complexity of our technology and the uncertainty of intellectual property litigation and could divert our management and key personnel from our business operations. A claim of intellectual property infringement could force us to enter into a costly or restrictive license agreement, which might not be available under acceptable terms or at all, could require us to redesign our products, which would be costly and time-consuming, and/or could subject us to significant damages or to an injunction against the development and sale of certain of our products or services. Our intellectual property portfolio may not be useful in asserting a counterclaim, or negotiating a license, in response to a claim of intellectual property infringement. In certain of our businesses, we rely on third party intellectual property licenses and we cannot ensure that these licenses will continue to be available to us in the future or can be expanded to cover new products on favorable terms or at all.


51

Third parties may infringe our intellectual property and we may suffer competitive injury or expend significant resources enforcing our rights.

Our success depends in large part on our proprietary technology, including technology we obtained through acquisitions. We rely on various intellectual property rights, including patents, copyrights, trademarks and trade secrets, as well as confidentiality provisions and licensing arrangements, to establish our proprietary rights. If we do not enforce our intellectual property rights successfully, our competitive position may suffer which could harm our operating results.

Our pending patent, copyright and trademark registration applications may not be allowed or competitors may challenge the validity or scope of our patents, copyrights or trademarks. In addition, our patents, copyrights, trademarks and other intellectual property rights may not provide us with a significant competitive advantage.

We may need to spend significant resources monitoring and enforcing our intellectual property rights and we may not be aware of or able to detect or prove infringement by third parties. Our competitive position may be harmed if we cannot detect infringement and enforce our intellectual property rights quickly or at all. In some circumstances, we may choose to not pursue enforcement because an infringer has a dominant intellectual property position or for other business reasons. In addition, competitors might avoid infringement by designing around our intellectual property rights or by developing non-infringing competing technologies. Intellectual property rights and our ability to enforce them may be unavailable or limited in some countries which could make it easier for competitors to capture market share and could result in lost revenues. Furthermore, some of our intellectual property is licensed to others which may allow them to compete with us using that intellectual property.

Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could have a material adverse effect on our results of operations, financial condition and liquidity.

We are subject to taxes in the U.S., Singapore and various foreign jurisdictions. Governments in the jurisdictions in which we operate implement changes to tax laws and regulations periodically. Any implementation of tax laws that fundamentally change the taxation of corporations in the U.S. or Singapore could materially impact our effective tax rate and could have a significant adverse impact on our financial results.

The U.S. Tax Cuts and Job Act ("the Tax Act") significantly changed the taxation of U.S. based multinational corporations. Our compliance with the Tax Act requires the use of estimates in our financial statements and exercise of significant judgment in accounting for its provisions. The implementation of the Tax Act requires interpretations and implementing regulations by the Internal Revenue Service ("IRS"), as well as state tax authorities. The legislation could be subject to potential amendments and technical corrections, any of which could materially lessen or increase certain adverse impacts of the legislation. As regulations and guidance evolve with respect to the Tax Act, and as we gather information and perform more analysis, our results may differ from previous estimates and may materially affect our financial position.

We are also subject to examinations of our tax returns by tax authorities in various jurisdictions around the world. We regularly assess the likelihood of adverse outcomes resulting from ongoing tax examinations to determine the adequacy of our provision for taxes. These assessments can require a high degree of judgment and estimation. Intercompany transactions associated with the sale of inventory, services, intellectual property and cost share arrangements are complex and affect our tax liabilities. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in multiple jurisdictions. There can be no assurance that the outcomes from ongoing tax examinations will not have an adverse effect on our operating results and financial condition. A difference in the ultimate resolution of tax uncertainties from what is currently estimated could have an adverse effect on our financial results and condition.

If tax incentives change or cease to be in effect, our income taxes could increase significantly.

We benefit from tax incentives extended to our foreign subsidiaries to encourage investment or employment. Several jurisdictions have granted us tax incentives which require renewal at various times in the future. The incentives are conditioned on achieving various thresholds of investments and employment, or specific types of income. Our taxes could increase if the incentives are not renewed upon expiration. If we cannot or do not wish to satisfy all or parts of the tax incentive conditions, we may lose the related tax incentive and could be required to refund tax incentives previously realized. As a result, our effective tax rate could be higher than it would have been had we maintained the benefits of the tax incentives.


52

We have outstanding debt and may incur other debt in the future, which could adversely affect our financial condition, liquidity and results of operations.

We are party to a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. As of January 31, 2020, the company had $175 million borrowings outstanding under the credit facility. On August 7, 2019, we entered into an amendment to the credit agreement, which provided for a $500 million short-term loan facility that was used in full to complete the acquisition of BioTek and is outstanding as of January 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental loan facilities as of January 31, 2020. We also currently have outstanding an aggregate principal amount of $1.8 billion in senior unsecured notes. We may borrow additional amounts in the future and use the proceeds from any future borrowing for general corporate purposes, future acquisitions, expansion of our business or repurchases of our outstanding shares of common stock.

Our incurrence of this debt, and increases in our aggregate levels of debt, may adversely affect our operating results and financial condition by, among other things:

•
increasing our vulnerability to downturns in our business, to competitive pressures and to adverse economic and industry conditions; 
•
requiring the dedication of an increased portion of our expected cash flows from operations to service our indebtedness, thereby reducing the amount of expected cash flows available for other purposes, including capital expenditures, acquisitions, stock repurchases and dividends; and 
•
limiting our flexibility in planning for, or reacting to, changes in our business and our industry.

Our credit facility imposes restrictions on us, including restrictions on our ability to create liens on our assets and engage in certain types of sale and leaseback transactions and the ability of our subsidiaries to incur indebtedness, and requires us to maintain compliance with specified financial ratios. Our ability to comply with these ratios may be affected by events beyond our control. In addition, the indentures governing our senior notes contain covenants that may adversely affect our ability to incur certain liens or engage in certain types of sale and leaseback transactions. If we breach any of the covenants and do not obtain a waiver from the lenders or noteholders, then, subject to applicable cure periods, our outstanding indebtedness could be declared immediately due and payable.

If we suffer a loss to our factories, facilities or distribution system due to catastrophe, our operations could be seriously harmed.

Our factories, facilities and distribution system are subject to catastrophic loss due to fire, flood, terrorism, public health crises, increasing severity or frequency of extreme weather events, or other natural or man-made disasters. For example, in the first quarter of fiscal year 2020, a public health crisis in China led to an extension of the Lunar New Year holiday, which impacted our business, reduced the number of selling days and otherwise impacted our supply chain. This negatively impacted our results for the first quarter of fiscal year 2020 and may continue to affect our business and operating results. In addition, several of our facilities could be subject to a catastrophic loss caused by earthquake due to their locations. Our production facilities, headquarters and laboratories in California, and our production facilities in Japan, are all located in areas with above-average seismic activity. If any of our facilities were to experience a catastrophic loss, it could disrupt our operations, delay production, shipments and revenue and result in large expenses to repair or replace the facility. If such a disruption were to occur, we could breach agreements, our reputation could be harmed, and our business and operating results could be adversely affected. In addition, because we have consolidated our manufacturing facilities and we may not have redundant manufacturing capability readily available, we are more likely to experience an interruption to our operations in the event of a catastrophe in any one location. Although we carry insurance for property damage and business interruption, we do not carry insurance or financial reserves for interruptions or potential losses arising from earthquakes or terrorism. Also, our third party insurance coverage will vary from time to time in both type and amount depending on availability, cost and our decisions with respect to risk retention. Economic conditions and uncertainties in global markets may adversely affect the cost and other terms upon which we are able to obtain third party insurance. If our third party insurance coverage is adversely affected or to the extent we have elected to self-insure, we may be at a greater risk that our financial condition will be harmed by a catastrophic loss.

If we experience a significant disruption in, or breach in security of, our information technology systems, or if we fail to implement new systems and software successfully, our business could be adversely affected.

We rely on several centralized information technology systems throughout our company to provide products and services, keep financial records, process orders, manage inventory, process shipments to customers and operate other critical functions. Our information technology systems may be susceptible to damage, disruptions or shutdowns due to power outages, hardware failures,

53

computer viruses, attacks by computer hackers, telecommunication failures, user errors, catastrophes or other unforeseen events. Our information technology systems also may experience interruptions, delays or cessations of service or produce errors in connection with system integration, software upgrades or system migration work that takes place from time to time. If we were to experience a prolonged system disruption in the information technology systems that involve our interactions with customers or suppliers, it could result in the loss of sales and customers and significant incremental costs, which could adversely affect our business. In addition, security breaches of our information technology systems could result in the misappropriation or unauthorized disclosure of confidential information belonging to us or to our employees, partners, customers or suppliers, which could result in our suffering significant financial or reputational damage.

Adverse conditions in the global banking industry and credit markets may adversely impact the value of our cash investments or impair our liquidity.

As of January 31, 2020, we had cash and cash equivalents of approximately $1.2 billion invested or held in a mix of money market funds, time deposit accounts and bank demand deposit accounts. Disruptions in the financial markets may, in some cases, result in an inability to access assets such as money market funds that traditionally have been viewed as highly liquid. Any failure of our counterparty financial institutions or funds in which we have invested may adversely impact our cash and cash equivalent positions and, in turn, our operating results and financial condition.

Regulations related to “conflict minerals” may cause us to incur additional expenses and could limit the supply and increase the cost of certain metals used in manufacturing our products.

We are subject to the rules of the SEC which require disclosures by public companies of specified minerals, known as conflict minerals, that are necessary to the functionality or production of products manufactured or contracted to be manufactured. The rule, which requires an annual disclosure report to be filed with the SEC by May 31st of each year, requires companies to perform due diligence, disclose and report whether or not such minerals originate from the Democratic Republic of Congo or an adjoining country. Our ongoing implementation of these rules could affect sourcing at competitive prices and availability in sufficient quantities of certain minerals used in the manufacture of our products, including tin, tantalum, gold and tungsten. The number of suppliers who provide conflict-free minerals may be limited. In addition, there may be material costs associated with complying with the disclosure requirements, such as costs related to the due diligence process of determining the source of certain minerals used in our products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of such verification activities. As our supply chain is complex and we use contract manufacturers for some of our products, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we implement, which may harm our reputation. We may also encounter challenges to satisfy those customers who require that all of the components of our products be certified as conflict-free, which could place us at a competitive disadvantage if we are unable to do so.

We cannot assure that we will continue to pay dividends on our common stock.

Since the first quarter of fiscal year 2012, we have paid a quarterly dividend on our common stock. The timing, declaration, amount and payment of any future dividends fall within the discretion of our Board of Directors and will depend on many factors, including our available cash, estimated cash needs, earnings, financial condition, operating results, capital requirements, as well as limitations in our contractual agreements, applicable law, regulatory constraints, industry practice and other business considerations that our Board of Directors considers relevant. A change in our dividend program could have an adverse effect on the market price of our common stock.

54

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
ISSUER PURCHASES OF EQUITY SECURITIES

The table below summarizes information about the company’s purchases, based on trade date, of its equity securities registered pursuant to Section 12 of the Exchange Act during the quarterly period ended January 31, 2020.
 
Period

Total Number of
Shares of Common
Stock Purchased (1)

Weighted Average
Price Paid per Share
of
Common Stock (2)

Total
Number of
Shares of Common
Stock Purchased as
Part of Publicly
Announced Plans or
Programs (1)

Maximum
Approximate Dollar
Value of Shares of
Common Stock that
May Yet Be
Purchased Under the
Plans or Programs
(in millions) (1)
 

(a)

(b)

(c)

(d)
November 1, 2019 through November 30, 2019

258,761


$
77.80


258,761


$
1,007

December 1, 2019 through December 31, 2019

249,887


$
83.46


249,887


$
986

January 1, 2020 through January 31, 2020

217,179


$
87.47


217,179


$
967

Total

725,827


$
82.64


725,827


$
967

 

(1)
On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at an time. As of January 31, 2020, all repurchased shares to date have been retired.

(2)
The weighted average price paid per share of common stock does not include the cost of commissions.
 

55

ITEM 6. EXHIBITS
 
(a)Exhibits:

 
Exhibit
 
 
Number
 
Description
 
 
 
 
 
 
31.1

 
 
 
 
31.2

 
 
 
 
32.1

 
 
 
 
32.2

 
 
 
 
101.INS XBRL
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
101.SCH XBRL
 
Schema Document
 
 
 
101.CAL XBRL
 
Calculation Linkbase Document
 
 
 
101.LAB XBRL
 
Labels Linkbase Document
 
 
 
101.PRE XBRL
 
Presentation Linkbase Document
 
 
 
101.DEF XBRL
 
Definition Linkbase Document
 
 
 
 
 
 



56

AGILENT TECHNOLOGIES, INC.

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Dated:
March 3, 2020
By:
/s/ Robert W. McMahon
 
 
 
Robert W. McMahon
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)
 
 
 
 
 
 
 
 
Dated:
March 3, 2020
By:
/s/ Rodney Gonsalves
 
 
 
Rodney Gonsalves
 
 
 
Vice President, Corporate Controllership
 
 
 
(Principal Accounting Officer)






































 

57
 EX-31.1 2 a-01312020xex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
 
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Michael R. McMullen, certify that:

1.
I have reviewed this Form 10-Q of Agilent Technologies, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 

 
Date:
March 3, 2020
 
 
 
/s/ Michael R. McMullen
 
 
Michael R. McMullen
 
 
Director and Chief Executive Officer
 




 EX-31.2 3 a-01312020xex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
 
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 
I, Robert W. McMahon, certify that:
 
1.
I have reviewed this Form 10-Q of Agilent Technologies, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
March 3, 2020
/s/ Robert W. McMahon
 
 
Robert W. McMahon
 
 
Senior Vice President and Chief Financial Officer
 




 EX-32.1 4 a-01312020xex321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Agilent Technologies, Inc. (the “Company”) on Form 10-Q for the period ended January 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael R. McMullen, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
  
Date:
March 3, 2020
/s/ Michael R. McMullen
 
 
Michael R. McMullen
 
 
Director and Chief Executive Officer
 




 EX-32.2 5 a-01312020xex322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Agilent Technologies, Inc. (the “Company”) on Form 10-Q for the period ended January 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert W. McMahon, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:
March 3, 2020
/s/ Robert W. McMahon
 
 
Robert W. McMahon
 
 
Senior Vice President and Chief Financial Officer
 




 EX-101.SCH 6 a-20200131.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2406403 - Disclosure - ACQUISITIONS - Assets and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - ACQUISITIONS - Intangible Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - ACQUISITIONS (Notes) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - ACQUISITIONS - Proforma Operating Results (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - ACQUISITIONS - Text (Details) link:presentationLink link:calculationLink link:definitionLink 1005001 - Statement - CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF EQUITY link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2417405 - Disclosure - DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2417404 - Disclosure - DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - DERIVATIVES- Foreign Exchange Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - DERIVATIVES (Notes) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - DERIVATIVES (Tables) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - DERIVATIVES- Terminated Interest Rate Swaps (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Notes) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - INCOME TAXES (Notes) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - INVENTORY (Notes) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - LEASES - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - LEASES - Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - LEASES (Notes) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - LEASES - Supplemental Cash Flows Information (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - LEASES - Text (Details) link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - LONG-TERM DEBT (Notes) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - NET INCOME PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - NET INCOME PER SHARE (Notes) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - NET INCOME PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS- Initial Adoption (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Notes) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS - JWPIL (Details) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - REVENUE - Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - REVENUE (Notes) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - REVENUE - Revenue by End Markets (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - REVENUE- Revenue by Region (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - REVENUE - Revenue by Type (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - SEGMENT INFORMATION (Notes) link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - SEGMENT INFORMATION - Profitability (Details) link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) link:presentationLink link:calculationLink link:definitionLink 2423404 - Disclosure - SEGMENT INFORMATION - Segment Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - SHARE-BASED COMPENSATION Capitalized (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - SHARE-BASED COMPENSATION Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - SHARE-BASED COMPENSATION (Notes) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2420401 - Disclosure - SHORT-TERM DEBT Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - SHORT-TERM DEBT (Notes) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - STOCKHOLDER"S EQUITY - Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - STOCKHOLDERS' EQUITY (Notes) link:presentationLink link:calculationLink link:definitionLink 2422405 - Disclosure - STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - SUBSEQUENT EVENTS (Notes) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - SUBSEQUENT EVENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - WARRANTIES AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - WARRANTIES AND CONTINGENCIES (Notes) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - WARRANTIES AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 a-20200131_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 a-20200131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 a-20200131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Financial Position [Abstract] Liabilities and Equity [Abstract] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, issued and outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, issued and outstanding (in shares) Common Stock, Shares, Outstanding Treasury Stock (in Shares) Treasury Stock, Common, Shares Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] BioTek BioTek [Member] BioTek [Member] ACEA Biosciences, Inc. ACEA Biosciences, Inc. [Member] ACEA Biosciences, Inc. [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Purchase Price Business Combination, Consideration Transferred Cash Payment to Acquire Businesses Payments to Acquire Businesses, Gross Payment to Acquire Business with Debt Business Combination, Consideration Transferred, Liabilities Incurred estimated costs to complete in-process research and development projects estimated costs to complete in-process research and development projects estimated costs to complete in-process research and development projects Acquisition and Integration Costs Business Acquisition, Transaction Costs Goodwill and Intangible Assets Disclosure [Abstract] Remainder of 2020 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2021 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2025 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Statement [Table] Statement [Table] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Statement Line Items Statement [Line Items] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventory Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Long-term investments Long-term Investments Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Employee compensation and benefits Employee-related Liabilities, Current Deferred revenue Deferred Revenue, Current Short-term Debt Short-term Debt Other accrued liabilities Other Accrued Liabilities Total current liabilities Liabilities, Current Long-term debt Long-term Debt, Excluding Current Maturities Retirement and post-retirement benefits Liability, Defined Benefit Plan, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and Contingencies (Note 14) Commitments and Contingencies Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding Preferred Stock, Value, Issued Common stock; $0.01 par value; 2 billion shares authorized; 310 million shares at January 31, 2020 and 309 million shares at October 31, 2019, issued Common Stock, Value, Issued Treasury Stock, Value Treasury Stock, Value Additional paid-in-capital Additional Paid in Capital Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholder's equity Stockholders' Equity Attributable to Parent Total liabilities and equity Liabilities and Equity Retirement Benefits [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Pension Plan Pension Plan [Member] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Foreign Plan Foreign Plan [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Industry Sector [Axis] Industry Sector [Axis] Industry Sector [Domain] Industry Sector [Domain] Investment Objective [Axis] Investment Objective [Axis] Investment Objective [Domain] Investment Objective [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Defined Benefit Plan Disclosure Defined Benefit Plan Disclosure [Line Items] Settlement gain Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Hedging Designation [Axis] Hedging Designation Hedging Designation [Domain] Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Hedging Relationship [Axis] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Net Investment Hedging [Member] Net Investment Hedging [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign Exchange Contracts Foreign Exchange Contract [Member] Interest Rate Swap Interest Rate Swap [Member] Other Current Assets Other Current Assets [Member] Other Accrued Liabilities Accrued Liabilities [Member] Derivative Derivative [Line Items] Derivative Fair Value by Balance Sheet Location Derivative, Fair Value, Net [Abstract] Derivatives asset fair value Derivative Asset, Fair Value, Gross Asset Derivatives liabilities fair value Derivative Liability, Fair Value, Gross Liability Pro Forma Revenue Business Acquisition, Pro Forma Revenue Pro Forma Net Income Business Acquisition, Pro Forma Net Income (Loss) Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Basic Pro Forma Earnings Per Share, Diluted Business Acquisition, Pro Forma Earnings Per Share, Diluted Derivative [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Senior Notes 2022 Senior Notes 2022 [Member] Bond that takes priority over other debt securities by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured ( general) creditors. Senior Notes 2026 Senior Notes 2026 [Member] Senior Notes 2026 Senior Notes 2029 Senior Notes 2029 [Member] Senior Notes 2029 [Member] Treasury Lock [Member] Treasury Lock [Member] Hedging Designation [Axis] Not Designated as Hedging Instruments Derivatives Designated as Hedging Instrument Hedging Relationship [Axis] Hedging Relationship [Domain] Fair Value Hedging Fair Value Hedging [Member] Derivative Instruments, Gain (Loss) by Income Statement Location [Axis] Income Statement Location [Axis] Income Statement and Other Comprehensive Income (Loss) Location [Domain] Income Statement Location [Domain] Derivative Instruments and Hedging Activities Disclosure Derivative Instrument Detail [Abstract] Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position Derivative, Net Liability Position, Aggregate Fair Value Terminated Derivative Contracts Interest Rate Derivatives [Abstract] Number of interest rate swap contracts terminated Number of Interest Rate Derivatives Held Derivative, Notional Amount Derivative, Notional Amount Interest rate swap payments interest rate swap payments interest rate swap payments Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge Remaining gain (loss) to be amortized on derivative Remaining gain loss to be amortized on derivative Remaining gain loss to be amortized on derivative Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer Revenue from Contract with Customer [Text Block] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Tax Examination [Table] Income Tax Examination [Table] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Income Tax Disclosure Income Tax Examination [Line Items] Provision (benefit) for income taxes Income Tax Expense (Benefit) Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Discrete tax expense (benefit) Other Tax Expense (Benefit) Excess tax benefit from stock based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount Statement of Comprehensive Income [Abstract] Net income Net Income (Loss) Attributable to Parent Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $0 and $(2) Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0 and $(1) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Foreign currency translation, net of tax expense (benefit) of $0 and $(9) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Net defined benefit pension cost and post retirement plan costs: Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract] Change in actuarial net loss, net of tax expense of $3 and $4 Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Change in net prior service benefit, net of tax expense of $1 and $0 Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Total comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Leases [Abstract] Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Lease Cost Lease, Cost [Table Text Block] Lessee, Lease Assets and Liabilities Lessee, Lease Assets and Liabilities [Table Text Block] Lessee, Lease Assets and Liabilities [Table Text Block] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Share-based Payment Arrangement, Noncash Expense [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] LTPP LTPP [Member] Long Term Performance Plan. Cost of Products and Services Cost of Sales [Member] Research and Development Expense Research and Development Expense [Member] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Inventory Inventory [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based compensation expense Share-based Payment Arrangement, Expense Inventory, Net [Abstract] Finished goods Inventory, Finished Goods, Gross Purchased parts and fabricated assemblies Inventory, Work in Process and Raw Materials Inventory DERIVATIVES Derivative Instruments and Hedging Activities Disclosure [Text Block] Restricted Cash [Abstract] Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Subsequent Events [Abstract] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Americas Americas [Member] Europe Europe [Member] Asia Pacific Asia Pacific [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Life Sciences and Applied Markets Life Sciences and Applied Markets [Member] Life Sciences and Applied Markets [Member] Diagnostics and Genomics Diagnostics and Genomics [Member] Diagnostics and Genomics segment includes; DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation profiling; gene expression profiling; and automated gel electrophoresis-based sample analysis systems. Agilent CrossLab Agilent CrossLab [Member] Agilent CrossLab [Member] Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Document and Entity Information [Abstract] Document and Entity Information [Abstract] Title of 12(b) Security Title of 12(b) Security Entity Tax Identification Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Document Quarterly Report Document Quarterly Report Amendment Flag Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Shell Company Entity Shell Company Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Schedule of Prospective Adoption of New Accounting Pronouncements Schedule of Prospective Adoption of New Accounting Pronouncements [Table Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Summary of New Accounting Pronouncements Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Debt Disclosure [Abstract] LONG-TERM DEBT Long-term Debt [Text Block] Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Income Statement Location [Axis] Income Statement Location [Domain] Cost of Sales Other income (expense) Other Nonoperating Income (Expense) [Member] Accumulated Other Comprehensive Income (Loss) Gain (loss) recognized in accumulated other comprehensive loss Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Gain (loss) recognized in other income (expense) Derivative, Gain (Loss) on Derivative, Net Cash flow hedge net gain to be reclassified within next Twelve Months Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Fair Value Disclosures [Abstract] Fair Value Assets And Liabilities Measured On Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Stockholders' Equity Note [Abstract] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Prior Service Credits Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member] Actuarial Losses Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member] Unrealized Gains (Losses) on Derivatives AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member] Operating Activities [Axis] Operating Activities [Axis] Operating Activities [Domain] Operating Activities [Domain] Beginning Balance Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, before Tax Amounts reclassified out of accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Tax expense (benefit) Other Comprehensive Income (Loss), Tax Other comprehensive income (loss) Ending Balance Earnings Per Share [Abstract] NET INCOME PER SHARE Earnings Per Share [Text Block] Goodwill balances and movements for each reportable segment during the period Schedule of Goodwill [Table Text Block] Components of other intangible assets during the period Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of estimated future amortization expense of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] INCOME TAXES Income Tax Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] WARRANTIES AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Amount of Litigation Settlement Awarded from Twist Bioscience Litigation Settlement, Amount Awarded from Other Party Operating Lease, Cost Operating Lease, Cost Variable Lease, Cost Variable Lease, Cost Sublease Income Sublease Income Lease, Cost Lease, Cost Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Segment Reporting Information Segment Reporting Information [Line Items] Reconciliation of Operating Profit from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Total reportable segment's income from operations Segment income (loss) from operations The net result for the period of deducting segment operating expenses from segment operating revenues. Transformational initiatives Transformational Programs The charge against earnings in the period, comprised of costs associated with restructuring activities not otherwise specified in the taxonomy that are not part of a specific plan as required by GAAP. Amortization of intangible assets related to business combinations Amortization Acquisition and integration costs Business Combination, Acquisition Related Costs Business exit and divestiture costs Business Exit Costs NASD site costs Property, Plant and Equipment, Additions Special compliance costs Special compliance costs Special compliance costs Other Other Amount of an item in the reconciliation of total profit or loss from reportable segments, to the entity's consolidated income before income taxes, extraordinary items, discontinued operations. Interest income Investment Income, Interest Interest expense Interest Expense Other income (expense), net Other Nonoperating Income (Expense) Income before taxes, as reported Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets Short - term Cash equivalents (money market funds) Cash and Cash Equivalents, Fair Value Disclosure Derivative instruments (foreign exchange contracts) Foreign Currency Contract, Asset, Fair Value Disclosure Assets, Long-term Assets, Noncurrent [Abstract] Trading securities Debt Securities, Trading, and Equity Securities, FV-NI Other investments Investments, Fair Value Disclosure Total assets measured at fair value Assets, Fair Value Disclosure Liabilities, Short-term Derivative instruments (foreign exchange contracts) Foreign Currency Contracts, Liability, Fair Value Disclosure Liabilities Long-term Liabilities, Noncurrent [Abstract] Deferred compensation liability Deferred Compensation Liability, Classified, Noncurrent Total liabilities measured at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Segment Reporting Information Segment Reporting Information, Profit (Loss) [Abstract] Number of operating segments Number of Operating Segments Segment Total Segment Total [Member] Reportable amounts associated with all reporting segments included in a reconciliation from segment reporting to consolidated income from operations, before taxes. Income from operations Operating Income (Loss) FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Cash and Cash and Equivalents acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounts Receivable acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Inventories acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Other Current Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Property, Plant, and Equipment acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Intangible Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Goodwill arising from acquisitions Goodwill, Acquired During Period Total Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Accounts Payable assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Deferred Revenue assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Employee compensation and benefits assumed Employee compensation and benefits assumed Total obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer) assumed at the acquisition date. Other Accrued Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Long-term Debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Net Assets Acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Reconciliation of the numerators and denominators of the basic and diluted net income per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Long-term Debt Instruments [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Senior Notes 2023 Senior Notes 2023 [Member] Senior Notes 2023 [Member] Debt Instrument Debt Instrument [Line Items] Long-term debt Long-term Debt End Markets [Axis] End Markets [Axis] End Markets [Axis] End Markets [Domain] End Markets [Domain] [Domain] for End Markets [Axis] Pharmaceutical and Biopharmaceutical Market Pharmaceutical and Biopharmaceutical Market [Member] Pharmaceutical and Biopharmaceutical Market [Member] Chemical and Energy Market Chemical and Energy Market [Member] Chemical and Energy Market [Member] Diagnostics and Clinical Market Diagnostics and Clinical Market [Member] Diagnostics and Clinical Market [Member] Food Market Food Market [Member] Food Market [Member] Academia and Government Market Academia and Government Market [Member] Academia and Government Market [Member] Environmental and Forensics Market Environmental and Forensics Market [Member] Environmental and Forensics Market [Member] Operating lease payments Operating Lease, Payments, Use Non-Cash Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] 2019 Repurchase Program [Member] 2019 Repurchase Program [Member] 2019 Repurchase Program [Member] 2015 Repurchase Program 2015 Repurchase Program [Member] 2015 Repurchase Program - On May 28, 2015 we announced that our board of directors had approved a new share repurchase program. The new share repurchase program authorizes the purchase of up to $1.14 billion of our common stock through and including November 1, 2018. The new program will commence, at the option of the company, on either November 1, 2015, or the date on which we complete the purchase of $365 million of common stock under the existing stock repurchase program in fiscal 2015. Upon commencement, the new program replaces our existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs. Share repurchase program Equity, Class of Treasury Stock [Line Items] Share repurchase program authorized amount Stock Repurchase Program, Authorized Amount Stock repurchased and retired during period, (Shares) Stock Repurchased and Retired During Period, Shares Stock repurchased and retired during period, (Value) Stock Repurchased and Retired During Period, Value Remaining authorized repurchase amount under share repurchase program Stock Repurchase Program, Remaining Authorized Repurchase Amount 2020 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2021 Operating Leases, Future Minimum Payments, Due in Two Years 2022 Operating Leases, Future Minimum Payments, Due in Three Years 2023 Operating Leases, Future Minimum Payments, Due in Four Years 2024 Operating Leases, Future Minimum Payments, Due in Five Years 2025 and thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total future minimum lease payments Operating Leases, Future Minimum Payments Due Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill Roll Forward Goodwill [Roll Forward] Goodwill beginning balance Foreign currency translation impact Goodwill, Translation and Purchase Accounting Adjustments Measurement period adjustment to goodwill Indefinite-lived Intangible Assets, Purchase Accounting Adjustments Goodwill ending balance Initial Application Period Cumulative Effect Trransition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Contract Assets Contract with Customer, Asset, after Allowance for Credit Loss [Abstract] Contract Assets (Unbilled Accounts Receivable) Contract with Customer, Asset, after Allowance for Credit Loss Increase in Contract Asset Balance Increase in Contract Asset Balance Increase (decrease) in Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Contract Liabilities Contract with Customer, Liability [Abstract] Contract liability ending balance as of October 31, 2019 Contract with Customer, Liability Impact of adoption of new guidance on contract liabilities (deferred revenue) Deferred Revenue, Period Increase (Decrease) Net revenue deferred in the period Increase (Decrease) in Contract with Customer, Liability Revenue recognized that was included in the contract liability balance at the beginning of the period Contract with Customer, Liability, Revenue Recognized Change in deferrals from customer cash advances, net of revenue recognized Increase (Decrease) in Deferred Revenue and Customer Advances and Deposits Contract liabilities acquired in business combinations Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Currency Translation and Other Adjustment Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) Contract liability ending balance as of Jan 31, 2020 Transaction Price Allocated to Remaining Performance Obligation Revenue, Performance Obligation [Abstract] Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Majority of Remaining Performance Obligation Expected Timing of Satisfaction, Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period INVENTORY Inventory Disclosure [Text Block] Defined Benefit Plan [Abstract] United States UNITED STATES Defined Benefit Plans Contributions Payment for Pension and Other Postretirement Benefits [Abstract] Contributions to defined benefit plans Defined Benefit Plan, Plan Assets, Contributions by Employer Estimated future employer contributions in remainder of current fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Purchased Technology Developed Technology Rights [Member] Backlog Order or Production Backlog [Member] Trademark/Tradenames Trademarks [Member] Customer Relationships Customer Relationships [Member] Third-Party Technology and Licenses Third-Party Technology and Licenses [Member] Third-Party Technology and Licenses [Member] Total amortizable intangible assets Total Amortizable Intangible Assets [Member] Sum of the gross carrying amounts before accumulated amortization as of the balance sheet date of all intangible assets having statutory or estimated useful lives. The aggregate gross carrying amount (including any previously recognized impairment charges) of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. In-Process R&D In Process Research and Development [Member] Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Book Value Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract] In-Process R&D Indefinite-lived Intangible Assets (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Treasury Stock Treasury Stock [Member] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Total Stockholder's Equity Parent [Member] Non-controlling Interest Noncontrolling Interest [Member] Adjustments for Change in Accounting Principle [Axis] Adjustments for Change in Accounting Principle [Axis] Adjustments for Change in Accounting Principle [Domain] Adjustments for Change in Accounting Principle [Domain] Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Beginning Treasury Stock, Shares Treasury Stock, Shares Beginning Treasury Stock, Value Beginning Balance (in Shares) Shares, Issued Beginning Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative Effect of New Accounting Principle in Period of Adoption Components of comprehensive income, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Other comprehensive income Total comprehensive income (loss), net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Change in non-controlling interest increase (decrease) Noncontrolling Interest, Period Increase (Decrease) Cash dividends declared Dividends, Common Stock, Cash Share-based awards issued, net of tax (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Share-based awards issued Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Repurchase of common stock Stock Repurchased During Period, Value Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Ending Treasury Stock, Shares Ending Treasury Stock, Value Ending Balance (in Shares) Ending Balance Other assets Other Noncurrent Assets [Member] Other accrued liabilities Other Current Liabilities [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Right-of-Use Asset Operating Lease, Right-of-Use Asset Operating lease liability, Current Operating Lease, Liability, Current Operating lease liability, Noncurrent Operating Lease, Liability, Noncurrent Weighted average remaining lease term (in years) - Operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate - Operating leases Operating Lease, Weighted Average Discount Rate, Percent Finite-Lived Intangible Assets, Major Class Name [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Additions to goodwill Addition to other intangible assets Finite-Lived Intangible Assets, Period Increase (Decrease) Foreign Currency Translation Gain (Loss) Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Impairment of IPR&D Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Goodwill impairment Goodwill, Impairment Loss Amortization of intangible assets during the period Amortization of Intangible Assets Acquisition INVENTORY Schedule of Inventory, Current [Table Text Block] Share-based Payment Arrangement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount Share-based Payment Arrangement, Expensed and Capitalized, Amount Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Assets Income Statement [Abstract] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Product Product [Member] Service, Other Service, Other [Member] Net revenue: Revenues [Abstract] Costs and expenses: Costs and Expenses [Abstract] Cost of revenue Cost of Goods and Services Sold Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total costs and expenses Costs and Expenses Income from operations Other income (expense), net Income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Provision (benefit) for income taxes Net income Net income per share Basic Earnings Per Share, Basic Diluted Earnings Per Share, Diluted Weighted average shares used in computing net income per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic Weighted Average Number of Shares Outstanding, Basic Diluted Weighted Average Number of Shares Outstanding, Diluted Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Long-Lived Assets Assets Long Lived [Abstract] Assets Long Lived [Abstract] Impairment of Long-Lived Assets Held-for-use Impairment of Long-Lived Assets Held-for-use Impairment of non-marketable securities Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount Impairment of long-lived assets held for sale Impairment of Long-Lived Assets to be Disposed of Investments Other than Temporary Impairment Losses, Investments [Abstract] Impairment of Investments Other than Temporary Impairment Losses, Investments Non-Marketable Equity Securities without Readily Determinable Fair Value Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Unrealized gain on equity securities Unrealized Gain (Loss) on Investments Non-marketable equity securities carrying amount Equity Securities without Readily Determinable Fair Value, Amount Schedule of Senior Notes and Related Interest Rate Swaps Schedule of Long-term Debt Instruments [Table Text Block] RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Pension and Other Postretirement Benefits Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Share-based compensation Share-based Payment Arrangement, Noncash Expense Deferred taxes Deferred Income Tax Expense (Benefit) Excess and obsolete inventory related charges Inventory Write-down Unrealized gain on equity securities Other non-cash expense, net Other Noncash Income (Expense) Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Accounts payable Increase (Decrease) in Accounts Payable Employee compensation and benefits Increase (Decrease) in Employee Related Liabilities Other assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Investments in property, plant and equipment Payments to Acquire Property, Plant, and Equipment Payment to acquire fair value investment Payments to Acquire Investments Payments in exchange for convertible note Payments to Acquire Notes Receivable Acquisitions of businesses and intangible assets, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Issuance of common stock under employee stock plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Payment of taxes related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Payment of dividends Payments of Ordinary Dividends Purchase of non-controlling interest Payments to Acquire Additional Interest in Subsidiaries Proceeds from revolving credit facility Proceeds from Lines of Credit Repayments of revolving credit facility Repayments of Lines of Credit Repayment of revolving credit facility Repayments of Debt Repayment of finance lease Finance Lease, Principal Payments Treasury stock repurchases Payments for Repurchase of Common Stock Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate movements Effect of Exchange Rate on Cash and Cash Equivalents Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Income tax paid, net Income Taxes Paid, Net Interest payments Interest Paid, Excluding Capitalized Interest, Operating Activities Non-cash changes in investments in property, plant and equipment - increase (decrease) Non-cash changes in investments in property, plant and equipment increase (decrease) Changes to the cost of fixed assets that are not the result of cash capital expenditures. Short-term Debt [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Line of Credit Facility [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility Line of Credit Facility [Abstract] Initiation date of credit facility Line of Credit Facility, Initiation Date Expiration date of credit facility Line of Credit Facility, Expiration Date Proceeds from Lines of Credit Credit faciity terms (in years) Short-term Debt, Terms Maximum borrowing capacity of credit facility Line of Credit Facility, Maximum Borrowing Capacity Amount outstanding on credit facility Line of Credit Facility, Fair Value of Amount Outstanding Other Short-term loan facilities Short-term Debt, Other Disclosures [Abstract] Short-term loan facility Short-term Bank Loans and Notes Payable Other short term loan borrowing capacity Other term loan borrowing capacity Other term loan borrowing capacity Other Short-term Borrowings Other Short-term Borrowings Operating Leased assets - original cost Operating Leased assets - original cost Operating Leased assets - original cost Operating leased assets, net book value Operating leased assets, net book value Operating leased assets, net book value Sales-type Lease, Lease Receivable Sales-type Lease, Lease Receivable Other Postretirement Benefits Plan Other Postretirement Benefits Plan [Member] Defined Benefit Plan, Net Periodic Benefit Cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Service cost - benefits earned during the period Defined Benefit Plan, Service Cost Interest cost on benefit obligation Defined Benefit Plan, Interest Cost Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Amortization: Amortization and deferrals [Abstract] Amortization and deferrals [Abstract] Actuarial losses Defined Benefit Plan, Amortization of Gain (Loss) Prior service credits Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Total net plan costs Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Curtailments and Settlements Defined Benefit Plan, Settlement and Curtailment [Abstract] SHORT-TERM DEBT Short-term Debt [Text Block] SHARE-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Minimum Minimum [Member] Maximum Maximum [Member] Finite-Lived Intangible Assets by Major Class [Axis] Developed Product Technology Trademarks and Trade Names Trademarks and Trade Names [Member] Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Total Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Leases of Lessee Disclosure [Text Block] Leases of Lessee Disclosure [Text Block] Other comprehensive income (loss), tax, parenthetical disclosures Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract] Unrealized gain on derivative instruments, tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax Amounts reclassified into earnings related to derivative instruments, tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax Foreign currency translation, tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Net defined benefit pension cost and post retirement plan costs, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax [Abstract] Change in actuarial net loss, tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax Change in net prior service benefit, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax Movement in Standard Product Warranty Accrual Movement in Standard Product Warranty Accrual [Roll Forward] Beginning balance as of Standard Product Warranty Accrual Accruals for warranties including change in estimate Standard Product Warranty Accrual, Increase for Warranties Issued Settlements made during the period Standard Product Warranty Accrual, Decrease for Payments Ending balance at end of period Standard Product Warranty Disclosure Standard Product Warranty Disclosure [Abstract] Accruals for warranties due within one year Standard Product Warranty Accrual, Current Guarantees Guarantees [Abstract] Guarantees Bank Acceptances Executed Allocated share-based compensation expense disclosure Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Assumptions used to estimate fair value for LTPP Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, and long-term performance plan grants. Instrumentation Instrumentation [Member] Instrumentation [Member] Non-Instrumentation and Other Non-Instrumentation and Other [Member] Non-Instrumentation and Other[Member] Standard warranty Schedule of Product Warranty Liability [Table Text Block] Schedule of net pension and post-retirement benefit costs Schedule of Defined Benefit Plans Disclosures [Table Text Block] Overview and Basis of Presentation Business Description and Basis of Presentation [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Lessee, Leases Lessee, Leases [Policy Text Block] Dividends Per Share, Declared Common Stock, Dividends, Per Share, Declared Tax related to shares issued Tax related to shares issued Tax related to shares issued Dividends [Abstract] Dividends Payable [Table] Dividends Payable [Table] Dividends [Axis] Dividends [Axis] Dividends [Domain] Dividends [Domain] Dividends Payable [Line Items] Dividends Payable [Line Items] Dividends Paid Payments of Dividends [Abstract] Cash dividends paid per common share Common Stock, Dividends, Per Share, Cash Paid Aggregate amount of cash dividends paid Payments of Ordinary Dividends, Common Stock Dividends Declared Dividends, Common Stock [Abstract] Dividends Payable, Date Declared Dividends Payable, Date Declared Dividends Payable, Date of Record Dividends Payable, Date of Record Dividends Payable, Date to be Paid Dividends Payable, Date to be Paid Acquisitions Disclosure Business Combination Disclosure [Text Block] Segment Profitability and Segment Assets Schedule of Segment Reporting Information, by Segment [Table Text Block] Reconciliation of segment results to total enterprise results Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Position [Axis] Position [Axis] Position [Domain] Position [Domain] Sell Short [Member] Buy Long [Member] Foreign Exchange Forward Foreign Exchange Forward [Member] Forward Contracts USD Forward Contracts [Member] Options Held [Member] Options Held [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Euro Member Countries, Euro British Pound United Kingdom, Pounds Canadian Dollar Canada, Dollars Australian Dollar Australia, Dollars Malaysian Ringgit Malaysia, Ringgits Japanese Yen Japan, Yen Danish Krone Denmark, Kroner Korean Won Korea (South), Won Singapore Dollar Singapore, Dollars Swiss Franc Switzerland, Francs Chinese Yuan Renminbi China, Yuan Renminbi Polish Zloty Poland, Zlotych Swedish Krona Sweden, Kronor Other No currency Number of foreign exchange forward contracts (in units) Number of Foreign Currency Derivatives Held LTPP & RSU LTPP & RSU [Member] LTPP & RSU [Member] Volatility of Agilent shares Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility of selected peer-company shares - Minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Peer Company Shares Volatility Rate Range Minimum The measure of the percentage amount by which a share price fluctuates during a period for peer companies - minimum range. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Volatility of selected peer-company shares - Maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Peer Company Shares Volatility Rate Range Maximum The measure of the percentage amount by which a share price fluctuates during a period for peer companies - maximum range. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Pair-wise correlation with selected peers (in hundredths) Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Peer Company Shares Price Wise Correlationy Rate The measure of the percentage amount of share price correlation during the period with a selected group of peer companies. Pair-wise correlations with selected peers is calculated as the correlation between each pair and the sum of correlations divided by the number of pairs to produce the average correlation between each pair. Discount for post-vesting restrictions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions ESPP plan purchase price (in hundredths) Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Subsequent Events Subsequent Events [Text Block] STOCKHOLDERS EQUITY Stockholders' Equity Note Disclosure [Text Block] Impact of Adopting Accounting Standards Update 2016-02 - Leases Accounting Standards Update 2016-02 [Member] Liabilities Aggregated notional amounts by currency and designation Schedule of Derivative Instruments [Table Text Block] Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations Derivative Instruments, Gain (Loss) [Table Text Block] Fair Value of Financial Instruments Fair value of senior notes in excess of carrying value Fair value of long term debt in excess of carrying value Amount of fair value of long term debt in excess of carrying value. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Restricted Cash Restricted Cash Cash, cash equivalents, restricted cash and restricted cash equivalents Operating lease payments due in 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months Operating lease payments due in 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two Operating lease payments due in 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three Operating lease payments due in 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four Operating lease payments due in 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Operating lease payments due in 2025 and thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total undiscounted future minimum lease payments Lessee, Operating Lease, Liability, Payments, Due Amount of lease payments representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating lease liability Operating Lease, Liability Operating lease liability, Current NEW ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from EPS Computation Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Numerator: Numerator [Abstract] Numerator [Abstract] Denominators: Denominators [Abstract] Denominators [Abstract] Basic weighted-average shares (in shares) Potential common shares - stock options and other employee stock plans (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted average shares (in shares) Antidilutive securities excluded from computation of Earnings Per Share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Unrealized gain (loss) on derivatives Unrealized gains and (losses) on derivatives reclassified to cost of products, before tax Unrealized gains and losses on derivatives reclassified to cost of products, before tax Amount before tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss). Reclassification of (gains) and losses into earnings related to derivative instruments, tax Unrealized gains and (losses) on derivatives reclassified to cost of products, net of tax Actuarial net loss Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Prior service benefit Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Actuarial net loss and prior service benefit reclassified, before tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax Tax on actuarial net loss and prior service benefit reclassified Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax Actuarial net loss and prior service benefit reclassified, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Contract Liabilities and Changes in Balances Contract with Customer, Asset and Liability [Table Text Block] EX-101.PRE 10 a-20200131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENT OF EQUITY - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings (Accumulated Deficit)
Accumulated Other Comprehensive Income (Loss)
Total Stockholder's Equity
Non-controlling Interest
Cumulative Effect of New Accounting Principle in Period of Adoption $ 26       $ 33 $ (7) $ 26  
Beginning Treasury Stock, Shares at Oct. 31, 2018       0        
Beginning Treasury Stock, Value at Oct. 31, 2018       $ 0        
Beginning Balance (in Shares) at Oct. 31, 2018   317,715            
Beginning Balance at Oct. 31, 2018 4,571 $ 3 $ 5,308   (336) (408) 4,567 $ 4
Components of comprehensive income, net of tax                
Net income 504       504   504  
Other comprehensive income 34         34 34  
Total comprehensive income (loss), net of tax 538           538  
Change in non-controlling interest increase (decrease) (4)             (4)
Cash dividends declared (52)       (52)   (52)  
Share-based awards issued, net of tax (in shares)   946            
Share-based awards issued 8   8       8  
Repurchase of common stock (in shares)       (1,128)        
Repurchase of common stock (75)     $ (75)     (75)  
Retirement of treasury shares (in shares)   (1,128)   (1,128)        
Retirement of treasury shares 0 $ 0 (16) $ (75) (59)   0  
Share-based compensation 24   24       24  
Ending Treasury Stock, Shares at Jan. 31, 2019       0        
Ending Treasury Stock, Value at Jan. 31, 2019       $ 0        
Ending Balance (in Shares) at Jan. 31, 2019   317,533            
Ending Balance at Jan. 31, 2019 5,036 $ 3 5,324   90 (381) 5,036 0
Beginning Treasury Stock, Shares at Oct. 31, 2019       0        
Beginning Treasury Stock, Value at Oct. 31, 2019       $ 0        
Beginning Balance (in Shares) at Oct. 31, 2019   309,071            
Beginning Balance at Oct. 31, 2019 4,748 $ 3 5,277   (18) (514) 4,748 0
Components of comprehensive income, net of tax                
Net income 197       197   197  
Other comprehensive income (7)         (7) (7)  
Total comprehensive income (loss), net of tax 190           190  
Cash dividends declared (56)       (56)   (56)  
Share-based awards issued, net of tax (in shares)   1,703            
Share-based awards issued (1)   (1)       (1)  
Repurchase of common stock (in shares)       (726)        
Repurchase of common stock (60)     $ (60)     (60)  
Retirement of treasury shares (in shares)   (726)   (726)        
Retirement of treasury shares 0 $ 0 (10) $ (60) (50)   0  
Share-based compensation 27   27       27  
Ending Treasury Stock, Shares at Jan. 31, 2020       0        
Ending Treasury Stock, Value at Jan. 31, 2020       $ 0        
Ending Balance (in Shares) at Jan. 31, 2020   310,048            
Ending Balance at Jan. 31, 2020 $ 4,848 $ 3 $ 5,293   $ 73 $ (521) $ 4,848 $ 0
XML 12 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES (Notes)
 3 Months Ended
Jan. 31, 2020
Leases [Abstract]  
Leases of Lessee Disclosure [Text Block] LEASES

As a lessee, we have various non- cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms was well as payments for common area maintenance. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years.
Prior to the adoption of the new lease accounting standard, future minimum lease payments as of October 31, 2019 and previously disclosed in the company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2019 under non- cancelable leases with initial terms exceeding twelve months were as follows:
 
Operating Leases
 
(in millions)
2020
$
52

2021
41

2022
29

2023
21

2024
14

2025 and thereafter
56

Total future minimum lease payments
$
213



The components of lease cost for operating leases were as follows:
 
Three Months Ended
 
January 31, 2020
 
(in millions)
 
 
Operating lease cost
$
15

Variable lease cost (a)
4

Sublease income
(4
)
      Total lease cost
$
15

(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.

Supplemental cash flow information related to leases was as follows:
 
Three Months Ended
 
January 31, 2020
 
(in millions)
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flow from operating leases
$
15

Non-cash right of use assets obtained in exchange for operating lease obligations
$
14



Supplemental balance sheet information related to leases was as follows:

 
 
 
Three Months Ended
 
Financial Statement Line Item
 
January 31, 2020
 
 
 
(in millions, except lease term and discount rate)
Assets:
 
 
 
Operating lease:
 
 
 
Right of use asset
Other assets
 
$
191

 
 
 
 
Liabilities:
 
 
 
Current
 
 
 
Operating lease liabilities
Other accrued liabilities
 
$
51

Long-Term
 
 
 
Operating lease liabilities
Other long-term liabilities
 
$
141

 
 
 
 
Weighted average remaining lease term in years
 
 
 
Operating leases
 
 
8.25 years

Weighted average discount rate
 
 
 
Operating leases
 
 
2.1
%

Future minimum rents payable as of January 31, 2020 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the condensed consolidated balance sheet as follows:
 
 
Operating Leases
 
 
(in millions)
2020
 
$
41

2021
 
45

2022
 
33

2023
 
22

2024
 
14

2025 and thereafter
 
57

Total undiscounted future minimum lease payments
 
$
212

Less: amount of lease payments representing interest
 
(20
)
Present value of future minimum lease payments
 
$
192

Less: current liabilities
 
(51
)
Long-term lease liabilities
 
$
141

 
 
 


As of January 31, 2020, we had no additional significant operating or finance leases that had not yet commenced.

As a lessor, we have contracts for equipment leased to customers in connection with our diagnostics business which include both operating-type lease and sales-type lease arrangements. We account for the non-lease component under the revenue recognition rules and the lease component under the leasing guidance. Equipment lease revenue for operating lease agreements is recognized as visualization kits and reagents are shipped over the life of the lease and the cost of customer leased equipment is recorded within property, plant and equipment, net in the consolidated condensed balance sheet and depreciated over the equipment’s estimated
useful life. For arrangements that have been classified as sales-type leases revenue is recognized when the transfer of control of the underlying leased asset has occurred and the net investment the lease recorded which is calculated at the present value of the remaining lease payments due from the lessee.

Revenue allocated to the lease income for both finance/sales-type lease and operating lease rental arrangements represents less than one percent of total net revenue in the three months ended January 31, 2020.

As of January 31, 2020, the original cost and net book value of operating leased assets was $49 million and $16 million, respectively. As of January 31, 2020, lease receivables related to sales-type leases were $38 million.
XML 13 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)
 3 Months Ended
Jan. 31, 2020
Accounting Policies [Abstract]  
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.

Basis of Presentation. We have prepared the accompanying financial data for the three months ended January 31, 2020 and 2019 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2019 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2019.

In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of January 31, 2020 and October 31, 2019, condensed consolidated statement of comprehensive income (loss) for the three months ended January 31, 2020 and 2019, condensed consolidated statement of operations for the three months ended January 31, 2020 and 2019, condensed consolidated statement of cash flows for the three months ended January 31, 2020 and 2019 and condensed consolidated statement of equity for the three months ended January 31, 2020 and 2019.

Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement benefit plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes,.

Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $90 million and $62 million as of January 31, 2020 and October 31, 2019, respectively. The change in the fair value over carrying value in the three months ended January 31, 2020 is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 11, "Fair Value Measurements" for additional information on the fair value of financial instruments.

Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows:
 
January 31,
 
October 31
 
2020
 
2019
 
(in millions)
Cash and cash equivalents
$
1,226

 
$
1,382

Restricted cash included in other assets
6

 
6

Total cash, cash equivalents and restricted cash
$
1,232

 
$
1,388



Leases. We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") and lease liabilities on the condensed consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates we have used a number of factors including the parent credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.

A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.

   See also Note 2, "New Accounting Pronouncements" and Note 9, "Leases" for additional information about the company’s leases.
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Other comprehensive income (loss), tax, parenthetical disclosures    
Unrealized gain on derivative instruments, tax $ 0 $ (2)
Amounts reclassified into earnings related to derivative instruments, tax 0 (1)
Foreign currency translation, tax 0 (9)
Net defined benefit pension cost and post retirement plan costs, tax    
Change in actuarial net loss, tax 3 4
Change in net prior service benefit, tax $ 1 $ 0
XML 15 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SHARE-BASED COMPENSATION (Notes)
 3 Months Ended
Jan. 31, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
 
Agilent accounts for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, employee stock purchases made under our employee stock purchase plan (“ESPP”) and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values.

Participants in the LTPP are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the
performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award, for the company's executive officers and other key employees. Participants in this program are also entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets over the three-year period are met. The performance target for grants made beginning 2017 and later were based on Earnings Per Share ("EPS"). The performance targets for the LTPP-EPS grants for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period.

The final LTPP award may vary from zero to 200 percent of the target award. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant.
 
The impact on our results for share-based compensation was as follows:
 

Three Months Ended

January 31,
 
2020

2019
 
(in millions)
Cost of products and services
$
6


$
5

Research and development
3


2

Selling, general and administrative
18


17

Total share-based compensation expense
$
27

 
$
24

 
At January 31, 2020 and October 31, 2019, there was no share-based compensation capitalized within inventory.
                                               
The following assumptions were used to estimate the fair value of awards granted.
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
LTPP:
 
 
 
Volatility of Agilent shares
23%
 
22%
Volatility of selected peer-company shares
15%-44%
 
15%-66%
Pair-wise correlation with selected peers
29%
 
30%
 
 
 
 
Post-vest holding restriction discount for all executive awards
5.3%
 
5.0%
 
Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulations model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock.  For the volatility of our LTPP (TSR) grants, we used our own historical stock price volatility.  

The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value.

The estimated fair value of restricted stock units and LTPP (EPS) awards is determined based on the market price of Agilent’s common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period.

All awards granted to our senior management employees have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulations model and an expected dividend yield to compute the discount.
XML 16 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES (Tables)
 3 Months Ended
Jan. 31, 2020
Leases [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases
Prior to the adoption of the new lease accounting standard, future minimum lease payments as of October 31, 2019 and previously disclosed in the company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2019 under non- cancelable leases with initial terms exceeding twelve months were as follows:
 
Operating Leases
 
(in millions)
2020
$
52

2021
41

2022
29

2023
21

2024
14

2025 and thereafter
56

Total future minimum lease payments
$
213
Lease Cost
Supplemental cash flow information related to leases was as follows:
 
Three Months Ended
 
January 31, 2020
 
(in millions)
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flow from operating leases
$
15

Non-cash right of use assets obtained in exchange for operating lease obligations
$
14


The components of lease cost for operating leases were as follows:
 
Three Months Ended
 
January 31, 2020
 
(in millions)
 
 
Operating lease cost
$
15

Variable lease cost (a)
4

Sublease income
(4
)
      Total lease cost
$
15

(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.
Lessee, Lease Assets and Liabilities
Supplemental balance sheet information related to leases was as follows:

 
 
 
Three Months Ended
 
Financial Statement Line Item
 
January 31, 2020
 
 
 
(in millions, except lease term and discount rate)
Assets:
 
 
 
Operating lease:
 
 
 
Right of use asset
Other assets
 
$
191

 
 
 
 
Liabilities:
 
 
 
Current
 
 
 
Operating lease liabilities
Other accrued liabilities
 
$
51

Long-Term
 
 
 
Operating lease liabilities
Other long-term liabilities
 
$
141

 
 
 
 
Weighted average remaining lease term in years
 
 
 
Operating leases
 
 
8.25 years

Weighted average discount rate
 
 
 
Operating leases
 
 
2.1
%
Lessee, Operating Lease, Liability, Maturity
Future minimum rents payable as of January 31, 2020 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the condensed consolidated balance sheet as follows:
 
 
Operating Leases
 
 
(in millions)
2020
 
$
41

2021
 
45

2022
 
33

2023
 
22

2024
 
14

2025 and thereafter
 
57

Total undiscounted future minimum lease payments
 
$
212

Less: amount of lease payments representing interest
 
(20
)
Present value of future minimum lease payments
 
$
192

Less: current liabilities
 
(51
)
Long-term lease liabilities
 
$
141

 
 
 
XML 17 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue (Tables)
 3 Months Ended
Jan. 31, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue


The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
 
Three Months Ended January 31,
 
2020
 
2019
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
(in millions)
 
 
 
 
 
 
 
 
Revenue by Region
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Americas
$
209

 
$
118

 
$
167

 
$
494

 
$
168

 
$
109

 
$
156

 
$
433

Europe
167

 
92

 
133

 
392

 
164

 
91

 
128

 
383

Asia Pacific
262

 
39

 
170

 
471

 
275

 
35

 
158

 
468

Total
$
638

 
$
249

 
$
470

 
$
1,357

 
$
607

 
$
235

 
$
442

 
$
1,284

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Revenue by End Markets
 
 
 
Pharmaceutical and Biopharmaceutical
$
423

 
$
391

Chemical and Energy
312

 
308

Diagnostics and Clinical
194

 
187

Food
130

 
129

Academia and Government
141

 
116

Environmental and Forensics
157

 
153

Total
$
1,357

 
$
1,284

 
 
 
 
Revenue by Type
 
 
 
Instrumentation
$
593

 
$
567

Non-instrumentation and other
764

 
717

Total
$
1,357

 
$
1,284
Contract Liabilities and Changes in Balances
The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2020:

 
 
Contract
Liabilities
 
 
(in millions)
 
 
 
Ending balance as of October 31, 2019
 
$
386

Net revenue deferred in the period
 
180

Revenue recognized that was included in the contract liability balance at the beginning of the period
 
(142
)
Change in deferrals from customer cash advances, net of revenue recognized
 
9

Currency translation and other adjustments
 
(1
)
Ending balance as of January 31, 2020
 
$
432
XML 18 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE- Revenue by Region (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Net revenue $ 1,357 $ 1,284
Life Sciences and Applied Markets    
Net revenue 638 607
Diagnostics and Genomics    
Net revenue 249 235
Agilent CrossLab    
Net revenue 470 442
Americas    
Net revenue 494 433
Americas | Life Sciences and Applied Markets    
Net revenue 209 168
Americas | Diagnostics and Genomics    
Net revenue 118 109
Americas | Agilent CrossLab    
Net revenue 167 156
Europe    
Net revenue 392 383
Europe | Life Sciences and Applied Markets    
Net revenue 167 164
Europe | Diagnostics and Genomics    
Net revenue 92 91
Europe | Agilent CrossLab    
Net revenue 133 128
Asia Pacific    
Net revenue 471 468
Asia Pacific | Life Sciences and Applied Markets    
Net revenue 262 275
Asia Pacific | Diagnostics and Genomics    
Net revenue 39 35
Asia Pacific | Agilent CrossLab    
Net revenue $ 170 $ 158
XML 19 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs    
Share-based compensation expense $ 27 $ 24
Cost of Products and Services    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs    
Share-based compensation expense 6 5
Research and Development Expense    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs    
Share-based compensation expense 3 2
Selling, General and Administrative Expenses    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs    
Share-based compensation expense $ 18 $ 17
XML 20 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Beginning Balance $ (514)  
Other comprehensive income (loss) before reclassifications (15)  
Amounts reclassified out of accumulated other comprehensive income (loss) 12  
Tax expense (benefit) (4)  
Other comprehensive income (loss) (7) $ 34
Ending Balance (521)  
Foreign Currency Translation    
Beginning Balance (204)  
Other comprehensive income (loss) before reclassifications (11)  
Amounts reclassified out of accumulated other comprehensive income (loss) 0  
Tax expense (benefit) 0  
Other comprehensive income (loss) (11)  
Ending Balance (215)  
Prior Service Credits    
Beginning Balance 131  
Other comprehensive income (loss) before reclassifications 0  
Amounts reclassified out of accumulated other comprehensive income (loss) (2)  
Tax expense (benefit) (1)  
Other comprehensive income (loss) (3)  
Ending Balance 128  
Actuarial Losses    
Beginning Balance (437)  
Other comprehensive income (loss) before reclassifications (5)  
Amounts reclassified out of accumulated other comprehensive income (loss) 14  
Tax expense (benefit) (3)  
Other comprehensive income (loss) 6  
Ending Balance (431)  
Unrealized Gains (Losses) on Derivatives    
Beginning Balance (4)  
Other comprehensive income (loss) before reclassifications 1  
Amounts reclassified out of accumulated other comprehensive income (loss) 0  
Tax expense (benefit) 0  
Other comprehensive income (loss) 1  
Ending Balance $ (3)  
XML 21 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
DERIVATIVES- Foreign Exchange Forward Contracts (Details)
$ in Millions
Jan. 31, 2020
USD ($)
contracts
Foreign Exchange Forward | Derivatives Designated as Hedging Instrument | Cash Flow Hedging  
Derivative  
Number of foreign exchange forward contracts (in units) | contracts 267
Foreign Exchange Forward | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member]  
Derivative  
Number of foreign exchange forward contracts (in units) | contracts 1
Foreign Exchange Forward | Derivatives Not Designated as Hedging Instruments  
Derivative  
Number of foreign exchange forward contracts (in units) | contracts 172
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging  
Derivative  
Derivative, Notional Amount $ (342)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Euro  
Derivative  
Derivative, Notional Amount (63)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | British Pound  
Derivative  
Derivative, Notional Amount (43)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Canadian Dollar  
Derivative  
Derivative, Notional Amount (39)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Japanese Yen  
Derivative  
Derivative, Notional Amount (83)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Korean Won  
Derivative  
Derivative, Notional Amount (62)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Chinese Yuan Renminbi  
Derivative  
Derivative, Notional Amount (71)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Swedish Krona  
Derivative  
Derivative, Notional Amount 0
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member]  
Derivative  
Derivative, Notional Amount (55)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Euro  
Derivative  
Derivative, Notional Amount (55)
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | British Pound  
Derivative  
Derivative, Notional Amount 0
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Canadian Dollar  
Derivative  
Derivative, Notional Amount 0
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Japanese Yen  
Derivative  
Derivative, Notional Amount 0
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Korean Won  
Derivative  
Derivative, Notional Amount 0
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Chinese Yuan Renminbi  
Derivative  
Derivative, Notional Amount 0
Sell | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Swedish Krona  
Derivative  
Derivative, Notional Amount 0
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | British Pound  
Derivative  
Derivative, Notional Amount (4)
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | Japanese Yen  
Derivative  
Derivative, Notional Amount (10)
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | Korean Won  
Derivative  
Derivative, Notional Amount (36)
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | Chinese Yuan Renminbi  
Derivative  
Derivative, Notional Amount (40)
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | Swedish Krona  
Derivative  
Derivative, Notional Amount (8)
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | Other  
Derivative  
Derivative, Notional Amount (9)
Buy | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Singapore Dollar  
Derivative  
Derivative, Notional Amount 15
Buy | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Other  
Derivative  
Derivative, Notional Amount 4
Buy | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Singapore Dollar  
Derivative  
Derivative, Notional Amount 0
Buy | Forward Contracts USD | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Other  
Derivative  
Derivative, Notional Amount 0
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments  
Derivative  
Derivative, Notional Amount 9
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | Euro  
Derivative  
Derivative, Notional Amount 64
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | Canadian Dollar  
Derivative  
Derivative, Notional Amount 26
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Net Investment Hedging [Member] | Singapore Dollar  
Derivative  
Derivative, Notional Amount $ 26
XML 22 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details)
$ in Millions
Jan. 31, 2020
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Remainder of 2020 $ 138
2021 172
2022 150
2023 107
2024 86
2025 68
Thereafter $ 223
XML 23 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SHORT-TERM DEBT Credit Facility (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 13, 2019
Jan. 31, 2020
Jan. 31, 2019
Oct. 21, 2019
Line of Credit Facility        
Proceeds from Lines of Credit   $ 432 $ 0  
Repayments of revolving credit facility   372 $ 0  
Other Short-term loan facilities        
Short-term loan facility   500    
Other short term loan borrowing capacity       $ 500
Other Short-term Borrowings   0    
Revolving Credit Facility [Member]        
Line of Credit Facility        
Initiation date of credit facility Mar. 13, 2019      
Expiration date of credit facility Mar. 13, 2024      
Proceeds from Lines of Credit   432    
Repayments of revolving credit facility   372    
Credit faciity terms (in years) five      
Maximum borrowing capacity of credit facility $ 1,000      
Amount outstanding on credit facility   $ 175    
XML 24 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual) - Pension Plan - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
United States    
Defined Benefit Plans Contributions    
Contributions to defined benefit plans $ 0 $ 0
Estimated future employer contributions in remainder of current fiscal year 0  
Foreign Plan    
Defined Benefit Plans Contributions    
Contributions to defined benefit plans 5 $ 6
Estimated future employer contributions in remainder of current fiscal year $ 19  
XML 25 R89.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION - Segment Assets (Details) - USD ($)
$ in Millions
Jan. 31, 2020
Oct. 31, 2019
Segment Reporting Information    
Assets $ 9,501 $ 9,452
Life Sciences and Applied Markets    
Segment Reporting Information    
Assets 3,187 3,202
Diagnostics and Genomics    
Segment Reporting Information    
Assets 2,612 2,620
Agilent CrossLab    
Segment Reporting Information    
Assets 1,360 1,331
Segment Total    
Segment Reporting Information    
Assets $ 7,159 $ 7,153
XML 26 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NEW ACCOUNTING PRONOUNCEMENTS- Initial Adoption (Details) - USD ($)
$ in Millions
Jan. 31, 2020
Nov. 01, 2019
Oct. 31, 2019
Assets      
Other assets $ 789 $ 803 $ 611
Liabilities      
Other accrued liabilities 256 488 440
Other long-term liabilities $ 620 617 $ 473
Impact of Adopting Accounting Standards Update 2016-02 - Leases      
Assets      
Other assets   192  
Liabilities      
Other accrued liabilities   48  
Other long-term liabilities   $ 144  
XML 27 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LONG-TERM DEBT (Tables)
 3 Months Ended
Jan. 31, 2020
Debt Disclosure [Abstract]  
Schedule of Senior Notes and Related Interest Rate Swaps
The following table summarizes the company’s long-term senior notes:
 
 
January 31, 2020
 
October 31, 2019
 
Amortized
Principal
 
Amortized
Principal
 
 
2022 Senior Notes
$
399

 
$
399

2023 Senior Notes
597

 
597

2026 Senior Notes
298

 
298

2029 Senior Notes
493

 
492

Total
$
1,787

 
$
1,786
XML 28 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details)
$ in Millions
 3 Months Ended
Jan. 31, 2020
USD ($)
Goodwill Roll Forward  
Goodwill beginning balance $ 3,593
Foreign currency translation impact (4)
Goodwill ending balance 3,589
Life Sciences and Applied Markets  
Goodwill Roll Forward  
Goodwill beginning balance 1,438
Foreign currency translation impact 0
Goodwill ending balance 1,438
Diagnostics and Genomics  
Goodwill Roll Forward  
Goodwill beginning balance 1,594
Foreign currency translation impact (2)
Goodwill ending balance 1,592
Agilent CrossLab  
Goodwill Roll Forward  
Goodwill beginning balance 561
Foreign currency translation impact (2)
Goodwill ending balance $ 559
XML 29 R90.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUBSEQUENT EVENTS (Details)
$ in Millions
Feb. 06, 2020
USD ($)
Subsequent Event [Member]  
Subsequent Event [Line Items]  
Amount of Litigation Settlement Awarded from Twist Bioscience $ 22.5
XML 30 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NET INCOME PER SHARE (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Numerator:    
Net income $ 197 $ 504
Denominators:    
Basic weighted-average shares (in shares) 310 318
Potential common shares - stock options and other employee stock plans (in shares) 3 4
Diluted weighted average shares (in shares) 313 322
XML 31 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Supplemental Cash Flows Information (Details)
$ in Millions
 3 Months Ended
Jan. 31, 2020
USD ($)
Leases [Abstract]  
Operating lease payments $ 15
Non-Cash Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 14
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)
 3 Months Ended
Jan. 31, 2020
Defined Benefit Plan [Abstract]  
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS

Components of net periodic costs. For the three months ended January 31, 2020 and 2019, our net pension and post retirement benefit costs were comprised of the following:
 
 
Three Months Ended January 31,
 
U.S.
Pension Plans
 
Non-U.S.
Pension Plans
 
U.S. Post Retirement
Benefit Plans
 
2020
 
2019
 
2020
 
2019
 
2020
 
2019
 
(in millions)
Service cost—benefits earned during the period
$
—

 
$
—

 
$
7

 
$
6

 
$
—

 
$
—

Interest cost on benefit obligation
4

 
5

 
2

 
3

 
1

 
—

Expected return on plan assets
(8
)
 
(7
)
 
(12
)
 
(11
)
 
(1
)
 
(1
)
Amortization:
 
 
 
 
 
 
 
 
 
 
 
Actuarial losses
1

 
—

 
12

 
9

 
1

 
1

Prior service credits
—

 
—

 
—

 
—

 
(2
)
 
(2
)
Total net plan costs
$
(3
)
 
$
(2
)
 
$
9

 
$
7

 
$
(1
)
 
$
(2
)

 
 
 
 
 
 
 
 
 
 
 
 

The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.

We made no contributions to our U.S. defined benefit plans during the three months ended January 31, 2020. We contributed $5 million to our non-U.S. defined benefit plans during the three months ended January 31, 2020.

We made no contributions to our U.S. defined benefit plans during the three months ended January 31, 2019. We contributed $6 million to our non-U.S. defined benefit plans during the three months ended January 31, 2019.

We do not expect to contribute to our U.S. defined benefit plans during the remainder of 2020 and we expect to contribute $19 million to our non-U.S. defined benefit plans during the remainder of 2020.
XML 33 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
STOCKHOLDERS' EQUITY (Notes)
 3 Months Ended
Jan. 31, 2020
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY
 
Stock Repurchase Program
 
On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the three months ended January 31, 2020, we repurchased and retired approximately 725,827 shares for $60 million under this authorization. During the three months ended January 31, 2019, we repurchased and retired approximately 1.1 million shares for $75 million under this authorization. As of January 31, 2020, we had remaining authorization to repurchase up to $967 million of our common stock under this program.

 
Cash Dividends on Shares of Common Stock
 
During the three months ended January 31, 2020, we paid cash dividends of $0.180 per common share or $56 million on the company's common stock. During the three months ended January 31, 2019, we paid cash dividends of $0.164 per common share or $52 million on the company's common stock.


Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions):
 
 
 
 
Net defined benefit pension cost and post retirement plan costs
 
 
 
 
Three Months Ended January 31, 2020
 
Foreign currency translation
 
Prior service credits
 
Actuarial Losses
 
Unrealized gains (losses) on derivatives
 
Total
 
 
(in millions)
As of October 31, 2019
 
$
(204
)
 
$
131

 
$
(437
)
 
$
(4
)
 
$
(514
)
 
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
 
(11
)
 
—

 
(5
)
 
1

 
(15
)

 
 
 
 
 
 
 
 
 
 
Amounts reclassified out of accumulated other comprehensive income (loss)
 
—

 
(2
)
 
14

 
—

 
12


 
 
 
 
 
 
 
 
 
 
Tax expense
 
—

 
(1
)
 
(3
)
 
—

 
(4
)

 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss)
 
(11
)
 
(3
)
 
6

 
1

 
(7
)

 
 
 
 
 
 
 
 
 
 
As of January 31, 2020
 
$
(215
)
 
$
128

 
$
(431
)
 
$
(3
)
 
$
(521
)
 
 
 
 
 
 
 
 
 
 
 


Reclassifications out of accumulated other comprehensive income (loss) for the three months ended January 31, 2020 and 2019 were as follows (in millions):
Details about accumulated other
comprehensive income (loss) components
 
Amounts Reclassified from
other comprehensive income (loss)
 
Affected line item in
statement of operations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
January 31,
 
 
 
 
2020

2019
 
 
 
 



 
 
Unrealized gain (loss) on derivatives
 
$
—


$
5

 
Cost of products
 
 
—


5

 
Total before income tax
 
 
—


(1
)
 
Provision for income tax
 
 
—


4

 
Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
 



 
 
 
 



 
 
Actuarial net loss
 
(14
)

(10
)
 
 
Prior service benefit
 
2


2

 
 
 
 
(12
)

(8
)
 
Total before income tax
 
 
6


4

 
Benefit for income tax
 
 
(6
)

(4
)
 
Total net of income tax
 
 



 
 
Total reclassifications for the period
 
$
(6
)

$
—

 
 


Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss).

Reclassifications out of accumulated other comprehensive income (loss) of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost together with curtailments and settlements (see Note 13, "Retirement Plans and Post Retirement Pension Plans").
XML 34 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
$ in Millions
Jan. 31, 2020
Oct. 31, 2019
Jan. 31, 2019
Oct. 31, 2018
Fair Value of Financial Instruments        
Fair value of senior notes in excess of carrying value $ 90 $ 62    
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents        
Cash and cash equivalents 1,226 1,382    
Restricted Cash 6 6    
Cash, cash equivalents, restricted cash and restricted cash equivalents $ 1,232 $ 1,388 $ 2,064 $ 2,254
XML 35 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
WARRANTIES AND CONTINGENCIES (Tables)
 3 Months Ended
Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Standard warranty
A summary of the standard warranty accrual activity is shown in the table below:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Beginning balance as of November 1,
$
32

 
$
35

Accruals for warranties including change in estimate
12

 
13

Settlements made during the period
(14
)
 
(16
)
Ending balance as of January 31,
$
30


$
32

 
 
 
 
Accruals for warranties due within one year
$
30

 
$
32

 
XML 36 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 37 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
INVENTORY (Details) - USD ($)
$ in Millions
Jan. 31, 2020
Oct. 31, 2019
Inventory, Net [Abstract]    
Finished goods $ 423 $ 416
Purchased parts and fabricated assemblies 283 263
Inventory $ 706 $ 679
XML 38 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Supplemental Balance Sheet Information (Details)
$ in Millions
Jan. 31, 2020
USD ($)
Operating lease liability, Current $ 51
Operating lease liability, Noncurrent $ 141
Weighted average remaining lease term (in years) - Operating leases 8 years 3 months
Weighted average discount rate - Operating leases 2.10%
Other assets  
Right-of-Use Asset $ 191
Other accrued liabilities  
Operating lease liability, Current 51
Other long-term liabilities  
Operating lease liability, Noncurrent $ 141
XML 39 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) - USD ($)
$ in Millions
Jan. 31, 2020
Oct. 31, 2019
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount $ 2,085 $ 2,086
Accumulated Amortization 1,026 979
Net Book Value 1,059 1,107
Purchased Technology    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 1,412 1,413
Accumulated Amortization 787 763
Net Book Value 625 650
Backlog    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 5 5
Accumulated Amortization 5 5
Net Book Value 0 0
Trademark/Tradenames    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 196 196
Accumulated Amortization 106 102
Net Book Value 90 94
Customer Relationships    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 329 329
Accumulated Amortization 105 87
Net Book Value 224 242
Third-Party Technology and Licenses    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 28 28
Accumulated Amortization 23 22
Net Book Value 5 6
Total amortizable intangible assets    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 1,970 1,971
Accumulated Amortization 1,026 979
Net Book Value 944 992
In-Process R&D    
Indefinite-Lived Intangible Assets (Excluding Goodwill)    
In-Process R&D $ 115 $ 115
EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 41 a-01312020x10q_htm.xml IDEA: XBRL DOCUMENT 0001090872 2019-11-01 2020-01-31 0001090872 2020-02-27 0001090872 2018-11-01 2019-01-31 0001090872 us-gaap:ProductMember 2018-11-01 2019-01-31 0001090872 us-gaap:ServiceOtherMember 2018-11-01 2019-01-31 0001090872 us-gaap:ProductMember 2019-11-01 2020-01-31 0001090872 us-gaap:ServiceOtherMember 2019-11-01 2020-01-31 0001090872 2020-01-31 0001090872 2019-10-31 0001090872 2018-10-31 0001090872 2019-01-31 0001090872 us-gaap:NoncontrollingInterestMember 2020-01-31 0001090872 us-gaap:RetainedEarningsMember 2019-11-01 2020-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2019-11-01 2020-01-31 0001090872 us-gaap:RetainedEarningsMember 2020-01-31 0001090872 us-gaap:ParentMember 2019-11-01 2020-01-31 0001090872 us-gaap:ParentMember 2019-10-31 0001090872 us-gaap:CommonStockMember 2020-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001090872 us-gaap:TreasuryStockMember 2019-11-01 2020-01-31 0001090872 us-gaap:TreasuryStockMember 2019-10-31 0001090872 us-gaap:ParentMember 2020-01-31 0001090872 us-gaap:CommonStockMember 2019-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001090872 us-gaap:CommonStockMember 2019-11-01 2020-01-31 0001090872 us-gaap:TreasuryStockMember 2020-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-31 0001090872 us-gaap:RetainedEarningsMember 2019-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2019-10-31 0001090872 us-gaap:ParentMember 2018-10-31 0001090872 us-gaap:TreasuryStockMember 2018-10-31 0001090872 us-gaap:CommonStockMember 2019-01-31 0001090872 us-gaap:ParentMember 2018-11-01 2019-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0001090872 us-gaap:TreasuryStockMember 2018-11-01 2019-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-31 0001090872 us-gaap:TreasuryStockMember 2019-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-01 2019-01-31 0001090872 us-gaap:RetainedEarningsMember 2018-10-31 0001090872 us-gaap:CommonStockMember 2018-11-01 2019-01-31 0001090872 us-gaap:RetainedEarningsMember 2018-11-01 2019-01-31 0001090872 us-gaap:ParentMember 2019-01-31 0001090872 us-gaap:CommonStockMember 2018-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2018-11-01 2019-01-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001090872 us-gaap:RetainedEarningsMember 2019-01-31 0001090872 us-gaap:NoncontrollingInterestMember 2018-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2018-11-01 2019-01-31 0001090872 us-gaap:NoncontrollingInterestMember 2019-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0001090872 2019-11-01 0001090872 us-gaap:AccountingStandardsUpdate201602Member 2019-11-01 0001090872 a:BioTekMember 2019-08-22 2019-08-23 0001090872 a:BioTekMember 2020-01-31 0001090872 a:ACEABiosciencesInc.Member 2018-11-14 2018-11-14 0001090872 a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-23 0001090872 a:BioTekMember us-gaap:TrademarksAndTradeNamesMember 2019-08-23 0001090872 a:BioTekMember 2019-08-23 0001090872 a:BioTekMember us-gaap:OrderOrProductionBacklogMember 2019-08-23 0001090872 a:BioTekMember us-gaap:TrademarksAndTradeNamesMember 2019-08-22 2019-08-23 0001090872 a:BioTekMember us-gaap:OrderOrProductionBacklogMember 2019-08-22 2019-08-23 0001090872 a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-23 0001090872 srt:MinimumMember a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-22 2019-08-23 0001090872 srt:MinimumMember a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-22 2019-08-23 0001090872 srt:MaximumMember a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-22 2019-08-23 0001090872 srt:MaximumMember a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-22 2019-08-23 0001090872 a:DiagnosticsandClinicalMarketMember 2018-11-01 2019-01-31 0001090872 a:EnvironmentalandForensicsMarketMember 2018-11-01 2019-01-31 0001090872 a:PharmaceuticalandBiopharmaceuticalMarketMember 2019-11-01 2020-01-31 0001090872 a:DiagnosticsandClinicalMarketMember 2019-11-01 2020-01-31 0001090872 a:InstrumentationMember 2019-11-01 2020-01-31 0001090872 a:NonInstrumentationandOtherMember 2019-11-01 2020-01-31 0001090872 a:InstrumentationMember 2018-11-01 2019-01-31 0001090872 a:EnvironmentalandForensicsMarketMember 2019-11-01 2020-01-31 0001090872 a:ChemicalandEnergyMarketMember 2019-11-01 2020-01-31 0001090872 a:AcademiaandGovernmentMarketMember 2018-11-01 2019-01-31 0001090872 a:FoodMarketMember 2019-11-01 2020-01-31 0001090872 a:PharmaceuticalandBiopharmaceuticalMarketMember 2018-11-01 2019-01-31 0001090872 a:AcademiaandGovernmentMarketMember 2019-11-01 2020-01-31 0001090872 a:FoodMarketMember 2018-11-01 2019-01-31 0001090872 a:NonInstrumentationandOtherMember 2018-11-01 2019-01-31 0001090872 a:ChemicalandEnergyMarketMember 2018-11-01 2019-01-31 0001090872 srt:AsiaPacificMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-01-31 0001090872 a:AgilentCrossLabMember 2019-11-01 2020-01-31 0001090872 srt:AmericasMember a:AgilentCrossLabMember 2018-11-01 2019-01-31 0001090872 srt:AsiaPacificMember 2018-11-01 2019-01-31 0001090872 a:DiagnosticsAndGenomicsMember 2019-11-01 2020-01-31 0001090872 a:DiagnosticsAndGenomicsMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember 2018-11-01 2019-01-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-01-31 0001090872 srt:AsiaPacificMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-01-31 0001090872 srt:AmericasMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-01-31 0001090872 srt:AmericasMember a:AgilentCrossLabMember 2019-11-01 2020-01-31 0001090872 srt:AsiaPacificMember 2019-11-01 2020-01-31 0001090872 srt:EuropeMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-01-31 0001090872 srt:EuropeMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-01-31 0001090872 srt:AsiaPacificMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-01-31 0001090872 srt:AsiaPacificMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-01-31 0001090872 srt:EuropeMember 2019-11-01 2020-01-31 0001090872 srt:AsiaPacificMember a:AgilentCrossLabMember 2018-11-01 2019-01-31 0001090872 srt:AmericasMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-01-31 0001090872 srt:AsiaPacificMember a:AgilentCrossLabMember 2019-11-01 2020-01-31 0001090872 a:AgilentCrossLabMember 2018-11-01 2019-01-31 0001090872 srt:AmericasMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-01-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember a:AgilentCrossLabMember 2018-11-01 2019-01-31 0001090872 srt:AmericasMember 2018-11-01 2019-01-31 0001090872 srt:EuropeMember a:AgilentCrossLabMember 2019-11-01 2020-01-31 0001090872 srt:AmericasMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-01-31 0001090872 srt:AmericasMember 2019-11-01 2020-01-31 0001090872 us-gaap:PublicUtilitiesInventoryTypeDomain 2019-11-01 2020-01-31 0001090872 us-gaap:CostOfSalesMember 2018-11-01 2019-01-31 0001090872 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-11-01 2020-01-31 0001090872 us-gaap:ResearchAndDevelopmentExpenseMember 2019-11-01 2020-01-31 0001090872 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-11-01 2019-01-31 0001090872 us-gaap:ResearchAndDevelopmentExpenseMember 2018-11-01 2019-01-31 0001090872 us-gaap:CostOfSalesMember 2019-11-01 2020-01-31 0001090872 a:LtppMember 2018-11-01 2019-01-31 0001090872 a:LtppMember 2019-11-01 2020-01-31 0001090872 a:LTPPRSUMember 2019-11-01 2020-01-31 0001090872 a:LTPPRSUMember 2018-11-01 2019-01-31 0001090872 us-gaap:PublicUtilitiesInventoryTypeDomain 2018-11-01 2019-10-31 0001090872 us-gaap:OtherCurrentLiabilitiesMember 2020-01-31 0001090872 us-gaap:OtherNoncurrentAssetsMember 2020-01-31 0001090872 us-gaap:OtherNoncurrentLiabilitiesMember 2020-01-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2019-10-31 0001090872 a:AgilentCrossLabMember 2020-01-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2020-01-31 0001090872 a:DiagnosticsAndGenomicsMember 2020-01-31 0001090872 a:DiagnosticsAndGenomicsMember 2019-10-31 0001090872 a:AgilentCrossLabMember 2019-10-31 0001090872 us-gaap:InProcessResearchAndDevelopmentMember 2019-10-31 0001090872 us-gaap:TrademarksMember 2019-10-31 0001090872 a:ThirdPartyTechnologyandLicensesMember 2019-10-31 0001090872 us-gaap:CustomerRelationshipsMember 2019-10-31 0001090872 us-gaap:DevelopedTechnologyRightsMember 2020-01-31 0001090872 us-gaap:OrderOrProductionBacklogMember 2019-10-31 0001090872 us-gaap:InProcessResearchAndDevelopmentMember 2020-01-31 0001090872 a:TotalAmortizableIntangibleAssetsMember 2019-10-31 0001090872 us-gaap:CustomerRelationshipsMember 2020-01-31 0001090872 us-gaap:OrderOrProductionBacklogMember 2020-01-31 0001090872 us-gaap:DevelopedTechnologyRightsMember 2019-10-31 0001090872 us-gaap:TrademarksMember 2020-01-31 0001090872 a:ThirdPartyTechnologyandLicensesMember 2020-01-31 0001090872 a:TotalAmortizableIntangibleAssetsMember 2020-01-31 0001090872 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0001090872 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0001090872 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0001090872 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-01-31 0001090872 currency:GBP us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:KRW us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:KRW us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:JPY us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:XXX us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:XXX us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:JPY us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:GBP us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:CNY us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:GBP us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SGD us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-31 0001090872 currency:JPY us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SGD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-01-31 0001090872 currency:XXX us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-31 0001090872 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-01-31 0001090872 currency:CAD us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SEK us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:CNY us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SGD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-31 0001090872 currency:KRW us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 currency:CAD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-01-31 0001090872 currency:CNY us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:CAD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SEK us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-31 0001090872 currency:SEK us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-01-31 0001090872 a:SeniorNotes2022Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 a:SeniorNotes2026Member us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 a:SeniorNotes2029Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 a:SeniorNotes2026Member us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-02-01 0001090872 a:SeniorNotes2022Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2012-07-01 0001090872 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-01-31 0001090872 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 a:SeniorNotes2029Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-08-16 0001090872 a:SeniorNotes2026Member us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-14 2016-09-15 0001090872 us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-11-01 2020-01-31 0001090872 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-01-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-10-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-01-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-11-01 2019-01-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-11-01 2020-01-31 0001090872 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-11-01 2019-01-31 0001090872 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-11-01 2019-01-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-11-01 2020-01-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-01-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-01-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-01-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-01-31 0001090872 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-11-01 2019-01-31 0001090872 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-11-01 2020-01-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-31 0001090872 us-gaap:RevolvingCreditFacilityMember 2020-01-31 0001090872 us-gaap:RevolvingCreditFacilityMember 2019-11-01 2020-01-31 0001090872 2019-10-21 0001090872 us-gaap:RevolvingCreditFacilityMember 2019-03-13 2019-03-13 0001090872 us-gaap:RevolvingCreditFacilityMember 2019-03-13 0001090872 a:SeniorNotes2029Member 2020-01-31 0001090872 a:SeniorNotes2026Member 2020-01-31 0001090872 a:SeniorNotes2026Member 2019-10-31 0001090872 a:SeniorNotes2022Member 2020-01-31 0001090872 a:SeniorNotes2023Member 2020-01-31 0001090872 a:SeniorNotes2022Member 2019-10-31 0001090872 a:SeniorNotes2023Member 2019-10-31 0001090872 a:SeniorNotes2029Member 2019-10-31 0001090872 a:A2019RepurchaseProgramMember 2018-11-01 2019-01-31 0001090872 a:A2019RepurchaseProgramMember 2019-11-01 2020-01-31 0001090872 a:A2015RepurchaseProgramMember 2018-11-01 2019-01-31 0001090872 a:A2019RepurchaseProgramMember 2020-01-31 0001090872 a:A2019RepurchaseProgramMember 2018-11-19 0001090872 us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedTranslationAdjustmentMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2019-10-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2019-11-01 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2020-01-31 0001090872 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2019-10-31 0001090872 us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-10-31 0001090872 us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2020-01-31 0001090872 us-gaap:AccumulatedTranslationAdjustmentMember 2019-10-31 0001090872 a:SegmentTotalMember 2018-11-01 2019-01-31 0001090872 a:SegmentTotalMember 2019-11-01 2020-01-31 0001090872 a:SegmentTotalMember 2020-01-31 0001090872 a:SegmentTotalMember 2019-10-31 0001090872 us-gaap:SubsequentEventMember 2020-02-06 2020-02-06 pure a:contracts shares iso4217:USD iso4217:USD shares 0.66 0.44 0.15 0.15 13000000 33000000 false --10-31 Q1 2020 0001090872 false Large Accelerated Filer false P8Y P13Y P3Y P5Y 40000000 0.01 0.01 2000000000 2000000000 309000000 310000000 0 0 0 0 0 0 0 0 4000000 3000000 0 1000000 -9000000 0 -2000000 0 0.01 0.01 125000000 125000000 0 0 P0Y12M0D 0.85 0 10-Q true 2020-01-31 false 001-15405 AGILENT TECHNOLOGIES, INC. DE 77-0518772 5301 Stevens Creek Blvd., Santa Clara, CA 95051 (800) 227-9770 Common Stock, $0.01 par value A NYSE Yes Yes Large Accelerated Filer false false false 309651359 1023000000 980000000 334000000 304000000 1357000000 1284000000 454000000 414000000 180000000 163000000 634000000 577000000 104000000 102000000 404000000 355000000 1142000000 1034000000 215000000 250000000 3000000 10000000 20000000 18000000 21000000 6000000 219000000 248000000 22000000 -256000000 197000000 504000000 0.64 1.58 0.63 1.57 310000000 318000000 313000000 322000000 197000000 504000000 1000000 -4000000 0 4000000 -11000000 38000000 6000000 6000000 3000000 2000000 -7000000 34000000 190000000 538000000 1226000000 1382000000 966000000 930000000 706000000 679000000 204000000 198000000 3102000000 3189000000 844000000 850000000 3589000000 3593000000 1059000000 1107000000 118000000 102000000 789000000 611000000 9501000000 9452000000 329000000 354000000 253000000 334000000 379000000 336000000 675000000 616000000 256000000 440000000 1892000000 2080000000 1787000000 1791000000 354000000 360000000 620000000 473000000 4653000000 4704000000 0 0 3000000 3000000 5293000000 5277000000 73000000 -18000000 -521000000 -514000000 4848000000 4748000000 9501000000 9452000000 197000000 504000000 79000000 54000000 27000000 24000000 10000000 -281000000 4000000 4000000 16000000 0 -2000000 -3000000 40000000 22000000 32000000 12000000 -15000000 -16000000 -80000000 -71000000 195000000 -26000000 -59000000 213000000 34000000 39000000 1000000 2000000 0 1000000 0 248000000 -35000000 -290000000 32000000 22000000 33000000 13000000 56000000 52000000 0 4000000 432000000 0 372000000 0 4000000 0 60000000 75000000 -61000000 -122000000 -1000000 9000000 -156000000 -190000000 1388000000 2254000000 1232000000 2064000000 241000000 21000000 17000000 25000000 -9000000 -13000000 309071000 3000000 5277000000 0 0 -18000000 -514000000 4748000000 0 4748000000 197000000 197000000 197000000 -7000000 -7000000 -7000000 190000000 190000000 56000000 56000000 56000000 1703000 -1000000 -1000000 -1000000 726000 60000000 60000000 60000000 726000 0 10000000 726000 60000000 50000000 0 0 27000000 27000000 27000000 310048000 3000000 5293000000 0 0 73000000 -521000000 4848000000 0 4848000000 317715000 3000000 5308000000 0 0 -336000000 -408000000 4567000000 4000000 4571000000 33000000 -7000000 26000000 26000000 504000000 504000000 504000000 34000000 34000000 34000000 538000000 538000000 -4000000 -4000000 52000000 52000000 52000000 946000 8000000 8000000 8000000 1128000 75000000 75000000 75000000 1128000 0 16000000 1128000 75000000 59000000 0 0 24000000 24000000 24000000 317533000 3000000 5324000000 0 0 90000000 -381000000 5036000000 0 5036000000 OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Overview. </span><span style="font-family:inherit;font-size:10pt;">Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;">. We have prepared the accompanying financial data for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:10pt;"> pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, condensed consolidated statement of comprehensive income (loss) for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, condensed consolidated statement of operations for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and condensed consolidated statement of equity for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</span><span style="font-family:inherit;font-size:10pt;"> The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement benefit plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes,.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments.</span><span style="font-family:inherit;font-size:10pt;"> The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The change in the fair value over carrying value in the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 11, "Fair Value Measurements" for additional information on the fair value of financial instruments.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash and Restricted Cash Equivalents. </span><span style="font-family:inherit;font-size:10pt;">Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases. </span><span style="font-family:inherit;font-size:10pt;">We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") and lease liabilities on the condensed consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates we have used a number of factors including the parent credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   See also Note 2, "New Accounting Pronouncements" and Note 9, "Leases" for additional information about the company’s leases.</span></div> <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Overview. </span><span style="font-family:inherit;font-size:10pt;">Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;">. We have prepared the accompanying financial data for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:10pt;"> pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, condensed consolidated statement of comprehensive income (loss) for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, condensed consolidated statement of operations for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and condensed consolidated statement of equity for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</span><span style="font-family:inherit;font-size:10pt;"> The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement benefit plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes,.</span></div> <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments.</span><span style="font-family:inherit;font-size:10pt;"> The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The change in the fair value over carrying value in the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 11, "Fair Value Measurements" for additional information on the fair value of financial instruments.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash and Restricted Cash Equivalents. </span><span style="font-family:inherit;font-size:10pt;">Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 90000000 62000000 <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash and Restricted Cash Equivalents. </span><span style="font-family:inherit;font-size:10pt;">Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1226000000 1382000000 6000000 6000000 1232000000 1388000000 <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases. </span><span style="font-family:inherit;font-size:10pt;">We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") and lease liabilities on the condensed consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates we have used a number of factors including the parent credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   See also Note 2, "New Accounting Pronouncements" and Note 9, "Leases" for additional information about the company’s leases.</span></div> NEW ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no changes to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> except for the following:</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;">In December 2019, the Financial Accounting Standards Board ("FASB") issued new guidance to simplify the accounting for income taxes. This guidance eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences.</span><span style="font-family:inherit;font-size:10pt;">The new guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We are evaluating the impact of this guidance on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to record most leases on the balance sheet as lease liabilities, initially measured at the present value of future lease payments, with a corresponding right-of-use asset. The accounting applied by a lessor is largely unchanged from that applied under the prior </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">accounting standard. </span></div><div style="line-height:120%;padding-top:17px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 1, 2019, we adopted the new accounting guidance using the modified retrospective method, by applying the transition approach, for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning November 1, 2019 are presented under the new accounting standard, while prior period amounts have not been restated. The standard had a significant impact on the condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, but did not have a significant impact on the condensed consolidated statement of operations or condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of new accounting standard, we elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. We also elected to exclude leases with a term of 12 months or less in the ROU assets and lease liabilities. The adoption of this standard had no impact on our results of operations, cash flows and retained earnings.</span></div><div style="line-height:120%;padding-top:17px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adoption of the new guidance impacted the condensed consolidated balance sheet as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of Adopting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">November 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Lease Guidance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adopted</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>617</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.</span></div> <div style="line-height:120%;padding-top:17px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adoption of the new guidance impacted the condensed consolidated balance sheet as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of Adopting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">November 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Lease Guidance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adopted</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>803</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>617</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 611000000 192000000 803000000 440000000 48000000 488000000 473000000 144000000 617000000 ACQUISITIONS<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of BioTek</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">and ACEA</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 23, 2019 we completed the acquisition of privately-owned Lionheart Technologies LLC ("BioTek"), a leader in the design, manufacture and distribution of innovative life science instrumentation for </span><span style="font-family:inherit;font-size:10pt;"><span>$1.17 billion</span></span><span style="font-family:inherit;font-size:10pt;">, under the merger agreement. As a result of the acquisition, BioTek has become a wholly-owned subsidiary of Agilent. Accordingly, the results of BioTek are included in Agilent's condensed consolidated financial statements from the acquisition date. The acquisition of BioTek and its portfolio is another step to expand our position in the cell analysis market.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consideration paid was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.17 billion</span></span><span style="font-family:inherit;font-size:10pt;">. Agilent funded the acquisition using existing cash of </span><span style="font-family:inherit;font-size:10pt;"><span>$470 million</span></span><span style="font-family:inherit;font-size:10pt;"> and debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$700 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The BioTek acquisition was accounted for in accordance with the authoritative accounting guidance. The acquired assets and assumed liabilities were recorded by Agilent at their estimated fair values. Agilent determined the estimated fair values with the assistance of appraisals or valuations performed by third party specialists, discounted cash flow analyses, and estimates made by management. We expect to realize revenue synergies, leverage and expand the existing sales channels and product development resources, and utilize the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of BioTek’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired was allocated to our operating segments and reporting units as a part of the purchase price allocation. All goodwill was allocated to the life sciences and applied markets reporting unit. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agilent’s acquisition of BioTek is treated as an asset purchase for tax purposes. The tax basis of the acquired assets equals the fair market value on acquisition date.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:90%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>641</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,193</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee compensation and benefits</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of cash and cash equivalents, accounts receivable, other current assets, accounts payable and other accrued liabilities were generally determined using historical carrying values given the short-term nature of these assets and liabilities.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values for acquired intangible assets and deferred revenue were determined with the input from third party valuation specialists.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of certain other assets, inventory, property, plant and equipment, investments, long-term debt, and certain other long-term liabilities were determined internally using historical carrying values and estimates made by management.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuations of intangible assets acquired</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed product technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5-13 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3-8 years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Backlog</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2 months</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradenames and trademarks</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets subject to amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>641</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, the intangible assets, including in-process research and development, were valued with input from valuation specialists. Agilent used variations of the income approach in determining the fair value of intangible assets acquired in the BioTek acquisition. Specifically, the developed product technology and in-process research and development were valued using the multi-period excess earnings method under the income approach by discounting forecasted cash flows directly related to the products expecting to result from the projects, net of returns on contributory assets. The company utilized the incremental cash flow method for determining the fair value of the customer relationships acquired, and the relief from royalty method to determine the fair value of the tradename. Order backlog was valued on a direct cash flow basis. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The primary in-process research and development project acquired relates to a next version of a product which will be released later in 2020. Total costs to complete for all BioTek in-process research and development were estimated at approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of the close date.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition and integration costs directly related to the BioTek acquisition totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and were recorded in selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;">. The financial results of ACEA have been included in our financial results from the acquisition date.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's condensed consolidated statements of operations as of the beginning of fiscal 2019 (in millions, except per share amounts): </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,326</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share — basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share — diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited proforma financial information assumes that the companies were combined as of November 1, 2017 and include business combination accounting effects from the acquisition including amortization charges from acquired intangible assets, the impact on cost of sales due to the respective estimated fair value adjustments to inventory, changes to interest income for cash used in the acquisition, interest expense and currency losses associated with debt paid in connection with the acquisition and acquisition related transaction costs and tax related effects. The proforma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited proforma financial information for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> combines the historical results of Agilent (which includes ACEA after the acquisition date), the first two weeks of the quarter for ACEA and BioTek for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 1170000000 1170000000 470000000 700000000 <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:90%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>641</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,193</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee compensation and benefits</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10000000 28000000 21000000 2000000 8000000 641000000 483000000 1193000000 4000000 5000000 7000000 2000000 4000000 1171000000 <div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed product technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5-13 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3-8 years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Backlog</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2 months</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradenames and trademarks</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets subject to amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>641</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 387000000 202000000 5000000 P2M 43000000 P10Y 637000000 4000000 641000000 2000000 4000000 250000000 <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's condensed consolidated statements of operations as of the beginning of fiscal 2019 (in millions, except per share amounts): </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,326</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share — basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share — diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1326000000 474000000 1.49 1.47 REVENUE <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Diagnostics and Genomics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Agilent CrossLab</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Diagnostics and Genomics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Agilent CrossLab</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenue by Region</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Americas</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>433</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>468</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>638</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the company’s total revenue disaggregated by end markets and by revenue type:</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenue by End Markets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical and Biopharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chemical and Energy</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics and Clinical</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Food</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Academia and Government</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Environmental and Forensics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenue by Type</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Instrumentation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>593</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-instrumentation and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>764</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Balances</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Assets</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheet. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of contract assets as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$131 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$110 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The increase in unbilled receivables during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> is a result of recognition of revenue upon the transfer of the control to the customer. In some instances, transfer of control is prior to invoicing the customers and excluding amounts transferred to trade receivables during the period amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$21 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Liabilities</span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of October 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net revenue deferred in the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in deferrals from customer cash advances, net of revenue recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currency translation and other adjustments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of January 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> revenue recognized that was included in the contract liability balance at </span><span style="font-family:inherit;font-size:10pt;">October 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheet based on the timing of when we expect to complete our performance obligation.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incremental costs of obtaining a contract with a customer are recognized as an asset if it expects the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and are included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transaction Price Allocated to the Remaining Performance Obligations </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;"><span>$210 million</span></span>, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, and software maintenance contracts and revenue associated with lease arrangements. <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Diagnostics and Genomics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Agilent CrossLab</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Diagnostics and Genomics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Agilent CrossLab</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenue by Region</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Americas</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>433</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>468</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>638</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the company’s total revenue disaggregated by end markets and by revenue type:</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenue by End Markets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical and Biopharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chemical and Energy</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics and Clinical</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Food</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Academia and Government</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Environmental and Forensics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenue by Type</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Instrumentation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>593</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-instrumentation and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>764</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 209000000 118000000 167000000 494000000 168000000 109000000 156000000 433000000 167000000 92000000 133000000 392000000 164000000 91000000 128000000 383000000 262000000 39000000 170000000 471000000 275000000 35000000 158000000 468000000 638000000 249000000 470000000 1357000000 607000000 235000000 442000000 1284000000 423000000 391000000 312000000 308000000 194000000 187000000 130000000 129000000 141000000 116000000 157000000 153000000 1357000000 1284000000 593000000 567000000 764000000 717000000 1357000000 1284000000 131000000 110000000 21000000 <div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of October 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net revenue deferred in the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in deferrals from customer cash advances, net of revenue recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currency translation and other adjustments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of January 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 386000000 180000000 -142000000 9000000 -1000000 432000000 -125000000 210000000 SHARE-BASED COMPENSATION<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agilent accounts for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, employee stock purchases made under our employee stock purchase plan (“ESPP”) and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Participants in the LTPP are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award, for the company's executive officers and other key employees. Participants in this program are also entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets over the three-year period are met. The performance target for grants made beginning 2017 and later were based on Earnings Per Share ("EPS"). The performance targets for the LTPP-EPS grants for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The final LTPP award may vary from zero to 200 percent of the target award. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact on our results for share-based compensation was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products and services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> share-based compensation capitalized within inventory. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">                                               </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following assumptions were used to estimate the fair value of awards granted.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LTPP:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility of Agilent shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility of selected peer-company shares</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15%-44%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15%-66%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pair-wise correlation with selected peers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Post-vest holding restriction discount for all executive awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.0%</span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulations model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock.  For the volatility of our LTPP (TSR) grants, we used our own historical stock price volatility.  </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The ESPP allows eligible employees to purchase shares of our common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>85 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the price at purchase and uses the purchase date to establish the fair market value. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of restricted stock units and LTPP (EPS) awards is determined based on the market price of Agilent’s common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>All awards granted to our senior management employees have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulations model and an expected dividend yield to compute the discount. <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact on our results for share-based compensation was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products and services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div> 6000000 5000000 3000000 2000000 18000000 17000000 27000000 24000000 0 <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following assumptions were used to estimate the fair value of awards granted.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LTPP:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility of Agilent shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility of selected peer-company shares</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15%-44%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15%-66%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pair-wise correlation with selected peers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Post-vest holding restriction discount for all executive awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.0%</span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div> 0.23 0.22 0.29 0.30 0.053 0.050 0.85 INCOME TAXES <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the company's income tax expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$22 million</span></span><span style="font-family:inherit;font-size:10pt;"> with an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>10.0 percent</span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, our effective tax rate and the resulting provision for income taxes were significantly impacted by a discrete benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$13 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the excess tax benefits from stock-based compensation.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the company's income tax benefit was </span><span style="font-family:inherit;font-size:10pt;"><span>$256 million</span></span><span style="font-family:inherit;font-size:10pt;"> with an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>(103.2) percent</span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our effective tax rate and the resulting provision for income taxes were significantly impacted by a discrete benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$299 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the extension of the company’s tax incentive in Singapore. The income taxes for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> also includes the excess tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:10pt;"> from stock-based compensation.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In the U.S., tax years remain open back to the year 2016 for federal income tax purposes and the year 2015 for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is reasonably possible there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits. The company will continue to assess the impact of the further guidance from federal and state tax authorities on its business and consolidated financial statements. Any future adjustments will be recognized as discrete income tax expense or benefit in the period the adjustments are determined.</span></div> 22000000 0.100 13000000 -256000000 -1.032 299000000 4000000 NET INCOME PER SHARE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic weighted-average shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential common shares— stock options and other employee stock plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted weighted-average shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards.</span></div><div style="line-height:120%;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive.   </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, the impact of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share was not material.</span></div> <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic weighted-average shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential common shares— stock options and other employee stock plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted weighted-average shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 197000000 504000000 310000000 318000000 3000000 4000000 313000000 322000000 INVENTORY<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>416</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchased parts and fabricated assemblies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>679</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> INVENTORY<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>416</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchased parts and fabricated assemblies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>679</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 423000000 416000000 283000000 263000000 706000000 679000000 LEASES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a lessee, we have various non- cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms was well as payments for common area maintenance. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of the new lease accounting standard, future minimum lease payments as of </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and previously disclosed in the company’s Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> under non- cancelable leases with initial terms exceeding twelve months were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease cost for operating leases were as follows</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sublease income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">      Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:17px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flow from operating leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash right of use assets obtained in exchange for operating lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:17px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:39%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financial Statement Line Item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions, except lease term and discount rate)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease: </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-Term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.25 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:17px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum rents payable as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the condensed consolidated balance sheet as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total undiscounted future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount of lease payments representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had no additional significant operating or finance leases that had not yet commenced.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a lessor, we have contracts for equipment leased to customers in connection with our diagnostics business which include both operating-type lease and sales-type lease arrangements. We account for the non-lease component under the revenue recognition rules and the lease component under the leasing guidance. Equipment lease revenue for operating lease agreements is recognized as visualization kits and reagents are shipped over the life of the lease and the cost of customer leased equipment is recorded within property, plant and equipment, net in the consolidated condensed balance sheet and depreciated over the equipment’s estimated </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">useful life. For arrangements that have been classified as sales-type leases revenue is recognized when the transfer of control of the underlying leased asset has occurred and the net investment the lease recorded which is calculated at the present value of the remaining lease payments due from the lessee. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue allocated to the lease income for both finance/sales-type lease and operating lease rental arrangements represents less than one percent of total net revenue in the three months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the original cost and net book value of operating leased assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, lease receivables related to sales-type leases were </span><span style="font-family:inherit;font-size:10pt;"><span>$38 million</span></span>. <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of the new lease accounting standard, future minimum lease payments as of </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and previously disclosed in the company’s Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> under non- cancelable leases with initial terms exceeding twelve months were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 52000000 41000000 29000000 21000000 14000000 56000000 213000000 15000000 4000000 4000000 15000000 <div style="line-height:120%;padding-top:17px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flow from operating leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash right of use assets obtained in exchange for operating lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease cost for operating leases were as follows</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sublease income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">      Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 15000000 14000000 <div style="line-height:120%;padding-top:17px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:39%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financial Statement Line Item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions, except lease term and discount rate)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease: </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-Term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.25 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 191000000 51000000 141000000 P8Y3M 0.021 <div style="line-height:120%;padding-top:17px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum rents payable as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the condensed consolidated balance sheet as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total undiscounted future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount of lease payments representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 41000000 45000000 33000000 22000000 14000000 57000000 212000000 20000000 192000000 51000000 141000000 49000000 16000000 38000000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents goodwill balances and the movements for each of our reportable segments during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Diagnostics and Genomics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Agilent CrossLab</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of October 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,594</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation impact</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of January 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,592</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>559</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of other intangible assets as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are shown in the table below:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Purchased Other Intangible Assets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">and Impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of October 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchased technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Backlog</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademark/Tradename</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third-party technology and licenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>979</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-Process R&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>979</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of January 31, 2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchased technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Backlog</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademark/Tradename</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third-party technology and licenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-Process R&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,026</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> additions to goodwill and there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> additions to other intangible assets. During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the impact of foreign currency translation on other intangible assets was not material. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In general, for United States federal tax purposes, goodwill from asset purchases is deductible, however any goodwill created as part of a stock acquisition is not deductible. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> indicators of impairments of indefinite-lived intangible assets or goodwill during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense of intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and for each of the five succeeding fiscal years and thereafter is estimated below:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:92%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated future amortization expense:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents goodwill balances and the movements for each of our reportable segments during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Diagnostics and Genomics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Agilent CrossLab</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of October 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,594</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation impact</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of January 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,592</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>559</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1438000000 1594000000 561000000 3593000000 0 -2000000 -2000000 -4000000 1438000000 1592000000 559000000 3589000000 <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of other intangible assets as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are shown in the table below:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Purchased Other Intangible Assets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">and Impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of October 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchased technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Backlog</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademark/Tradename</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third-party technology and licenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>979</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-Process R&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>979</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of January 31, 2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchased technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Backlog</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademark/Tradename</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third-party technology and licenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-Process R&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,026</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div> 1413000000 763000000 650000000 5000000 5000000 0 196000000 102000000 94000000 329000000 87000000 242000000 28000000 22000000 6000000 1971000000 979000000 992000000 115000000 115000000 2086000000 979000000 1107000000 1412000000 787000000 625000000 5000000 5000000 0 196000000 106000000 90000000 329000000 105000000 224000000 28000000 23000000 5000000 1970000000 1026000000 944000000 115000000 115000000 2085000000 1026000000 1059000000 0 0 0 48000000 29000000 <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and for each of the five succeeding fiscal years and thereafter is estimated below:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:92%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated future amortization expense:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 138000000 172000000 150000000 107000000 86000000 68000000 223000000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Hierarchy</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1</span><span style="font-family:inherit;font-size:10pt;">- applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2</span><span style="font-family:inherit;font-size:10pt;">- applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3</span><span style="font-family:inherit;font-size:10pt;">- applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement at January 31, 2020 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Markets for</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents (money market funds)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments (foreign exchange contracts)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments (foreign exchange contracts) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement at October 31, 2019 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Markets for</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents (money market funds)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments (foreign exchange contracts)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>851</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments (foreign exchange contracts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. It has been classified as level 2 </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading securities, which is comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive loss within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Investments.</span><span style="font-family:inherit;font-size:10pt;"> There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairments of investments for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairments of long-lived assets held and used or long-lived assets held for sale. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment of non-marketable securities. For the three months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, an unrealized gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, were included in net income as adjustments to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. As of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the carrying amount of non-marketable equity securities without readily determinable fair values was </span><span style="font-family:inherit;font-size:10pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$47 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair values for the non-marketable securities included in long-term investments on the condensed consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when it occurs.</span></div> <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement at January 31, 2020 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Markets for</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents (money market funds)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments (foreign exchange contracts)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments (foreign exchange contracts) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement at October 31, 2019 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Markets for</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents (money market funds)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments (foreign exchange contracts)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>851</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments (foreign exchange contracts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred compensation liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 602000000 602000000 0 0 6000000 0 6000000 0 29000000 29000000 0 0 25000000 0 25000000 0 662000000 631000000 31000000 0 6000000 0 6000000 0 29000000 0 29000000 0 35000000 0 35000000 0 784000000 784000000 0 0 12000000 0 12000000 0 30000000 30000000 0 0 25000000 0 25000000 0 851000000 814000000 37000000 0 6000000 0 6000000 0 30000000 0 30000000 0 36000000 0 36000000 0 0 0 0 16000000 0 63000000 47000000 DERIVATIVES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts, purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flow Hedges</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> ineffectiveness and gains and losses recognized in other income (expense) due to de-designation of cash flow hedge contracts were not significant. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2012, Agilent executed treasury lock agreements for </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, Agilent executed </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> forward-starting pay fixed/receive variable interest rate swaps for the notional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$300 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:10pt;"> and we recognized this as a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$6 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2019, Agilent executed treasury lock agreements for </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$6 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Investment Hedges </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) and are assessed for effectiveness against the underlying exposure every reporting period.  If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Hedges</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors.  We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$3 million</span></span><span style="font-family:inherit;font-size:10pt;">. The credit-risk-related contingent features underlying these agreements had not been triggered as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span>267</span></span><span style="font-family:inherit;font-size:10pt;"> foreign exchange forward contracts open as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and designated as cash flow hedges. There were </span><span style="font-family:inherit;font-size:10pt;"><span>172</span></span><span style="font-family:inherit;font-size:10pt;"> foreign exchange forward contracts open as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> not designated as hedging instruments. There was </span><span style="font-family:inherit;font-size:10pt;"><span>1</span></span><span style="font-family:inherit;font-size:10pt;"> foreign exchange forward contracts open as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Designated as </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Designated as <br/>Net Investment Hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives </span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Not Designated as </span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hedging Instruments</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Forward</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contracts USD</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Forward<br/>Contracts USD</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Forward</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contracts USD</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Buy/(Sell)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Buy/(Sell)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Buy/(Sell)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">British Pound</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canadian Dollar</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japanese Yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Korean Won</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Singapore Dollar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chinese Yuan Renminbi</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Swedish Krona</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Totals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Values of Derivative Instruments</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset Derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, <br/>2019</span></div></td></tr><tr><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) recognized in accumulated other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) on time value of forward contracts recorded in cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) recognized in other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the estimated amount of existing net gain that is expected to be reclassified from accumulated other comprehensive loss to cost of sales within the next twelve months is </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$4 million</span></span>. 400000000 1000000 3 300000000 10000000 6000000 250000000 6000000 3000000 267 172 1 The aggregated notional amounts by currency and designation as of <span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span><div style="line-height:120%;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Designated as </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Designated as <br/>Net Investment Hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives </span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Not Designated as </span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hedging Instruments</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Forward</span></div><div style="padding-bottom:0px;padding-left:0px;padding-right:0px;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contracts USD</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Forward<br/>Contracts USD</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Forward</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contracts USD</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Buy/(Sell)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Buy/(Sell)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Buy/(Sell)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">British Pound</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canadian Dollar</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japanese Yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Korean Won</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Singapore Dollar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chinese Yuan Renminbi</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Swedish Krona</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Totals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div> -63000000 -55000000 64000000 -43000000 0 -4000000 -39000000 0 26000000 -83000000 0 -10000000 -62000000 0 -36000000 15000000 0 26000000 -71000000 0 -40000000 0 0 -8000000 4000000 0 -9000000 -342000000 -55000000 9000000 Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of <span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Values of Derivative Instruments</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset Derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, <br/>2019</span></div></td></tr><tr><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3000000 3000000 2000000 2000000 3000000 9000000 4000000 4000000 6000000 12000000 6000000 6000000 <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange contracts:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) recognized in accumulated other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) on time value of forward contracts recorded in cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) recognized in other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1000000 -6000000 0 5000000 0 1000000 -2000000 -3000000 4000000 RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS<div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Components of net periodic costs.</span><span style="font-family:inherit;font-size:10pt;"> For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, our net pension and post retirement benefit costs were comprised of the following:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. <br/>Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-U.S.<br/>Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Post Retirement</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost—benefits earned during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost on benefit obligation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial losses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior service credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net plan costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:41%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We made </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> contributions to our U.S. defined benefit plans during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. We contributed </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to our non-U.S. defined benefit plans during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We made </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> contributions to our U.S. defined benefit plans during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We contributed </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$6 million</span></span><span style="font-family:inherit;font-size:10pt;"> to our non-U.S. defined benefit plans during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not expect to contribute to our U.S. defined benefit plans during the remainder of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and we expect to contribute </span><span style="font-family:inherit;font-size:10pt;"><span>$19 million</span></span><span style="font-family:inherit;font-size:10pt;"> to our non-U.S. defined benefit plans during the remainder of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Components of net periodic costs.</span><span style="font-family:inherit;font-size:10pt;"> For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, our net pension and post retirement benefit costs were comprised of the following:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. <br/>Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-U.S.<br/>Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Post Retirement</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost—benefits earned during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost on benefit obligation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial losses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior service credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net plan costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:41%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.</span></div> 0 0 7000000 6000000 0 0 4000000 5000000 2000000 3000000 1000000 0 8000000 7000000 12000000 11000000 1000000 1000000 -1000000 0 -12000000 -9000000 -1000000 -1000000 0 0 0 0 -2000000 -2000000 -3000000 -2000000 9000000 7000000 -1000000 -2000000 0 5000000 0 6000000 19000000 WARRANTIES AND CONTINGENCIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warranties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product. </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the standard warranty accrual activity is shown in the table below:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance as of November 1,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals for warranties including change in estimate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements made during the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of January 31,</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals for warranties due within one year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bank Guarantees</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable and reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.</span></div> <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the standard warranty accrual activity is shown in the table below:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance as of November 1,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals for warranties including change in estimate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements made during the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of January 31,</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals for warranties due within one year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div> 32000000 35000000 12000000 13000000 14000000 16000000 30000000 32000000 30000000 32000000 40000000 SHORT-TERM DEBT<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit Facilities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 13, 2019</span></span></span><span style="font-family:inherit;font-size:10pt;">, Agilent entered into a credit agreement with a group of financial institutions which provided for a </span><span style="font-family:inherit;font-size:10pt;"><span>$1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;">-year unsecured credit facility that will expire on </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 13, 2024</span></span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we borrowed </span><span style="font-family:inherit;font-size:10pt;"><span>$432 million</span></span><span style="font-family:inherit;font-size:10pt;"> and repaid </span><span style="font-family:inherit;font-size:10pt;"><span>$372 million</span></span><span style="font-family:inherit;font-size:10pt;"> under the credit facility. As of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the company had borrowings of </span><span style="font-family:inherit;font-size:10pt;"><span>$175 million</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding under the credit facility. We were in compliance with the covenants for the credit facility during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. On August 7, 2019, we entered into an amendment to the credit agreement, which provided for a </span><span style="font-family:inherit;font-size:10pt;"><span>$500 million</span></span><span style="font-family:inherit;font-size:10pt;"> short-term loan facility that was used in full to complete the BioTek acquisition and which is outstanding at </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$500 million</span></span><span style="font-family:inherit;font-size:10pt;">. We had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> borrowings under the additional incremental loan facilities as of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 2019-03-13 1000000000 five 2024-03-13 432000000 372000000 175000000 500000000 500000000 0 LONG-TERM DEBT<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Senior Notes</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the company’s long-term senior notes:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022 Senior Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2026 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2029 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>492</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,787</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,786</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. There have been no changes to the principal, maturity, interest rates and interest payment terms of the Agilent senior notes, detailed in the table above, in the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">October 31, 2019</span>. <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the company’s long-term senior notes:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022 Senior Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2026 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2029 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>492</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,787</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,786</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 399000000 399000000 597000000 597000000 298000000 298000000 493000000 492000000 1787000000 1786000000 STOCKHOLDERS' EQUITY <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Repurchase Program</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.75 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we repurchased and retired approximately </span><span style="font-family:inherit;font-size:10pt;"><span>725,827</span></span><span style="font-family:inherit;font-size:10pt;"> shares for </span><span style="font-family:inherit;font-size:10pt;"><span>$60 million</span></span><span style="font-family:inherit;font-size:10pt;"> under this authorization. During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we repurchased and retired approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares for </span><span style="font-family:inherit;font-size:10pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:10pt;"> under this authorization. As of </span><span style="font-family:inherit;font-size:10pt;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had remaining authorization to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$967 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our common stock under this program.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Dividends on Shares of Common Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we paid cash dividends of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.180</span></span><span style="font-family:inherit;font-size:10pt;"> per common share or </span><span style="font-family:inherit;font-size:10pt;"><span>$56 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the company's common stock. During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">January 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we paid cash dividends of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.164</span></span><span style="font-family:inherit;font-size:10pt;"> per common share or </span><span style="font-family:inherit;font-size:10pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the company's common stock. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions):</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net defined benefit pension cost and post retirement plan costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended January 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Prior service credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Actuarial Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized gains (losses) on derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of October 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(437</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of January 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(215</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(431</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassifications out of accumulated other comprehensive income (loss) for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;text-indent:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Details about accumulated other </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">comprehensive income (loss) components</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts Reclassified from </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Affected line item in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">statement of operations</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total before income tax</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income tax</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net of income tax</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net defined benefit pension cost and post retirement plan costs:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior service benefit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total before income tax</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit for income tax</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net of income tax</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total reclassifications for the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss).</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassifications out of accumulated other comprehensive income (loss) of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost together with curtailments and settlements (see Note 13, "Retirement Plans and Post Retirement Pension Plans").</span></div> 1750000000 725827 60000000 1100000 75000000 967000000 0.180 56000000 0.164 52000000 <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions):</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net defined benefit pension cost and post retirement plan costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended January 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Prior service credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Actuarial Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized gains (losses) on derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of October 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(437</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of January 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(215</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(431</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -204000000 131000000 -437000000 -4000000 -514000000 -11000000 0 -5000000 1000000 -15000000 0 -2000000 14000000 0 12000000 0 1000000 3000000 0 4000000 -11000000 -3000000 6000000 1000000 -7000000 -215000000 128000000 -431000000 -3000000 -521000000 <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassifications out of accumulated other comprehensive income (loss) for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;text-indent:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Details about accumulated other </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">comprehensive income (loss) components</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts Reclassified from </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Affected line item in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">statement of operations</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total before income tax</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income tax</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net of income tax</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net defined benefit pension cost and post retirement plan costs:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior service benefit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total before income tax</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit for income tax</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net of income tax</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total reclassifications for the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 5000000 0 5000000 0 -1000000 0 4000000 14000000 10000000 2000000 2000000 -12000000 -8000000 6000000 4000000 -6000000 -4000000 -6000000 0 SEGMENT INFORMATION<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Description of segments.</span><span style="font-family:inherit;font-size:10pt;"> We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A description of our three reportable segments is as follows:</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&amp;E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples.  Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acquisition-related intangible assets, transformational initiatives expenses, acquisition and integration costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations and in-sourcing or outsourcing of activities. </span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The profitability of each of the segments is measured after excluding transformational initiatives, acquisition and integration costs, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below:</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>638</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics and Genomics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agilent CrossLab</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Income From Operations:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics and Genomics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agilent CrossLab</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment income from operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total reportable segments’ income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transformational initiatives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets related to business combinations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition and integration costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NASD site costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes, as reported</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:12px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) The other category primarily includes legal costs related to our pursuing our claim against a third party in addition to other miscellaneous adjustments and settlements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics and Genomics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,612</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agilent CrossLab</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,331</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3 <div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The profitability of each of the segments is measured after excluding transformational initiatives, acquisition and integration costs, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below:</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>638</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics and Genomics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agilent CrossLab</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Income From Operations:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics and Genomics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agilent CrossLab</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment income from operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">October 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Life Sciences and Applied Markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics and Genomics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,612</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agilent CrossLab</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,331</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 638000000 607000000 249000000 235000000 470000000 442000000 1357000000 1284000000 158000000 159000000 34000000 33000000 119000000 105000000 311000000 297000000 <div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total reportable segments’ income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transformational initiatives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets related to business combinations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition and integration costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NASD site costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes, as reported</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:12px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) The other category primarily includes legal costs related to our pursuing our claim against a third party in addition to other miscellaneous adjustments and settlements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 311000000 297000000 13000000 5000000 48000000 28000000 13000000 10000000 0 2000000 -22000000 -2000000 3000000 10000000 20000000 18000000 21000000 6000000 219000000 248000000 3187000000 3202000000 2612000000 2620000000 1360000000 1331000000 7159000000 7153000000 SUBSEQUENT EVENT<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, the company reached a settlement agreement with Twist Bioscience Corporation ("Twist") under which Twist has agreed to pay us </span><span style="font-family:inherit;font-size:10pt;"><span>$22.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to settle our intellectual property claim against Twist. The settlement agreement provides a license to Twist for discrete aspects of Agilent’s oligo-synthesis technology and successfully resolves all outstanding litigation between all parties.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 22500000 XML 42 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
WARRANTIES AND CONTINGENCIES (Notes)
 3 Months Ended
Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
WARRANTIES AND CONTINGENCIES WARRANTIES AND CONTINGENCIES
 
Warranties
 
We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product.
 
A summary of the standard warranty accrual activity is shown in the table below:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Beginning balance as of November 1,
$
32

 
$
35

Accruals for warranties including change in estimate
12

 
13

Settlements made during the period
(14
)
 
(16
)
Ending balance as of January 31,
$
30


$
32

 
 
 
 
Accruals for warranties due within one year
$
30

 
$
32

 
Bank Guarantees

Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $40 million as of January 31, 2020 and October 31, 2019. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss.

Contingencies
 
We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable and reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 255 425 1 false 90 0 false 5 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.agilent.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) Sheet http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) Sheet http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) Statements 3 false false R4.htm 1002001 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) Sheet http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) Sheet http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) Statements 5 false false R6.htm 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) Sheet http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) Sheet http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF EQUITY Sheet http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity CONDENSED CONSOLIDATED STATEMENT OF EQUITY Statements 8 false false R9.htm 1005001 - Statement - CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL) Sheet http://www.agilent.com/role/CondensedConsolidateStatementOfEquityParenthetical CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL) Statements 9 false false R10.htm 2101100 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes) Notes http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNotes OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes) Notes 10 false false R11.htm 2105100 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Notes) Notes http://www.agilent.com/role/NewAccountingPronouncementsNotes NEW ACCOUNTING PRONOUNCEMENTS (Notes) Notes 11 false false R12.htm 2106100 - Disclosure - ACQUISITIONS (Notes) Notes http://www.agilent.com/role/AcquisitionsNotes ACQUISITIONS (Notes) Notes 12 false false R13.htm 2107100 - Disclosure - REVENUE (Notes) Notes http://www.agilent.com/role/RevenueNotes REVENUE (Notes) Notes 13 false false R14.htm 2108100 - Disclosure - SHARE-BASED COMPENSATION (Notes) Notes http://www.agilent.com/role/ShareBasedCompensationNotes SHARE-BASED COMPENSATION (Notes) Notes 14 false false R15.htm 2109100 - Disclosure - INCOME TAXES (Notes) Notes http://www.agilent.com/role/IncomeTaxesNotes INCOME TAXES (Notes) Notes 15 false false R16.htm 2110100 - Disclosure - NET INCOME PER SHARE (Notes) Notes http://www.agilent.com/role/NetIncomePerShareNotes NET INCOME PER SHARE (Notes) Notes 16 false false R17.htm 2111100 - Disclosure - INVENTORY (Notes) Notes http://www.agilent.com/role/InventoryNotes INVENTORY (Notes) Notes 17 false false R18.htm 2114100 - Disclosure - LEASES (Notes) Notes http://www.agilent.com/role/LeasesNotes LEASES (Notes) Notes 18 false false R19.htm 2115100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Notes) Notes http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsNotes GOODWILL AND OTHER INTANGIBLE ASSETS (Notes) Notes 19 false false R20.htm 2116100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes) Notes http://www.agilent.com/role/FairValueMeasurementsNotes FAIR VALUE MEASUREMENTS (Notes) Notes 20 false false R21.htm 2117100 - Disclosure - DERIVATIVES (Notes) Notes http://www.agilent.com/role/DerivativesNotes DERIVATIVES (Notes) Notes 21 false false R22.htm 2118100 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes) Notes http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansNotes RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes) Notes 22 false false R23.htm 2119100 - Disclosure - WARRANTIES AND CONTINGENCIES (Notes) Notes http://www.agilent.com/role/WarrantiesAndContingenciesNotes WARRANTIES AND CONTINGENCIES (Notes) Notes 23 false false R24.htm 2120100 - Disclosure - SHORT-TERM DEBT (Notes) Notes http://www.agilent.com/role/ShortTermDebtNotes SHORT-TERM DEBT (Notes) Notes 24 false false R25.htm 2121100 - Disclosure - LONG-TERM DEBT (Notes) Notes http://www.agilent.com/role/LongTermDebtNotes LONG-TERM DEBT (Notes) Notes 25 false false R26.htm 2122100 - Disclosure - STOCKHOLDERS' EQUITY (Notes) Notes http://www.agilent.com/role/StockholdersEquityNotes STOCKHOLDERS' EQUITY (Notes) Notes 26 false false R27.htm 2123100 - Disclosure - SEGMENT INFORMATION (Notes) Notes http://www.agilent.com/role/SegmentInformationNotes SEGMENT INFORMATION (Notes) Notes 27 false false R28.htm 2124100 - Disclosure - SUBSEQUENT EVENTS (Notes) Notes http://www.agilent.com/role/SubsequentEventsNotes SUBSEQUENT EVENTS (Notes) Notes 28 false false R29.htm 2201201 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 29 false false R30.htm 2301302 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables) Sheet http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOverviewBasisOfPresentationAndSummaryOfAccountingPoliciesTables OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables) Tables 30 false false R31.htm 2305301 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://www.agilent.com/role/NewAccountingPronouncementsTables NEW ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://www.agilent.com/role/NewAccountingPronouncementsNotes 31 false false R32.htm 2306301 - Disclosure - ACQUISITIONS (Tables) Sheet http://www.agilent.com/role/AcquisitionsTables ACQUISITIONS (Tables) Tables http://www.agilent.com/role/AcquisitionsNotes 32 false false R33.htm 2307301 - Disclosure - Revenue (Tables) Sheet http://www.agilent.com/role/RevenueTables Revenue (Tables) Tables 33 false false R34.htm 2308301 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://www.agilent.com/role/ShareBasedCompensationTables SHARE-BASED COMPENSATION (Tables) Tables http://www.agilent.com/role/ShareBasedCompensationNotes 34 false false R35.htm 2310301 - Disclosure - NET INCOME PER SHARE (Tables) Sheet http://www.agilent.com/role/NetIncomePerShareTables NET INCOME PER SHARE (Tables) Tables http://www.agilent.com/role/NetIncomePerShareNotes 35 false false R36.htm 2311301 - Disclosure - INVENTORY (Tables) Sheet http://www.agilent.com/role/InventoryTables INVENTORY (Tables) Tables http://www.agilent.com/role/InventoryNotes 36 false false R37.htm 2314301 - Disclosure - LEASES (Tables) Sheet http://www.agilent.com/role/LeasesTables LEASES (Tables) Tables http://www.agilent.com/role/LeasesNotes 37 false false R38.htm 2315301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsNotes 38 false false R39.htm 2316301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.agilent.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.agilent.com/role/FairValueMeasurementsNotes 39 false false R40.htm 2317301 - Disclosure - DERIVATIVES (Tables) Sheet http://www.agilent.com/role/DerivativesTables DERIVATIVES (Tables) Tables http://www.agilent.com/role/DerivativesNotes 40 false false R41.htm 2318301 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables) Sheet http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansTables RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables) Tables http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansNotes 41 false false R42.htm 2319301 - Disclosure - WARRANTIES AND CONTINGENCIES (Tables) Sheet http://www.agilent.com/role/WarrantiesAndContingenciesTables WARRANTIES AND CONTINGENCIES (Tables) Tables http://www.agilent.com/role/WarrantiesAndContingenciesNotes 42 false false R43.htm 2321301 - Disclosure - LONG-TERM DEBT (Tables) Sheet http://www.agilent.com/role/LongTermDebtTables LONG-TERM DEBT (Tables) Tables http://www.agilent.com/role/LongTermDebtNotes 43 false false R44.htm 2322301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.agilent.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.agilent.com/role/StockholdersEquityNotes 44 false false R45.htm 2323301 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.agilent.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) Tables http://www.agilent.com/role/SegmentInformationNotes 45 false false R46.htm 2401403 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOverviewBasisOfPresentationAndSummaryOfAccountingPoliciesTables 46 false false R47.htm 2405402 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS- Initial Adoption (Details) Sheet http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails NEW ACCOUNTING PRONOUNCEMENTS- Initial Adoption (Details) Details 47 false false R48.htm 2406402 - Disclosure - ACQUISITIONS - Text (Details) Sheet http://www.agilent.com/role/AcquisitionsTextDetails ACQUISITIONS - Text (Details) Details 48 false false R49.htm 2406403 - Disclosure - ACQUISITIONS - Assets and Liabilities Assumed (Details) Sheet http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails ACQUISITIONS - Assets and Liabilities Assumed (Details) Details 49 false false R50.htm 2406404 - Disclosure - ACQUISITIONS - Intangible Assets Acquired (Details) Sheet http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails ACQUISITIONS - Intangible Assets Acquired (Details) Details 50 false false R51.htm 2406405 - Disclosure - ACQUISITIONS - Proforma Operating Results (Details) Sheet http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails ACQUISITIONS - Proforma Operating Results (Details) Details 51 false false R52.htm 2407402 - Disclosure - REVENUE- Revenue by Region (Details) Sheet http://www.agilent.com/role/RevenueRevenueByRegionDetails REVENUE- Revenue by Region (Details) Details 52 false false R53.htm 2407403 - Disclosure - REVENUE - Revenue by End Markets (Details) Sheet http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails REVENUE - Revenue by End Markets (Details) Details 53 false false R54.htm 2407404 - Disclosure - REVENUE - Revenue by Type (Details) Sheet http://www.agilent.com/role/RevenueRevenueByTypeDetails REVENUE - Revenue by Type (Details) Details 54 false false R55.htm 2407405 - Disclosure - REVENUE - Contract Balances (Details) Sheet http://www.agilent.com/role/RevenueContractBalancesDetails REVENUE - Contract Balances (Details) Details 55 false false R56.htm 2408402 - Disclosure - SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) Sheet http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) Details 56 false false R57.htm 2408403 - Disclosure - SHARE-BASED COMPENSATION Fair Value Assumptions (Details) Sheet http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails SHARE-BASED COMPENSATION Fair Value Assumptions (Details) Details 57 false false R58.htm 2408404 - Disclosure - SHARE-BASED COMPENSATION Capitalized (Details) Sheet http://www.agilent.com/role/ShareBasedCompensationCapitalizedDetails SHARE-BASED COMPENSATION Capitalized (Details) Details 58 false false R59.htm 2409401 - Disclosure - INCOME TAXES (Details) Sheet http://www.agilent.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.agilent.com/role/IncomeTaxesNotes 59 false false R60.htm 2410402 - Disclosure - NET INCOME PER SHARE (Details) Sheet http://www.agilent.com/role/NetIncomePerShareDetails NET INCOME PER SHARE (Details) Details http://www.agilent.com/role/NetIncomePerShareTables 60 false false R61.htm 2411402 - Disclosure - INVENTORY (Details) Sheet http://www.agilent.com/role/InventoryDetails INVENTORY (Details) Details http://www.agilent.com/role/InventoryTables 61 false false R62.htm 2414402 - Disclosure - LEASES - Future Minimum Lease Payments (Details) Sheet http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails LEASES - Future Minimum Lease Payments (Details) Details 62 false false R63.htm 2414403 - Disclosure - LEASES - Lease Costs (Details) Sheet http://www.agilent.com/role/LeasesLeaseCostsDetails LEASES - Lease Costs (Details) Details 63 false false R64.htm 2414404 - Disclosure - LEASES - Supplemental Cash Flows Information (Details) Sheet http://www.agilent.com/role/LeasesSupplementalCashFlowsInformationDetails LEASES - Supplemental Cash Flows Information (Details) Details 64 false false R65.htm 2414405 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) Sheet http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails LEASES - Supplemental Balance Sheet Information (Details) Details 65 false false R66.htm 2414406 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) Sheet http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails LEASES - Maturities of Lease Liabilities (Details) Details 66 false false R67.htm 2414407 - Disclosure - LEASES - Text (Details) Sheet http://www.agilent.com/role/LeasesTextDetails LEASES - Text (Details) Details 67 false false R68.htm 2415402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) Sheet http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) Details 68 false false R69.htm 2415403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) Sheet http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) Details 69 false false R70.htm 2415404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) Sheet http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) Details http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTables 70 false false R71.htm 2415405 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details) Sheet http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details) Details 71 false false R72.htm 2416402 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) Sheet http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) Details 72 false false R73.htm 2416403 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details) Sheet http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details) Details 73 false false R74.htm 2417402 - Disclosure - DERIVATIVES- Terminated Interest Rate Swaps (Details) Sheet http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails DERIVATIVES- Terminated Interest Rate Swaps (Details) Details 74 false false R75.htm 2417403 - Disclosure - DERIVATIVES- Foreign Exchange Forward Contracts (Details) Sheet http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails DERIVATIVES- Foreign Exchange Forward Contracts (Details) Details 75 false false R76.htm 2417404 - Disclosure - DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) Sheet http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) Details 76 false false R77.htm 2417405 - Disclosure - DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) Sheet http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) Details 77 false false R78.htm 2418402 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) Sheet http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) Details 78 false false R79.htm 2418403 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual) Sheet http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual) Details http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansTables 79 false false R80.htm 2419402 - Disclosure - WARRANTIES AND CONTINGENCIES (Details) Sheet http://www.agilent.com/role/WarrantiesAndContingenciesDetails WARRANTIES AND CONTINGENCIES (Details) Details http://www.agilent.com/role/WarrantiesAndContingenciesTables 80 false false R81.htm 2420401 - Disclosure - SHORT-TERM DEBT Credit Facility (Details) Sheet http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails SHORT-TERM DEBT Credit Facility (Details) Details 81 false false R82.htm 2421402 - Disclosure - LONG-TERM DEBT (Details) Sheet http://www.agilent.com/role/LongTermDebtDetails LONG-TERM DEBT (Details) Details http://www.agilent.com/role/LongTermDebtTables 82 false false R83.htm 2422402 - Disclosure - STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) Sheet http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) Details 83 false false R84.htm 2422403 - Disclosure - STOCKHOLDER"S EQUITY - Dividends (Details) Sheet http://www.agilent.com/role/StockholdersEquityDividendsDetails STOCKHOLDER"S EQUITY - Dividends (Details) Details 84 false false R85.htm 2422404 - Disclosure - STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) Sheet http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) Details 85 false false R86.htm 2422405 - Disclosure - STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) Sheet http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) Details 86 false false R87.htm 2423402 - Disclosure - SEGMENT INFORMATION - Profitability (Details) Sheet http://www.agilent.com/role/SegmentInformationProfitabilityDetails SEGMENT INFORMATION - Profitability (Details) Details 87 false false R88.htm 2423403 - Disclosure - SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) Sheet http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) Details 88 false false R89.htm 2423404 - Disclosure - SEGMENT INFORMATION - Segment Assets (Details) Sheet http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails SEGMENT INFORMATION - Segment Assets (Details) Details 89 false false R90.htm 2424402 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.agilent.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.agilent.com/role/SubsequentEventsNotes 90 false false All Reports Book All Reports a-01312020x10q.htm a-01312020xex311.htm a-01312020xex312.htm a-01312020xex321.htm a-01312020xex322.htm a-20200131.xsd a-20200131_cal.xml a-20200131_def.xml a-20200131_lab.xml a-20200131_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/currency/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true XML 44 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION (Notes)
 3 Months Ended
Jan. 31, 2020
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
 
Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments.
A description of our three reportable segments is as follows:

Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.

Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples.  Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.

A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of
acquisition-related intangible assets, transformational initiatives expenses, acquisition and integration costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations and in-sourcing or outsourcing of activities.

The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.

The profitability of each of the segments is measured after excluding transformational initiatives, acquisition and integration costs, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below:
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Net Revenue:
 
 
 
Life Sciences and Applied Markets
$
638

 
$
607

Diagnostics and Genomics
249

 
235

Agilent CrossLab
470

 
442

Total net revenue
$
1,357

 
$
1,284

 
 
 
 
Segment Income From Operations:


 


Life Sciences and Applied Markets
$
158

 
$
159

Diagnostics and Genomics
34

 
33

Agilent CrossLab
119

 
105

Total segment income from operations
$
311

 
$
297



The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Total reportable segments’ income from operations
$
311

 
$
297

Transformational initiatives
(13
)
 
(5
)
Amortization of intangible assets related to business combinations
(48
)
 
(28
)
Acquisition and integration costs
(13
)
 
(10
)
NASD site costs
—

 
(2
)
Other(1)
(22
)
 
(2
)
Interest income
3

 
10

Interest expense
(20
)
 
(18
)
Other income (expense), net
21

 
6

Income before taxes, as reported
$
219

 
$
248


(1) The other category primarily includes legal costs related to our pursuing our claim against a third party in addition to other miscellaneous adjustments and settlements.

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  
 
January 31,
2020
 
October 31,
2019
 
(in millions)
Segment Assets:
 
 
 
Life Sciences and Applied Markets
$
3,187

 
$
3,202

Diagnostics and Genomics
2,612

 
2,620

Agilent CrossLab
1,360

 
1,331

Total segment assets
$
7,159

 
$
7,153
XML 45 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NEW ACCOUNTING PRONOUNCEMENTS (Notes)
 3 Months Ended
Jan. 31, 2020
Accounting Policies [Abstract]  
NEW ACCOUNTING PRONOUNCEMENTS NEW ACCOUNTING PRONOUNCEMENTS

Accounting Pronouncements Not Yet Adopted

There were no changes to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2019 except for the following:

In December 2019, the Financial Accounting Standards Board ("FASB") issued new guidance to simplify the accounting for income taxes. This guidance eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences.The new guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We are evaluating the impact of this guidance on our consolidated financial statements and disclosures.

Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to record most leases on the balance sheet as lease liabilities, initially measured at the present value of future lease payments, with a corresponding right-of-use asset. The accounting applied by a lessor is largely unchanged from that applied under the prior
accounting standard.
On November 1, 2019, we adopted the new accounting guidance using the modified retrospective method, by applying the transition approach, for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning November 1, 2019 are presented under the new accounting standard, while prior period amounts have not been restated. The standard had a significant impact on the condensed consolidated balance sheet as of January 31, 2020, but did not have a significant impact on the condensed consolidated statement of operations or condensed consolidated statement of cash flows for the three months ended January 31, 2020. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of new accounting standard, we elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. We also elected to exclude leases with a term of 12 months or less in the ROU assets and lease liabilities. The adoption of this standard had no impact on our results of operations, cash flows and retained earnings.
Adoption of the new guidance impacted the condensed consolidated balance sheet as follows:

 
October 31, 2019
 
Impact of Adopting
 
November 1, 2019
 
As Reported
 
Lease Guidance
 
As Adopted
 
(in millions)
Other assets
$
611

 
$
192

 
$
803

Other accrued liabilities
$
440

 
$
48

 
$
488

Other long-term liabilities
$
473

 
$
144

 
$
617



Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.
XML 46 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($)
$ in Millions
Jan. 31, 2020
Oct. 31, 2019
Current assets:    
Cash and cash equivalents $ 1,226 $ 1,382
Accounts receivable, net 966 930
Inventory 706 679
Other current assets 204 198
Total current assets 3,102 3,189
Property, plant and equipment, net 844 850
Goodwill 3,589 3,593
Other intangible assets, net 1,059 1,107
Long-term investments 118 102
Other assets 789 611
Total assets 9,501 9,452
Current liabilities:    
Accounts payable 329 354
Employee compensation and benefits 253 334
Deferred revenue 379 336
Short-term Debt 675 616
Other accrued liabilities 256 440
Total current liabilities 1,892 2,080
Long-term debt 1,787 1,791
Retirement and post-retirement benefits 354 360
Other long-term liabilities 620 473
Total liabilities 4,653 4,704
Commitments and Contingencies (Note 14)
Stockholders' equity:    
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding 0 0
Common stock; $0.01 par value; 2 billion shares authorized; 310 million shares at January 31, 2020 and 309 million shares at October 31, 2019, issued 3 3
Additional paid-in-capital 5,293 5,277
Retained earnings (accumulated deficit) 73 (18)
Accumulated other comprehensive loss (521) (514)
Total stockholder's equity 4,848 4,748
Total liabilities and equity $ 9,501 $ 9,452
XML 47 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information - shares
 3 Months Ended
Jan. 31, 2020
Feb. 27, 2020
Document and Entity Information [Abstract]    
Title of 12(b) Security Common Stock, $0.01 par value  
Entity Tax Identification Number 77-0518772  
Entity Incorporation, State or Country Code DE  
Entity Registrant Name AGILENT TECHNOLOGIES, INC.  
Entity Central Index Key 0001090872  
Current Fiscal Year End Date --10-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   309,651,359
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Document Type 10-Q  
Document Quarterly Report true  
Amendment Flag false  
Entity Small Business false  
Entity Emerging Growth Company false  
Document Period End Date Jan. 31, 2020  
Document Transition Report false  
Entity File Number 001-15405  
Entity Address, Address Line One 5301 Stevens Creek Blvd.,  
Entity Address, City or Town Santa Clara,  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 95051  
City Area Code (800)  
Local Phone Number 227-9770  
Entity Shell Company false  
Trading Symbol A  
Security Exchange Name NYSE  
XML 48 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
INCOME TAXES (Notes)
 3 Months Ended
Jan. 31, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES

For the three months ended January 31, 2020, the company's income tax expense was $22 million with an effective tax rate of 10.0 percent. For the three months ended January 31, 2020, our effective tax rate and the resulting provision for income taxes were significantly impacted by a discrete benefit of $13 million related to the excess tax benefits from stock-based compensation.

For the three months ended January 31, 2019, the company's income tax benefit was $256 million with an effective tax rate of (103.2) percent. For the three months ended January 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by a discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore. The income taxes for the three months ended January 31, 2019 also includes the excess tax benefits of $4 million from stock-based compensation.

In the U.S., tax years remain open back to the year 2016 for federal income tax purposes and the year 2015 for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009.

It is reasonably possible there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits. The company will continue to assess the impact of the further guidance from federal and state tax authorities on its business and consolidated financial statements. Any future adjustments will be recognized as discrete income tax expense or benefit in the period the adjustments are determined.
XML 49 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Statement of Stockholders' Equity [Abstract]    
Tax related to shares issued $ 33 $ 13
XML 50 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)
 3 Months Ended
Jan. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
 
The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2020:
 
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
(in millions)
Goodwill as of October 31, 2019
$
1,438

 
$
1,594

 
$
561

 
$
3,593

Foreign currency translation impact
—

 
(2
)
 
(2
)
 
(4
)
Goodwill as of January 31, 2020
$
1,438

 
$
1,592

 
$
559

 
$
3,589


The components of other intangible assets as of January 31, 2020 and October 31, 2019 are shown in the table below:
 
 
Purchased Other Intangible Assets
 
Gross
Carrying
Amount
 
Accumulated
Amortization
and Impairments
 
Net Book
Value
 
(in millions)
As of October 31, 2019
 

 
 

 
 

Purchased technology
$
1,413

 
$
763

 
$
650

Backlog
5

 
5

 
—

Trademark/Tradename
196

 
102

 
94

Customer relationships
329

 
87

 
242

Third-party technology and licenses
28

 
22

 
6

Total amortizable intangible assets
1,971

 
979

 
992

In-Process R&D
115

 
—

 
115

Total
$
2,086

 
$
979

 
$
1,107

As of January 31, 2020
 

 
 

 
 

Purchased technology
$
1,412

 
$
787

 
$
625

Backlog
5

 
5

 
—

Trademark/Tradename
196

 
106

 
90

Customer relationships
329

 
105

 
224

Third-party technology and licenses
28

 
23

 
5

Total amortizable intangible assets
1,970

 
1,026

 
944

In-Process R&D
115

 
—

 
115

Total
$
2,085

 
$
1,026

 
$
1,059


During the three months ended January 31, 2020, there were no additions to goodwill and there were no additions to other intangible assets. During the three months ended January 31, 2020, the impact of foreign currency translation on other intangible assets was not material.

In general, for United States federal tax purposes, goodwill from asset purchases is deductible, however any goodwill created as part of a stock acquisition is not deductible. 

Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. There were no indicators of impairments of indefinite-lived intangible assets or goodwill during the three months ended January 31, 2020 and 2019, respectively.

Amortization expense of intangible assets was $48 million and $29 million for the three months ended January 31, 2020 and 2019, respectively.

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2020 and for each of the five succeeding fiscal years and thereafter is estimated below:
Estimated future amortization expense:
 
(in millions)
 
Remainder of 2020
$
138

2021
$
172

2022
$
150

2023
$
107

2024
$
86

2025
$
68

Thereafter
$
223
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
INVENTORY (Tables)
 3 Months Ended
Jan. 31, 2020
Inventory, Net [Abstract]  
INVENTORY INVENTORY
 
 
January 31,
2020
 
October 31,
2019
 
(in millions)
Finished goods
$
423

 
$
416

Purchased parts and fabricated assemblies
283

 
263

Inventory
$
706

 
$
679
XML 52 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
ACQUISITIONS (Tables)
 3 Months Ended
Jan. 31, 2020
Business Combinations [Abstract]  
Business Acquisition, Pro Forma Information
The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's condensed consolidated statements of operations as of the beginning of fiscal 2019 (in millions, except per share amounts):

 
Three Months Ended January 31,
 
2019
Net revenue
$
1,326

Net income
$
474

Net income per share — basic
$
1.49

Net income per share — diluted
$
1.47
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):
Cash and cash equivalents
 
 
$
10

 
Accounts receivable
 
 
28

 
Inventories
 
 
21

 
Other current assets
 
 
2

 
Property, plant and equipment
 
 
8

 
Intangible assets
 
 
641

 
Goodwill
 
 
483

 
Total assets acquired
 
1,193
 

Accounts payable
 
 
(4
)
 
Deferred revenue
 
 
(5
)
 
Employee compensation and benefits
 
 
(7
)
 
Other accrued liabilities
 
 
(2
)
 
Long-term debt
 
 
(4
)
 
Net assets acquired
 
 
$
1,171

 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination
The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):

 
Fair Value
 
Estimated
Useful Life
Developed product technology
 
$
387

 
 
5-13 years
Customer relationships
 
202

 
 
3-8 years
Backlog
 
5

 
 
2 months
Tradenames and trademarks
 
43

 
 
10 years
Total intangible assets subject to amortization
 
637

 
 
 
In-process research and development
 
4

 
 
 
Total intangible assets
 
$
641

 
 
 
XML 53 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE - Revenue by End Markets (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Net revenue $ 1,357 $ 1,284
Pharmaceutical and Biopharmaceutical Market    
Net revenue 423 391
Chemical and Energy Market    
Net revenue 312 308
Diagnostics and Clinical Market    
Net revenue 194 187
Food Market    
Net revenue 130 129
Academia and Government Market    
Net revenue 141 116
Environmental and Forensics Market    
Net revenue $ 157 $ 153
XML 54 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SHARE-BASED COMPENSATION Fair Value Assumptions (Details)
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award    
ESPP plan purchase price (in hundredths) 85.00% 85.00%
LTPP    
Share-based Compensation Arrangement by Share-based Payment Award    
Volatility of Agilent shares 23.00% 22.00%
Volatility of selected peer-company shares - Minimum 15.00% 15.00%
Volatility of selected peer-company shares - Maximum 44.00% 66.00%
Pair-wise correlation with selected peers (in hundredths) 29.00% 30.00%
LTPP & RSU    
Share-based Compensation Arrangement by Share-based Payment Award    
Discount for post-vesting restrictions 5.30% 5.00%
XML 55 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Pension Plan | United States    
Defined Benefit Plan, Net Periodic Benefit Cost    
Service cost - benefits earned during the period $ 0 $ 0
Interest cost on benefit obligation 4 5
Expected return on plan assets (8) (7)
Amortization:    
Actuarial losses 1 0
Prior service credits 0 0
Total net plan costs (3) (2)
Pension Plan | Foreign Plan    
Defined Benefit Plan, Net Periodic Benefit Cost    
Service cost - benefits earned during the period 7 6
Interest cost on benefit obligation 2 3
Expected return on plan assets (12) (11)
Amortization:    
Actuarial losses 12 9
Prior service credits 0 0
Total net plan costs 9 7
Other Postretirement Benefits Plan | United States    
Defined Benefit Plan, Net Periodic Benefit Cost    
Service cost - benefits earned during the period 0 0
Interest cost on benefit obligation 1 0
Expected return on plan assets (1) (1)
Amortization:    
Actuarial losses 1 1
Prior service credits (2) (2)
Total net plan costs $ (1) $ (2)
XML 56 R88.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Reconciliation of Operating Profit from Segments to Consolidated    
Total reportable segment's income from operations $ 311 $ 297
Transformational initiatives (13) (5)
Amortization of intangible assets related to business combinations (48) (28)
Acquisition and integration costs (13) (10)
NASD site costs 0 (2)
Other (22) (2)
Interest income 3 10
Interest expense (20) (18)
Other income (expense), net 21 6
Income before taxes, as reported $ 219 $ 248
XML 57 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
STOCKHOLDER"S EQUITY - Dividends (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Dividends Paid    
Cash dividends paid per common share $ 0.180 $ 0.164
Aggregate amount of cash dividends paid $ 56 $ 52
XML 58 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
DERIVATIVES- Terminated Interest Rate Swaps (Details)
$ in Millions
Sep. 15, 2016
USD ($)
Jan. 31, 2020
USD ($)
Aug. 16, 2019
USD ($)
Feb. 01, 2016
USD ($)
contracts
Jul. 01, 2012
USD ($)
Derivative Instruments and Hedging Activities Disclosure          
Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position   $ 3      
Senior Notes 2022 | Treasury Lock [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging          
Terminated Derivative Contracts          
Derivative, Notional Amount         $ 400
Remaining gain (loss) to be amortized on derivative   1      
Senior Notes 2026 | Interest Rate Swap | Derivatives Designated as Hedging Instrument | Cash Flow Hedging          
Terminated Derivative Contracts          
Number of interest rate swap contracts terminated | contracts       3  
Derivative, Notional Amount       $ 300  
Interest rate swap payments $ 10        
Remaining gain (loss) to be amortized on derivative   6      
Senior Notes 2029 | Treasury Lock [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging          
Terminated Derivative Contracts          
Derivative, Notional Amount     $ 250    
Remaining gain (loss) to be amortized on derivative   $ 6      
XML 59 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Finite-Lived Intangible Assets    
Addition to other intangible assets $ 0  
Impairment of IPR&D 0 $ 0
Goodwill impairment 0 0
Amortization of intangible assets during the period 48 $ 29
Life Sciences and Applied Markets    
Finite-Lived Intangible Assets    
Additions to goodwill $ 0  
XML 60 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
WARRANTIES AND CONTINGENCIES (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Oct. 31, 2019
Movement in Standard Product Warranty Accrual      
Beginning balance as of $ 32 $ 35  
Accruals for warranties including change in estimate 12 13  
Settlements made during the period (14) (16)  
Ending balance at end of period 30 32  
Standard Product Warranty Disclosure      
Accruals for warranties due within one year 30 $ 32  
Guarantees      
Guarantees $ 40   $ 40
XML 62 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Lease Costs (Details)
$ in Millions
 3 Months Ended
Jan. 31, 2020
USD ($)
Leases [Abstract]  
Operating Lease, Cost $ 15
Variable Lease, Cost 4
Sublease Income 4
Lease, Cost $ 15
XML 63 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Text (Details)
$ in Millions
Jan. 31, 2020
USD ($)
Leases [Abstract]  
Operating Leased assets - original cost $ 49
Operating leased assets, net book value 16
Sales-type Lease, Lease Receivable $ 38
XML 64 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Jan. 31, 2020
Schedule of Accumulated Other Comprehensive Income (Loss)
Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions):
 
 
 
 
Net defined benefit pension cost and post retirement plan costs
 
 
 
 
Three Months Ended January 31, 2020
 
Foreign currency translation
 
Prior service credits
 
Actuarial Losses
 
Unrealized gains (losses) on derivatives
 
Total
 
 
(in millions)
As of October 31, 2019
 
$
(204
)
 
$
131

 
$
(437
)
 
$
(4
)
 
$
(514
)
 
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
 
(11
)
 
—

 
(5
)
 
1

 
(15
)

 
 
 
 
 
 
 
 
 
 
Amounts reclassified out of accumulated other comprehensive income (loss)
 
—

 
(2
)
 
14

 
—

 
12


 
 
 
 
 
 
 
 
 
 
Tax expense
 
—

 
(1
)
 
(3
)
 
—

 
(4
)

 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss)
 
(11
)
 
(3
)
 
6

 
1

 
(7
)

 
 
 
 
 
 
 
 
 
 
As of January 31, 2020
 
$
(215
)
 
$
128

 
$
(431
)
 
$
(3
)
 
$
(521
)
 
 
 
 
 
 
 
 
 
 
 
Reclassification out of Accumulated Other Comprehensive Income
Reclassifications out of accumulated other comprehensive income (loss) for the three months ended January 31, 2020 and 2019 were as follows (in millions):
Details about accumulated other
comprehensive income (loss) components
 
Amounts Reclassified from
other comprehensive income (loss)
 
Affected line item in
statement of operations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
January 31,
 
 
 
 
2020

2019
 
 
 
 



 
 
Unrealized gain (loss) on derivatives
 
$
—


$
5

 
Cost of products
 
 
—


5

 
Total before income tax
 
 
—


(1
)
 
Provision for income tax
 
 
—


4

 
Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
 



 
 
 
 



 
 
Actuarial net loss
 
(14
)

(10
)
 
 
Prior service benefit
 
2


2

 
 
 
 
(12
)

(8
)
 
Total before income tax
 
 
6


4

 
Benefit for income tax
 
 
(6
)

(4
)
 
Total net of income tax
 
 



 
 
Total reclassifications for the period
 
$
(6
)

$
—

 
 
XML 65 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
DERIVATIVES (Tables)
 3 Months Ended
Jan. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Aggregated notional amounts by currency and designation The aggregated notional amounts by currency and designation as of January 31, 2020 were as follows:
 
 
 
Derivatives 
Designated as
Cash Flow Hedges
 
Derivatives
Designated as
Net Investment Hedges
 
Derivatives
Not Designated as 
Hedging Instruments
 
 
Forward
Contracts USD
 
Forward
Contracts USD
 
Forward
Contracts USD
Currency
 
Buy/(Sell)
 
Buy/(Sell)
 
Buy/(Sell)
 
 
(in millions)
Euro
 
$
(63
)
 
$
(55
)
 
$
64

British Pound
 
(43
)
 
—

 
(4
)
Canadian Dollar
 
(39
)
 
—

 
26

Japanese Yen
 
(83
)
 
—

 
(10
)
Korean Won
 
(62
)
 
—

 
(36
)
Singapore Dollar
 
15

 
—

 
26

Chinese Yuan Renminbi
 
(71
)
 
—

 
(40
)
Swedish Krona
 
—

 
—

 
(8
)
Other
 
4

 
—

 
(9
)
Totals
 
$
(342
)
 
$
(55
)
 
$
9

 
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of January 31, 2020 and October 31, 2019 were as follows:

Fair Values of Derivative Instruments
Asset Derivatives
 
Liability Derivatives
 
 
Fair Value
 
 
 
Fair Value
Balance Sheet Location
 
January 31,
2020
 
October 31, 2019
 
Balance Sheet Location
 
January 31,
2020
 
October 31,
2019
(in millions)
Derivatives designated as hedging instruments:
 
 

 
 

 
 
 
 

 
 

Cash flow hedges
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
 
 
 
 
 
 
 
 
 
 
Other current assets
 
$
3

 
$
3

 
Other accrued liabilities
 
$
2

 
$
2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 

 
 

 
 
 
 

 
 

Foreign exchange contracts
 
 

 
 

 
 
 
 

 
 

Other current assets
 
$
3

 
$
9

 
Other accrued liabilities
 
$
4

 
$
4

Total derivatives
 
$
6

 
$
12

 
 
 
$
6

 
$
6
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations
The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows

 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Derivatives designated as hedging instruments:
 

 
 

Cash Flow Hedges
 
 
 
Foreign exchange contracts:
 
 
 
Gain (loss) recognized in accumulated other comprehensive income
$
1

 
$
(6
)
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales
$
—

 
$
5

Gain (loss) on time value of forward contracts recorded in cost of sales
$
—

 
$
1

 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
Gain (loss) recognized in other income (expense)
$
(2
)
 
$
(3
)
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
ACQUISITIONS - Text (Details) - USD ($)
$ in Millions
Aug. 23, 2019
Nov. 14, 2018
Jan. 31, 2020
BioTek      
Business Acquisition [Line Items]      
Purchase Price $ 1,170    
Cash Payment to Acquire Businesses 470    
Payment to Acquire Business with Debt 700    
estimated costs to complete in-process research and development projects $ 2    
Acquisition and Integration Costs     $ 4
ACEA Biosciences, Inc.      
Business Acquisition [Line Items]      
Purchase Price   $ 250  
XML 67 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Jan. 31, 2020
Accounting Policies [Abstract]  
Overview and Basis of Presentation
Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.

Basis of Presentation. We have prepared the accompanying financial data for the three months ended January 31, 2020 and 2019 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2019 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2019.

In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of January 31, 2020 and October 31, 2019, condensed consolidated statement of comprehensive income (loss) for the three months ended January 31, 2020 and 2019, condensed consolidated statement of operations for the three months ended January 31, 2020 and 2019, condensed consolidated statement of cash flows for the three months ended January 31, 2020 and 2019 and condensed consolidated statement of equity for the three months ended January 31, 2020 and 2019.
Use of Estimates
Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement benefit plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes,.
Fair Value of Financial Instruments
Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $90 million and $62 million as of January 31, 2020 and October 31, 2019, respectively. The change in the fair value over carrying value in the three months ended January 31, 2020 is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 11, "Fair Value Measurements" for additional information on the fair value of financial instruments.

Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows:
 
January 31,
 
October 31
 
2020
 
2019
 
(in millions)
Cash and cash equivalents
$
1,226

 
$
1,382

Restricted cash included in other assets
6

 
6

Total cash, cash equivalents and restricted cash
$
1,232

 
$
1,388
Lessee, Leases
Leases. We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") and lease liabilities on the condensed consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates we have used a number of factors including the parent credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.

A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.

   See also Note 2, "New Accounting Pronouncements" and Note 9, "Leases" for additional information about the company’s leases.
XML 68 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
DERIVATIVES (Notes)
 3 Months Ended
Jan. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVES DERIVATIVES
 
We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts, purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates.
 
Cash Flow Hedges
 
We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of January 31, 2020 changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the three months ended January 31, 2020 and 2019 ineffectiveness and gains and losses recognized in other income (expense) due to de-designation of cash flow hedge contracts were not significant.

In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at January 31, 2020 was $1 million.

In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million and we recognized this as a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at January 31, 2020 was $6 million.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at January 31, 2020 was $6 million.

Net Investment Hedges

We enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) and are assessed for effectiveness against the underlying exposure every reporting period.  If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period.

Other Hedges
 
Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
 
Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors.  We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.

A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.

The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of January 31, 2020, was $3 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of January 31, 2020.

There were 267 foreign exchange forward contracts open as of January 31, 2020 and designated as cash flow hedges. There were 172 foreign exchange forward contracts open as of January 31, 2020 not designated as hedging instruments. There was 1 foreign exchange forward contracts open as of January 31, 2020 and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of January 31, 2020 were as follows:
 
 
 
Derivatives 
Designated as
Cash Flow Hedges
 
Derivatives
Designated as
Net Investment Hedges
 
Derivatives
Not Designated as 
Hedging Instruments
 
 
Forward
Contracts USD
 
Forward
Contracts USD
 
Forward
Contracts USD
Currency
 
Buy/(Sell)
 
Buy/(Sell)
 
Buy/(Sell)
 
 
(in millions)
Euro
 
$
(63
)
 
$
(55
)
 
$
64

British Pound
 
(43
)
 
—

 
(4
)
Canadian Dollar
 
(39
)
 
—

 
26

Japanese Yen
 
(83
)
 
—

 
(10
)
Korean Won
 
(62
)
 
—

 
(36
)
Singapore Dollar
 
15

 
—

 
26

Chinese Yuan Renminbi
 
(71
)
 
—

 
(40
)
Swedish Krona
 
—

 
—

 
(8
)
Other
 
4

 
—

 
(9
)
Totals
 
$
(342
)
 
$
(55
)
 
$
9

 
Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of January 31, 2020 and October 31, 2019 were as follows:

Fair Values of Derivative Instruments
Asset Derivatives
 
Liability Derivatives
 
 
Fair Value
 
 
 
Fair Value
Balance Sheet Location
 
January 31,
2020
 
October 31, 2019
 
Balance Sheet Location
 
January 31,
2020
 
October 31,
2019
(in millions)
Derivatives designated as hedging instruments:
 
 

 
 

 
 
 
 

 
 

Cash flow hedges
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
 
 
 
 
 
 
 
 
 
 
Other current assets
 
$
3

 
$
3

 
Other accrued liabilities
 
$
2

 
$
2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 

 
 

 
 
 
 

 
 

Foreign exchange contracts
 
 

 
 

 
 
 
 

 
 

Other current assets
 
$
3

 
$
9

 
Other accrued liabilities
 
$
4

 
$
4

Total derivatives
 
$
6

 
$
12

 
 
 
$
6

 
$
6


The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows

 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Derivatives designated as hedging instruments:
 

 
 

Cash Flow Hedges
 
 
 
Foreign exchange contracts:
 
 
 
Gain (loss) recognized in accumulated other comprehensive income
$
1

 
$
(6
)
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales
$
—

 
$
5

Gain (loss) on time value of forward contracts recorded in cost of sales
$
—

 
$
1

 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
Gain (loss) recognized in other income (expense)
$
(2
)
 
$
(3
)

At January 31, 2020, the estimated amount of existing net gain that is expected to be reclassified from accumulated other comprehensive loss to cost of sales within the next twelve months is $4 million.
XML 69 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LONG-TERM DEBT (Notes)
 3 Months Ended
Jan. 31, 2020
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
 
Senior Notes
 
The following table summarizes the company’s long-term senior notes:
 
 
January 31, 2020
 
October 31, 2019
 
Amortized
Principal
 
Amortized
Principal
 
 
2022 Senior Notes
$
399

 
$
399

2023 Senior Notes
597

 
597

2026 Senior Notes
298

 
298

2029 Senior Notes
493

 
492

Total
$
1,787

 
$
1,786


All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. There have been no changes to the principal, maturity, interest rates and interest payment terms of the Agilent senior notes, detailed in the table above, in the three months ended January 31, 2020 as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2019.
XML 70 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SHARE-BASED COMPENSATION (Tables)
 3 Months Ended
Jan. 31, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Allocated share-based compensation expense disclosure
The impact on our results for share-based compensation was as follows:
 

Three Months Ended

January 31,
 
2020

2019
 
(in millions)
Cost of products and services
$
6


$
5

Research and development
3


2

Selling, general and administrative
18


17

Total share-based compensation expense
$
27

 
$
24

 
Assumptions used to estimate fair value for LTPP
The following assumptions were used to estimate the fair value of awards granted.
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
LTPP:
 
 
 
Volatility of Agilent shares
23%
 
22%
Volatility of selected peer-company shares
15%-44%
 
15%-66%
Pair-wise correlation with selected peers
29%
 
30%
 
 
 
 
Post-vest holding restriction discount for all executive awards
5.3%
 
5.0%
 
XML 71 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)
 3 Months Ended
Jan. 31, 2020
Restricted Cash [Abstract]  
Restrictions on Cash and Cash Equivalents
Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows:
 
January 31,
 
October 31
 
2020
 
2019
 
(in millions)
Cash and cash equivalents
$
1,226

 
$
1,382

Restricted cash included in other assets
6

 
6

Total cash, cash equivalents and restricted cash
$
1,232

 
$
1,388
JSON 72 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a-01312020x10q.htm": { "axisCustom": 1, "axisStandard": 24, "contextCount": 255, "dts": { "calculationLink": { "local": [ "a-20200131_cal.xml" ] }, "definitionLink": { "local": [ "a-20200131_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a-01312020x10q.htm" ] }, "labelLink": { "local": [ "a-20200131_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "a-20200131_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "a-20200131.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 675, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 36, "http://www.agilent.com/20200131": 6, "http://xbrl.sec.gov/dei/2019-01-31": 8, "total": 50 }, "keyCustom": 20, "keyStandard": 405, "memberCustom": 24, "memberStandard": 65, "nsprefix": "a", "nsuri": "http://www.agilent.com/20200131", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.agilent.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)", "role": "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNotes", "shortName": "OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Notes)", "role": "http://www.agilent.com/role/NewAccountingPronouncementsNotes", "shortName": "NEW ACCOUNTING PRONOUNCEMENTS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - ACQUISITIONS (Notes)", "role": "http://www.agilent.com/role/AcquisitionsNotes", "shortName": "ACQUISITIONS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - REVENUE (Notes)", "role": "http://www.agilent.com/role/RevenueNotes", "shortName": "REVENUE (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - SHARE-BASED COMPENSATION (Notes)", "role": "http://www.agilent.com/role/ShareBasedCompensationNotes", "shortName": "SHARE-BASED COMPENSATION (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - INCOME TAXES (Notes)", "role": "http://www.agilent.com/role/IncomeTaxesNotes", "shortName": "INCOME TAXES (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - NET INCOME PER SHARE (Notes)", "role": "http://www.agilent.com/role/NetIncomePerShareNotes", "shortName": "NET INCOME PER SHARE (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - INVENTORY (Notes)", "role": "http://www.agilent.com/role/InventoryNotes", "shortName": "INVENTORY (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - LEASES (Notes)", "role": "http://www.agilent.com/role/LeasesNotes", "shortName": "LEASES (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)", "role": "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsNotes", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited)", "role": "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes)", "role": "http://www.agilent.com/role/FairValueMeasurementsNotes", "shortName": "FAIR VALUE MEASUREMENTS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - DERIVATIVES (Notes)", "role": "http://www.agilent.com/role/DerivativesNotes", "shortName": "DERIVATIVES (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)", "role": "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansNotes", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - WARRANTIES AND CONTINGENCIES (Notes)", "role": "http://www.agilent.com/role/WarrantiesAndContingenciesNotes", "shortName": "WARRANTIES AND CONTINGENCIES (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - SHORT-TERM DEBT (Notes)", "role": "http://www.agilent.com/role/ShortTermDebtNotes", "shortName": "SHORT-TERM DEBT (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - LONG-TERM DEBT (Notes)", "role": "http://www.agilent.com/role/LongTermDebtNotes", "shortName": "LONG-TERM DEBT (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - STOCKHOLDERS' EQUITY (Notes)", "role": "http://www.agilent.com/role/StockholdersEquityNotes", "shortName": "STOCKHOLDERS' EQUITY (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123100 - Disclosure - SEGMENT INFORMATION (Notes)", "role": "http://www.agilent.com/role/SegmentInformationNotes", "shortName": "SEGMENT INFORMATION (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - SUBSEQUENT EVENTS (Notes)", "role": "http://www.agilent.com/role/SubsequentEventsNotes", "shortName": "SUBSEQUENT EVENTS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited)", "role": "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)", "role": "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOverviewBasisOfPresentationAndSummaryOfAccountingPoliciesTables", "shortName": "OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Tables)", "role": "http://www.agilent.com/role/NewAccountingPronouncementsTables", "shortName": "NEW ACCOUNTING PRONOUNCEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - ACQUISITIONS (Tables)", "role": "http://www.agilent.com/role/AcquisitionsTables", "shortName": "ACQUISITIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Revenue (Tables)", "role": "http://www.agilent.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - SHARE-BASED COMPENSATION (Tables)", "role": "http://www.agilent.com/role/ShareBasedCompensationTables", "shortName": "SHARE-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - NET INCOME PER SHARE (Tables)", "role": "http://www.agilent.com/role/NetIncomePerShareTables", "shortName": "NET INCOME PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - INVENTORY (Tables)", "role": "http://www.agilent.com/role/InventoryTables", "shortName": "INVENTORY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - LEASES (Tables)", "role": "http://www.agilent.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "role": "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.agilent.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002001 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical)", "role": "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - DERIVATIVES (Tables)", "role": "http://www.agilent.com/role/DerivativesTables", "shortName": "DERIVATIVES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)", "role": "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansTables", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - WARRANTIES AND CONTINGENCIES (Tables)", "role": "http://www.agilent.com/role/WarrantiesAndContingenciesTables", "shortName": "WARRANTIES AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321301 - Disclosure - LONG-TERM DEBT (Tables)", "role": "http://www.agilent.com/role/LongTermDebtTables", "shortName": "LONG-TERM DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.agilent.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323301 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://www.agilent.com/role/SegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "a:Fairvalueoflongtermdebtinexcessofcarryingvalue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "a:Fairvalueoflongtermdebtinexcessofcarryingvalue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS- Initial Adoption (Details)", "role": "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails", "shortName": "NEW ACCOUNTING PRONOUNCEMENTS- Initial Adoption (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "I2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "D2019Q4_8.23.2019_Biotek_us-gaap_BusinessAcquisitionAxis_a_BioTekMember", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - ACQUISITIONS - Text (Details)", "role": "http://www.agilent.com/role/AcquisitionsTextDetails", "shortName": "ACQUISITIONS - Text (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "D2019Q4_8.23.2019_Biotek_us-gaap_BusinessAcquisitionAxis_a_BioTekMember", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "I2019Q4SharesOutstanding_us-gaap_BusinessAcquisitionAxis_a_BioTekMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - ACQUISITIONS - Assets and Liabilities Assumed (Details)", "role": "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails", "shortName": "ACQUISITIONS - Assets and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "I2019Q4SharesOutstanding_us-gaap_BusinessAcquisitionAxis_a_BioTekMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited)", "role": "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - ACQUISITIONS - Intangible Assets Acquired (Details)", "role": "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "shortName": "ACQUISITIONS - Intangible Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "I2019Q4SharesOutstanding_us-gaap_BusinessAcquisitionAxis_a_BioTekMember", "decimals": "-6", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2019Q1QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406405 - Disclosure - ACQUISITIONS - Proforma Operating Results (Details)", "role": "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails", "shortName": "ACQUISITIONS - Proforma Operating Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2019Q1QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - REVENUE- Revenue by Region (Details)", "role": "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "shortName": "REVENUE- Revenue by Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1QTD_srt_StatementGeographicalAxis_srt_AmericasMember", "decimals": "-6", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - REVENUE - Revenue by End Markets (Details)", "role": "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails", "shortName": "REVENUE - Revenue by End Markets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1QTD_a_EndMarketsAxis_a_PharmaceuticalandBiopharmaceuticalMarketMember", "decimals": "-6", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - REVENUE - Revenue by Type (Details)", "role": "http://www.agilent.com/role/RevenueRevenueByTypeDetails", "shortName": "REVENUE - Revenue by Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1QTD_srt_ProductOrServiceAxis_a_InstrumentationMember", "decimals": "-6", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - REVENUE - Contract Balances (Details)", "role": "http://www.agilent.com/role/RevenueContractBalancesDetails", "shortName": "REVENUE - Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details)", "role": "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "shortName": "SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - SHARE-BASED COMPENSATION Fair Value Assumptions (Details)", "role": "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails", "shortName": "SHARE-BASED COMPENSATION Fair Value Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_PublicUtilitiesInventoryTypeDomain", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - SHARE-BASED COMPENSATION Capitalized (Details)", "role": "http://www.agilent.com/role/ShareBasedCompensationCapitalizedDetails", "shortName": "SHARE-BASED COMPENSATION Capitalized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_PublicUtilitiesInventoryTypeDomain", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409401 - Disclosure - INCOME TAXES (Details)", "role": "http://www.agilent.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical)", "role": "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - NET INCOME PER SHARE (Details)", "role": "http://www.agilent.com/role/NetIncomePerShareDetails", "shortName": "NET INCOME PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - INVENTORY (Details)", "role": "http://www.agilent.com/role/InventoryDetails", "shortName": "INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - LEASES - Future Minimum Lease Payments (Details)", "role": "http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "LEASES - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - LEASES - Lease Costs (Details)", "role": "http://www.agilent.com/role/LeasesLeaseCostsDetails", "shortName": "LEASES - Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePaymentsUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - LEASES - Supplemental Cash Flows Information (Details)", "role": "http://www.agilent.com/role/LeasesSupplementalCashFlowsInformationDetails", "shortName": "LEASES - Supplemental Cash Flows Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePaymentsUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)", "role": "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "LEASES - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "a:LesseeLeaseAssetsandLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)", "role": "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails", "shortName": "LEASES - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "a:OperatingLeasedassetsoriginalcost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - LEASES - Text (Details)", "role": "http://www.agilent.com/role/LeasesTextDetails", "shortName": "LEASES - Text (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "a:OperatingLeasedassetsoriginalcost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details)", "role": "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details)", "role": "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)", "role": "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details)", "role": "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details)", "role": "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details)", "role": "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details)", "role": "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails", "shortName": "FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - DERIVATIVES- Terminated Interest Rate Swaps (Details)", "role": "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails", "shortName": "DERIVATIVES- Terminated Interest Rate Swaps (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfForeignCurrencyDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "contracts", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417403 - Disclosure - DERIVATIVES- Foreign Exchange Forward Contracts (Details)", "role": "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "shortName": "DERIVATIVES- Foreign Exchange Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfForeignCurrencyDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "contracts", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417404 - Disclosure - DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details)", "role": "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "shortName": "DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417405 - Disclosure - DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details)", "role": "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "shortName": "DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember", "decimals": "-6", "lang": null, "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details)", "role": "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418403 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual)", "role": "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF EQUITY", "role": "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - WARRANTIES AND CONTINGENCIES (Details)", "role": "http://www.agilent.com/role/WarrantiesAndContingenciesDetails", "shortName": "WARRANTIES AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLinesOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420401 - Disclosure - SHORT-TERM DEBT Credit Facility (Details)", "role": "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails", "shortName": "SHORT-TERM DEBT Credit Facility (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:ShortTermBankLoansAndNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421402 - Disclosure - LONG-TERM DEBT (Details)", "role": "http://www.agilent.com/role/LongTermDebtDetails", "shortName": "LONG-TERM DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "I2019Q1SD_us-gaap_ShareRepurchaseProgramAxis_a_A2019RepurchaseProgramMember", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422402 - Disclosure - STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details)", "role": "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "I2019Q1SD_us-gaap_ShareRepurchaseProgramAxis_a_A2019RepurchaseProgramMember", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422403 - Disclosure - STOCKHOLDER\"S EQUITY - Dividends (Details)", "role": "http://www.agilent.com/role/StockholdersEquityDividendsDetails", "shortName": "STOCKHOLDER\"S EQUITY - Dividends (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422404 - Disclosure - STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details)", "role": "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails", "shortName": "STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422405 - Disclosure - STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details)", "role": "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails", "shortName": "STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "a:Unrealizedgainsandlossesonderivativesreclassifiedtocostofproductsbeforetax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423402 - Disclosure - SEGMENT INFORMATION - Profitability (Details)", "role": "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "shortName": "SEGMENT INFORMATION - Profitability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "a:Segmentincomelossfromoperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423403 - Disclosure - SEGMENT INFORMATION - Reconciliation of Reportable Results (Details)", "role": "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails", "shortName": "SEGMENT INFORMATION - Reconciliation of Reportable Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "a:Segmentincomelossfromoperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423404 - Disclosure - SEGMENT INFORMATION - Segment Assets (Details)", "role": "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails", "shortName": "SEGMENT INFORMATION - Segment Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "FI2020Q1_us-gaap_StatementBusinessSegmentsAxis_a_LifeSciencesandAppliedMarketsMember", "decimals": "-6", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1005001 - Statement - CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL)", "role": "http://www.agilent.com/role/CondensedConsolidateStatementOfEquityParenthetical", "shortName": "CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL)", "subGroupType": "", "uniqueAnchor": null }, "R90": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "D2020Q2_2.6.2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424402 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.agilent.com/role/SubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a-01312020x10q.htm", "contextRef": "D2020Q2_2.6.2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 90, "tag": { "a_A2015RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2015 Repurchase Program - On May 28, 2015 we announced that our board of directors had approved a new share repurchase program. The new share repurchase program authorizes the purchase of up to $1.14 billion of our common stock through and including November 1, 2018. The new program will commence, at the option of the company, on either November 1, 2015, or the date on which we complete the purchase of $365 million of common stock under the existing stock repurchase program in fiscal 2015. Upon commencement, the new program replaces our existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs.", "label": "2015 Repurchase Program [Member]", "terseLabel": "2015 Repurchase Program" } } }, "localname": "A2015RepurchaseProgramMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "a_A2019RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 Repurchase Program [Member]", "label": "2019 Repurchase Program [Member]", "terseLabel": "2019 Repurchase Program [Member]" } } }, "localname": "A2019RepurchaseProgramMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "a_ACEABiosciencesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ACEA Biosciences, Inc. [Member]", "label": "ACEA Biosciences, Inc. [Member]", "terseLabel": "ACEA Biosciences, Inc." } } }, "localname": "ACEABiosciencesInc.Member", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "domainItemType" }, "a_AcademiaandGovernmentMarketMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Academia and Government Market [Member]", "label": "Academia and Government Market [Member]", "terseLabel": "Academia and Government Market" } } }, "localname": "AcademiaandGovernmentMarketMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_AgilentCrossLabMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agilent CrossLab [Member]", "label": "Agilent CrossLab [Member]", "terseLabel": "Agilent CrossLab" } } }, "localname": "AgilentCrossLabMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails", "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "a_AmortizationAndDeferralsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amortization and deferrals [Abstract]", "label": "Amortization and deferrals [Abstract]", "terseLabel": "Amortization:" } } }, "localname": "AmortizationAndDeferralsAbstract", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "stringItemType" }, "a_AssetsLongLivedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets Long Lived [Abstract]", "label": "Assets Long Lived [Abstract]", "terseLabel": "Long-Lived Assets" } } }, "localname": "AssetsLongLivedAbstract", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "stringItemType" }, "a_BioTekMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BioTek [Member]", "label": "BioTek [Member]", "terseLabel": "BioTek" } } }, "localname": "BioTekMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails", "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "domainItemType" }, "a_ChemicalandEnergyMarketMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Chemical and Energy Market [Member]", "label": "Chemical and Energy Market [Member]", "terseLabel": "Chemical and Energy Market" } } }, "localname": "ChemicalandEnergyMarketMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_DenominatorsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Denominators [Abstract]", "label": "Denominators [Abstract]", "terseLabel": "Denominators:" } } }, "localname": "DenominatorsAbstract", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "a_DiagnosticsAndGenomicsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Diagnostics and Genomics segment includes; DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation profiling; gene expression profiling; and automated gel electrophoresis-based sample analysis systems.", "label": "Diagnostics and Genomics [Member]", "terseLabel": "Diagnostics and Genomics" } } }, "localname": "DiagnosticsAndGenomicsMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails", "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "a_DiagnosticsandClinicalMarketMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Diagnostics and Clinical Market [Member]", "label": "Diagnostics and Clinical Market [Member]", "terseLabel": "Diagnostics and Clinical Market" } } }, "localname": "DiagnosticsandClinicalMarketMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.agilent.com/20200131", "xbrltype": "stringItemType" }, "a_Employeecompensationandbenefitsassumed": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer) assumed at the acquisition date.", "label": "Employee compensation and benefits assumed", "terseLabel": "Employee compensation and benefits assumed" } } }, "localname": "Employeecompensationandbenefitsassumed", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "a_EndMarketsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End Markets [Axis]", "label": "End Markets [Axis]", "terseLabel": "End Markets [Axis]" } } }, "localname": "EndMarketsAxis", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails" ], "xbrltype": "stringItemType" }, "a_EndMarketsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for End Markets [Axis]", "label": "End Markets [Domain]", "terseLabel": "End Markets [Domain]" } } }, "localname": "EndMarketsDomain", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_EnvironmentalandForensicsMarketMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Environmental and Forensics Market [Member]", "label": "Environmental and Forensics Market [Member]", "terseLabel": "Environmental and Forensics Market" } } }, "localname": "EnvironmentalandForensicsMarketMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_Estimatedcoststocompleteinprocessresearchanddevelopmentprojects": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "estimated costs to complete in-process research and development projects", "label": "estimated costs to complete in-process research and development projects", "terseLabel": "estimated costs to complete in-process research and development projects" } } }, "localname": "Estimatedcoststocompleteinprocessresearchanddevelopmentprojects", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "monetaryItemType" }, "a_Fairvalueoflongtermdebtinexcessofcarryingvalue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of fair value of long term debt in excess of carrying value.", "label": "Fair value of long term debt in excess of carrying value", "terseLabel": "Fair value of senior notes in excess of carrying value" } } }, "localname": "Fairvalueoflongtermdebtinexcessofcarryingvalue", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "a_FoodMarketMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Food Market [Member]", "label": "Food Market [Member]", "terseLabel": "Food Market" } } }, "localname": "FoodMarketMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_IncreaseinContractAssetBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase in Contract Asset Balance", "terseLabel": "Increase in Contract Asset Balance" } } }, "localname": "IncreaseinContractAssetBalance", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "a_InstrumentationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Instrumentation [Member]", "label": "Instrumentation [Member]", "terseLabel": "Instrumentation" } } }, "localname": "InstrumentationMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "domainItemType" }, "a_Interestrateswappayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "interest rate swap payments", "label": "interest rate swap payments", "terseLabel": "Interest rate swap payments" } } }, "localname": "Interestrateswappayments", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "a_LTPPRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "LTPP & RSU [Member]", "label": "LTPP & RSU [Member]", "terseLabel": "LTPP & RSU" } } }, "localname": "LTPPRSUMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "a_LesseeLeaseAssetsandLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Lease Assets and Liabilities [Table Text Block]", "label": "Lessee, Lease Assets and Liabilities [Table Text Block]", "terseLabel": "Lessee, Lease Assets and Liabilities" } } }, "localname": "LesseeLeaseAssetsandLiabilitiesTableTextBlock", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "a_LifeSciencesandAppliedMarketsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Life Sciences and Applied Markets [Member]", "label": "Life Sciences and Applied Markets [Member]", "terseLabel": "Life Sciences and Applied Markets" } } }, "localname": "LifeSciencesandAppliedMarketsMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails", "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "a_LtppMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long Term Performance Plan.", "label": "LTPP [Member]", "terseLabel": "LTPP" } } }, "localname": "LtppMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "a_NonInstrumentationandOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-Instrumentation and Other[Member]", "label": "Non-Instrumentation and Other [Member]", "terseLabel": "Non-Instrumentation and Other" } } }, "localname": "NonInstrumentationandOtherMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "domainItemType" }, "a_Noncashchangesininvestmentsinpropertyplantandequipmentincreasedecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Changes to the cost of fixed assets that are not the result of cash capital expenditures.", "label": "Non-cash changes in investments in property, plant and equipment increase (decrease)", "terseLabel": "Non-cash changes in investments in property, plant and equipment - increase (decrease)" } } }, "localname": "Noncashchangesininvestmentsinpropertyplantandequipmentincreasedecrease", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "a_NumeratorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Numerator [Abstract]", "label": "Numerator [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "a_OperatingLeasedassetsoriginalcost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Leased assets - original cost", "label": "Operating Leased assets - original cost", "terseLabel": "Operating Leased assets - original cost" } } }, "localname": "OperatingLeasedassetsoriginalcost", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/LeasesTextDetails" ], "xbrltype": "monetaryItemType" }, "a_Operatingleasedassetsnetbookvalue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating leased assets, net book value", "label": "Operating leased assets, net book value", "terseLabel": "Operating leased assets, net book value" } } }, "localname": "Operatingleasedassetsnetbookvalue", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/LeasesTextDetails" ], "xbrltype": "monetaryItemType" }, "a_Other": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of an item in the reconciliation of total profit or loss from reportable segments, to the entity's consolidated income before income taxes, extraordinary items, discontinued operations.", "label": "Other", "terseLabel": "Other" } } }, "localname": "Other", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "a_Othertermloanborrowingcapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other term loan borrowing capacity", "label": "Other term loan borrowing capacity", "terseLabel": "Other short term loan borrowing capacity" } } }, "localname": "Othertermloanborrowingcapacity", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "a_PharmaceuticalandBiopharmaceuticalMarketMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical and Biopharmaceutical Market [Member]", "label": "Pharmaceutical and Biopharmaceutical Market [Member]", "terseLabel": "Pharmaceutical and Biopharmaceutical Market" } } }, "localname": "PharmaceuticalandBiopharmaceuticalMarketMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_Remaininggainlosstobeamortizedonderivative": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Remaining gain loss to be amortized on derivative", "label": "Remaining gain loss to be amortized on derivative", "terseLabel": "Remaining gain (loss) to be amortized on derivative" } } }, "localname": "Remaininggainlosstobeamortizedonderivative", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "a_SegmentTotalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reportable amounts associated with all reporting segments included in a reconciliation from segment reporting to consolidated income from operations, before taxes.", "label": "Segment Total [Member]", "terseLabel": "Segment Total" } } }, "localname": "SegmentTotalMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "a_Segmentincomelossfromoperations": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting segment operating expenses from segment operating revenues.", "label": "Segment income (loss) from operations", "terseLabel": "Total reportable segment's income from operations" } } }, "localname": "Segmentincomelossfromoperations", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "a_SeniorNotes2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured ( general) creditors.", "label": "Senior Notes 2022 [Member]", "terseLabel": "Senior Notes 2022" } } }, "localname": "SeniorNotes2022Member", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails", "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "a_SeniorNotes2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2023 [Member]", "label": "Senior Notes 2023 [Member]", "terseLabel": "Senior Notes 2023" } } }, "localname": "SeniorNotes2023Member", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "a_SeniorNotes2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2026", "label": "Senior Notes 2026 [Member]", "terseLabel": "Senior Notes 2026" } } }, "localname": "SeniorNotes2026Member", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails", "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "a_SeniorNotes2029Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2029 [Member]", "label": "Senior Notes 2029 [Member]", "terseLabel": "Senior Notes 2029" } } }, "localname": "SeniorNotes2029Member", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails", "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, and long-term performance plan grants.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Text Block]", "verboseLabel": "Assumptions used to estimate fair value for LTPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTextBlock", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPeerCompanySharesPriceWiseCorrelationyRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The measure of the percentage amount of share price correlation during the period with a selected group of peer companies. Pair-wise correlations with selected peers is calculated as the correlation between each pair and the sum of correlations divided by the number of pairs to produce the average correlation between each pair.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Peer Company Shares Price Wise Correlationy Rate", "verboseLabel": "Pair-wise correlation with selected peers (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPeerCompanySharesPriceWiseCorrelationyRate", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPeerCompanySharesVolatilityRateRangeMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The measure of the percentage amount by which a share price fluctuates during a period for peer companies - maximum range. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Peer Company Shares Volatility Rate Range Maximum", "terseLabel": "Volatility of selected peer-company shares - Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPeerCompanySharesVolatilityRateRangeMaximum", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPeerCompanySharesVolatilityRateRangeMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The measure of the percentage amount by which a share price fluctuates during a period for peer companies - minimum range. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Peer Company Shares Volatility Rate Range Minimum", "terseLabel": "Volatility of selected peer-company shares - Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPeerCompanySharesVolatilityRateRangeMinimum", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "a_Specialcompliancecosts": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Special compliance costs", "label": "Special compliance costs", "negatedTerseLabel": "Special compliance costs" } } }, "localname": "Specialcompliancecosts", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "a_Taxrelatedtosharesissued": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax related to shares issued", "label": "Tax related to shares issued", "terseLabel": "Tax related to shares issued" } } }, "localname": "Taxrelatedtosharesissued", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/CondensedConsolidateStatementOfEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "a_ThirdPartyTechnologyandLicensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third-Party Technology and Licenses [Member]", "label": "Third-Party Technology and Licenses [Member]", "terseLabel": "Third-Party Technology and Licenses" } } }, "localname": "ThirdPartyTechnologyandLicensesMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "domainItemType" }, "a_TotalAmortizableIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sum of the gross carrying amounts before accumulated amortization as of the balance sheet date of all intangible assets having statutory or estimated useful lives. The aggregate gross carrying amount (including any previously recognized impairment charges) of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Total Amortizable Intangible Assets [Member]", "terseLabel": "Total amortizable intangible assets" } } }, "localname": "TotalAmortizableIntangibleAssetsMember", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "a_TransformationalPrograms": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings in the period, comprised of costs associated with restructuring activities not otherwise specified in the taxonomy that are not part of a specific plan as required by GAAP.", "label": "Transformational Programs", "negatedLabel": "Transformational initiatives" } } }, "localname": "TransformationalPrograms", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "a_Unrealizedgainsandlossesonderivativesreclassifiedtocostofproductsbeforetax": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Unrealized gains and losses on derivatives reclassified to cost of products, before tax", "terseLabel": "Unrealized gains and (losses) on derivatives reclassified to cost of products, before tax" } } }, "localname": "Unrealizedgainsandlossesonderivativesreclassifiedtocostofproductsbeforetax", "nsuri": "http://www.agilent.com/20200131", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Australia, Dollars", "verboseLabel": "Australian Dollar" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian Dollar" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Switzerland, Francs", "terseLabel": "Swiss Franc" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_CNY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "China, Yuan Renminbi", "terseLabel": "Chinese Yuan Renminbi" } } }, "localname": "CNY", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_DKK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Denmark, Kroner", "terseLabel": "Danish Krone" } } }, "localname": "DKK", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British Pound" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_JPY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Japan, Yen", "terseLabel": "Japanese Yen" } } }, "localname": "JPY", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_KRW": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Korea (South), Won", "terseLabel": "Korean Won" } } }, "localname": "KRW", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_MYR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Malaysia, Ringgits", "terseLabel": "Malaysian Ringgit" } } }, "localname": "MYR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_PLN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Poland, Zlotych", "terseLabel": "Polish Zloty" } } }, "localname": "PLN", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_SEK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Sweden, Kronor", "terseLabel": "Swedish Krona" } } }, "localname": "SEK", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_SGD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Singapore, Dollars", "terseLabel": "Singapore Dollar" } } }, "localname": "SGD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_XXX": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "No currency", "terseLabel": "Other" } } }, "localname": "XXX", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r463" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r464" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r466" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r461" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r462" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Americas [Member]", "terseLabel": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByRegionDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByRegionDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r142", "r152" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByRegionDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r153", "r232", "r235", "r453", "r454" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r459" ], "lang": { "en-US": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/IncomeTaxesDetails", "http://www.agilent.com/role/RevenueContractBalancesDetails", "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails", "http://www.agilent.com/role/StockholdersEquityTables" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r154", "r232", "r236", "r455", "r456", "r458" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueRevenueByRegionDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r204", "r416" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/IncomeTaxesDetails", "http://www.agilent.com/role/RevenueContractBalancesDetails", "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails", "http://www.agilent.com/role/StockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NewAccountingPronouncementsNotes", "http://www.agilent.com/role/NewAccountingPronouncementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Impact of Adopting Accounting Standards Update 2016-02 - Leases" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r20", "r156", "r157", "r233" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Other Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": { "auth_ref": [ "r58", "r63", "r66", "r258", "r330" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]", "terseLabel": "Prior Service Credits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": { "auth_ref": [ "r57", "r63", "r66", "r258", "r330" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Actuarial Losses" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r60", "r62", "r63" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r59", "r63", "r66", "r330" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r54", "r63", "r66", "r330" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r97", "r185" ], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "negatedLabel": "Amortization of intangible assets related to business combinations" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Information by type of change in accounting principle. Does not include error corrections.", "label": "Adjustments for Change in Accounting Principle [Axis]", "terseLabel": "Adjustments for Change in Accounting Principle [Axis]" } } }, "localname": "AdjustmentsForChangeInAccountingPrincipleAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForErrorCorrectionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the types error corrections made to the financial statements.", "label": "Adjustments for Error Correction [Domain]", "terseLabel": "Adjustments for Error Correction [Domain]" } } }, "localname": "AdjustmentsForErrorCorrectionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/LongTermDebtDetails", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r275", "r277", "r289", "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r277", "r285", "r288" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r97", "r178", "r185" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization of intangible assets during the period" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of Earnings Per Share, amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from EPS Computation" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": { "auth_ref": [ "r63", "r368" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent.", "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]", "terseLabel": "Unrealized Gains (Losses) on Derivatives" } } }, "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r147", "r426", "r440" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r50" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Assets Short - term", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r370" ], "calculation": { "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "verboseLabel": "Assets, Long-term" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r279", "r286" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.agilent.com/role/LongTermDebtDetails", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails", "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.agilent.com/role/ShareBasedCompensationCapitalizedDetails", "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r345", "r350" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.agilent.com/role/LongTermDebtDetails", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails", "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.agilent.com/role/ShareBasedCompensationCapitalizedDetails", "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankAcceptancesExecuted": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the financial institution's obligation to pay the holder of the customer's draft which the financial institution has guaranteed (i.e., Banker's Acceptance).", "label": "Bank Acceptances Executed", "terseLabel": "Guarantees" } } }, "localname": "BankAcceptancesExecuted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails", "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails", "http://www.agilent.com/role/AcquisitionsTextDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails", "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r311", "r312" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails", "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails", "http://www.agilent.com/role/AcquisitionsTextDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails", "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Acquisition and Integration Costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails", "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails", "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r309", "r310" ], "lang": { "en-US": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Pro Forma Earnings Per Share, Basic" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r309", "r310" ], "lang": { "en-US": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Pro Forma Earnings Per Share, Diluted" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r309", "r310" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business Acquisition, Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r309", "r310" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Pro Forma Net Income" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r309", "r310" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Pro Forma Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r308" ], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition and integration costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r321", "r322", "r323" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Purchase Price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r320", "r321", "r322", "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Payment to Acquire Business with Debt" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions Disclosure" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Total Assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and Cash and Equivalents acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other Current Assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts Receivable acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts Payable assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "terseLabel": "Deferred Revenue assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "terseLabel": "Other Accrued Liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible Assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r313", "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r313", "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Net Assets Acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "terseLabel": "Long-term Debt assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r313", "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, Plant, and Equipment acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Acquisition" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r111", "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Overview and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r97", "r197", "r199", "r200" ], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "negatedLabel": "Business exit and divestiture costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r30", "r99" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents (money market funds)" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r99", "r102" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r381" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Cash flow hedge net gain to be reclassified within next Twelve Months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A change from one generally accepted accounting principle to another generally accepted accounting principle when there are two or more generally accepted accounting principles that apply or when the accounting principle formerly used is no longer generally accepted. A change in the method of applying an accounting principle that is not treated as a change in accounting estimate also is considered a change in accounting principle.", "label": "Adjustments for Change in Accounting Principle [Domain]", "terseLabel": "Adjustments for Change in Accounting Principle [Domain]" } } }, "localname": "ChangeInAccountingPrincipleMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r219", "r220", "r221", "r222" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r203", "r432", "r447" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r202", "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "WARRANTIES AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Cash dividends paid per common share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends Per Share, Declared" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidateStatementOfEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r212" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, issued and outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock; $0.01 par value; 2 billion shares authorized; 310 million shares at January 31, 2020 and 309 million shares at October 31, 2019, issued" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r69", "r71", "r72" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income (loss), net of tax" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Components of comprehensive income, net of tax" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r69", "r71", "r329", "r332" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Contract Liabilities and Changes in Balances" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r224", "r226", "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract Assets (Unbilled Accounts Receivable)" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]", "terseLabel": "Contract Assets" } } }, "localname": "ContractWithCustomerAssetNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r224", "r225", "r233" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Contract liability ending balance as of Jan 31, 2020", "periodStartLabel": "Contract liability ending balance as of October 31, 2019" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract Liabilities" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r227" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "terseLabel": "Contract liabilities acquired in business combinations" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized that was included in the contract liability balance at the beginning of the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r79" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Products and Services", "verboseLabel": "Cost of Sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r78" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative Effect of New Accounting Principle in Period of Adoption" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r427", "r428", "r439" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails", "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails", "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r40", "r105", "r213", "r214", "r215", "r216", "r390", "r391", "r393", "r438" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount as of the balance sheet date of the unamortized adjustment to the carrying value of an interest-bearing hedged item made under an effective interest rate fair value hedge that is amortized upon discontinuation of the interest rate fair value hedge.", "label": "Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge", "terseLabel": "Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge" } } }, "localname": "DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r97", "r104", "r299", "r302" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenuePeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred revenue.", "label": "Deferred Revenue, Period Increase (Decrease)", "terseLabel": "Impact of adoption of new guidance on contract liabilities (deferred revenue)" } } }, "localname": "DeferredRevenuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan [Abstract]" } } }, "localname": "DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r254", "r268", "r272" ], "calculation": { "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Actuarial losses" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r255", "r269", "r272" ], "calculation": { "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "verboseLabel": "Prior service credits" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r248", "r249", "r259", "r272" ], "lang": { "en-US": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r245", "r248", "r249", "r271", "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Contributions to defined benefit plans" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear": { "auth_ref": [ "r271" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions expected to be received by defined benefit plan from employer in fiscal year. Excludes contributions paid by employer in current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year", "terseLabel": "Estimated future employer contributions in remainder of current fiscal year" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r253", "r267", "r272" ], "calculation": { "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r244", "r252", "r266", "r272" ], "calculation": { "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "verboseLabel": "Interest cost on benefit obligation" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r250", "r264", "r272" ], "calculation": { "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Total net plan costs" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r256", "r270" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "terseLabel": "Settlement gain" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r243", "r251", "r265", "r272" ], "calculation": { "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost - benefits earned during the period" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsAndCurtailmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Settlement and Curtailment [Abstract]", "terseLabel": "Curtailments and Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsAndCurtailmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r97", "r145" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r51", "r52", "r348", "r422" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "verboseLabel": "Derivatives asset fair value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r51", "r52", "r348", "r422" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "verboseLabel": "Derivatives liabilities fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative, Fair Value, Net [Abstract]", "terseLabel": "Derivative Fair Value by Balance Sheet Location" } } }, "localname": "DerivativeFairValueOfDerivativeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Gain (loss) recognized in other income (expense)" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentDetailAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instrument Detail [Abstract]", "verboseLabel": "Derivative Instruments and Hedging Activities Disclosure" } } }, "localname": "DerivativeInstrumentDetailAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r346", "r349", "r353", "r358" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r342", "r346", "r353" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r352", "r357" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Unrealized gain (loss) on derivatives", "verboseLabel": "Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": { "auth_ref": [ "r360" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.", "label": "Derivative, Net Liability Position, Aggregate Fair Value", "terseLabel": "Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position" } } }, "localname": "DerivativeNetLiabilityPositionAggregateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r336", "r338" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r110", "r335", "r337", "r338", "r342", "r344", "r351", "r353", "r361", "r362", "r365" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated as Hedging Instrument", "verboseLabel": "Derivatives Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Purchased Technology", "verboseLabel": "Developed Product Technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "Date the declared dividend will be paid, in CCYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Dividends Payable, Date to be Paid" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dividends [Abstract]" } } }, "localname": "DividendsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]", "terseLabel": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dividends, Common Stock [Abstract]", "terseLabel": "Dividends Declared" } } }, "localname": "DividendsCommonStockAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Cash dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]", "terseLabel": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "Date the dividend to be paid was declared, in CCYY-MM-DD format.", "label": "Dividends Payable, Date Declared", "terseLabel": "Dividends Payable, Date Declared" } } }, "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in CCYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Dividends Payable, Date of Record" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Dividends Payable [Line Items]", "terseLabel": "Dividends Payable [Line Items]" } } }, "localname": "DividendsPayableLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableTable": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.", "label": "Dividends Payable [Table]", "terseLabel": "Dividends Payable [Table]" } } }, "localname": "DividendsPayableTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r77", "r113", "r121", "r123", "r124", "r125", "r128", "r436", "r451" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r77", "r113", "r121", "r123", "r124", "r125", "r128", "r436", "r451" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET INCOME PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r381" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate movements" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r109", "r295", "r296" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r291", "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount", "terseLabel": "Excess tax benefit from stock based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "verboseLabel": "Employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Share repurchase program" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesByIndustryAxis": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Axis]", "terseLabel": "Industry Sector [Axis]" } } }, "localname": "EquitySecuritiesByIndustryAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesByInvestmentObjectiveAxis": { "auth_ref": [ "r247", "r272" ], "lang": { "en-US": { "role": { "documentation": "Information by investment objective.", "label": "Investment Objective [Axis]", "terseLabel": "Investment Objective [Axis]" } } }, "localname": "EquitySecuritiesByInvestmentObjectiveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]", "terseLabel": "Non-Marketable Equity Securities without Readily Determinable Fair Value" } } }, "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesIndustryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Domain]", "terseLabel": "Industry Sector [Domain]" } } }, "localname": "EquitySecuritiesIndustryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesInvestmentObjectiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Objective of investment.", "label": "Investment Objective [Domain]", "terseLabel": "Investment Objective [Domain]" } } }, "localname": "EquitySecuritiesInvestmentObjectiveMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r160" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Non-marketable equity securities carrying amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount", "terseLabel": "Impairment of non-marketable securities" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": { "auth_ref": [ "r115", "r116", "r117" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error correction.", "label": "Adjustments for Error Corrections [Axis]", "terseLabel": "Adjustments for Error Corrections [Axis]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails", "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r370", "r371", "r372", "r376" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails", "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r248", "r249", "r272", "r371", "r418" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails", "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r370", "r371", "r373", "r374", "r377" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails", "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r248", "r249", "r272", "r371", "r419" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r248", "r249", "r272", "r371", "r420" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r248", "r249", "r272", "r371", "r421" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails", "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails", "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r375", "r377" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r103", "r378", "r379" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r401", "r407" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Repayment of finance lease" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r184" ], "calculation": { "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r179", "r181", "r184", "r188", "r423" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign Currency Translation Gain (Loss)" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r184", "r423" ], "calculation": { "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r179", "r183" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Addition to other intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Derivative instruments (foreign exchange contracts)" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Derivative instruments (foreign exchange contracts)" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r248", "r356" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "Foreign Plan" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts USD" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r167", "r169" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill ending balance", "periodStartLabel": "Goodwill beginning balance", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill arising from acquisitions", "verboseLabel": "Additions to goodwill" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r97", "r168", "r171", "r175" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill Roll Forward" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r172", "r173", "r307" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "terseLabel": "Foreign currency translation impact" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Guarantees [Abstract]", "terseLabel": "Guarantees" } } }, "localname": "GuaranteesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r342", "r359" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r97", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of IPR&D" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r159" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Impairment of Investments" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r97", "r192", "r194", "r457" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Impairment of Long-Lived Assets Held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r97", "r191" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment of long-lived assets held for sale" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-Process R&D" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r75", "r113", "r424", "r434", "r452" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r107" ], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before taxes, as reported" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]", "verboseLabel": "Derivative Instruments, Gain (Loss) by Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails", "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]", "verboseLabel": "Income Statement and Other Comprehensive Income (Loss) Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails", "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax Disclosure" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r298", "r301" ], "lang": { "en-US": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r146", "r304" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision (benefit) for income taxes", "verboseLabel": "Provision (benefit) for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax paid, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r96" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Net revenue deferred in the period" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for current or future transactions, initial payment of the cost of an acquisition or for the right to enter into a contract or agreement, (c) the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable, or (d) some combination of (a), (b), and (c).", "label": "Increase (Decrease) in Deferred Revenue and Customer Advances and Deposits", "terseLabel": "Change in deferrals from customer cash advances, net of revenue recognized" } } }, "localname": "IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Employee compensation and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r96" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r122", "r127" ], "calculation": { "http://www.agilent.com/role/NetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Potential common shares - stock options and other employee stock plans (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "In-Process R&D" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]", "terseLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from purchase accounting adjustments.", "label": "Indefinite-lived Intangible Assets, Purchase Accounting Adjustments", "terseLabel": "Measurement period adjustment to goodwill" } } }, "localname": "IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Trransition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Total Intangible Assets, Gross (Excluding Goodwill)" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r177", "r182" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Net Book Value", "verboseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r74", "r144", "r389", "r392", "r437" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r92", "r94", "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest payments" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Interest Rate Derivatives [Abstract]", "terseLabel": "Terminated Derivative Contracts" } } }, "localname": "InterestRateDerivativesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/InventoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r46" ], "calculation": { "http://www.agilent.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r48", "r164" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.agilent.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory", "verboseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterials": { "auth_ref": [ "r47" ], "calculation": { "http://www.agilent.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials", "verboseLabel": "Purchased parts and fabricated assemblies" } } }, "localname": "InventoryWorkInProcessAndRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r165" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Excess and obsolete inventory related charges" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r81", "r143" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r370" ], "calculation": { "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Other investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r411", "r413" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r397" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases of Lessee Disclosure [Text Block]" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Lessee, Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r412" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Total undiscounted future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Operating lease payments due in 2025 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "Operating lease payments due in 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "Operating lease payments due in 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Operating lease payments due in 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Operating lease payments due in 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Operating lease payments due in 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Amount of lease payments representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r429", "r445" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Liabilities, Short-term", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r370" ], "calculation": { "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Liabilities Long-term" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Line of Credit Facility [Abstract]", "terseLabel": "Line of Credit Facility" } } }, "localname": "LineOfCreditFacilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r36", "r105" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Line of Credit Facility [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Date the credit facility terminates, in CCYY-MM-DD format.", "label": "Line of Credit Facility, Expiration Date", "terseLabel": "Expiration date of credit facility" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Amount outstanding on credit facility" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInitiationDate1": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Date the credit facility first became available, in CCYY-MM-DD format.", "label": "Line of Credit Facility, Initiation Date", "terseLabel": "Initiation date of credit facility" } } }, "localname": "LineOfCreditFacilityInitiationDate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity of credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r36", "r105" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount of Litigation Settlement Awarded from Twist Bioscience" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Buy" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r210", "r428", "r442" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LongTermDebtNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r31" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "verboseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.", "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Change in non-controlling interest increase (decrease)" } } }, "localname": "MinorityInterestPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r67", "r70", "r76", "r98", "r127", "r435", "r450" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging [Member]" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "NEW ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NewAccountingPronouncementsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Not Designated as Hedging Instruments", "verboseLabel": "Not Designated as Hedging Instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails", "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails", "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails", "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfForeignCurrencyDerivativesHeld": { "auth_ref": [ "r336", "r338" ], "lang": { "en-US": { "role": { "documentation": "Number of foreign currency exchange rate derivatives held by the entity at the reporting date.", "label": "Number of Foreign Currency Derivatives Held", "terseLabel": "Number of foreign exchange forward contracts (in units)" } } }, "localname": "NumberOfForeignCurrencyDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r336", "r338" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of interest rate swap contracts terminated" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "verboseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationProfitabilityDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Income from operations", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/SegmentInformationProfitabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r404", "r413" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedTerseLabel": "Operating lease liability, Current", "terseLabel": "Operating lease liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails", "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails", "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePaymentsUse": { "auth_ref": [ "r402", "r407" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments, Use", "terseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePaymentsUse", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesSupplementalCashFlowsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r399" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r410", "r413" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r409", "r413" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years) - Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Total future minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "2025 and thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]", "terseLabel": "Options Held [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrderOrProductionBacklogMember": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination.", "label": "Order or Production Backlog [Member]", "terseLabel": "Backlog" } } }, "localname": "OrderOrProductionBacklogMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r111", "r118", "r140", "r333" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r431", "r448" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "verboseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax": { "auth_ref": [ "r58", "r60", "r257" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "negatedLabel": "Change in net prior service benefit, net of tax expense of $1 and $0" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]", "verboseLabel": "Net defined benefit pension cost and post retirement plan costs:" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r57", "r60", "r257" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax", "verboseLabel": "Change in actuarial net loss, net of tax expense of $3 and $4" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax", "terseLabel": "Change in actuarial net loss, tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax [Abstract]", "verboseLabel": "Net defined benefit pension cost and post retirement plan costs, tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r55", "r60", "r382", "r383", "r387", "r388" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation, net of tax expense (benefit) of $0 and $(9)" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r60", "r64", "r65", "r257" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Prior service benefit" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax", "terseLabel": "Change in net prior service benefit, tax" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r53", "r61" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "verboseLabel": "Foreign currency translation, tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r68", "r71", "r73", "r212" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": { "auth_ref": [ "r60", "r64", "r65", "r343" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax", "negatedLabel": "Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0 and $(1)", "terseLabel": "Unrealized gains and (losses) on derivatives reclassified to cost of products, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited", "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax", "terseLabel": "Reclassification of (gains) and losses into earnings related to derivative instruments, tax", "verboseLabel": "Amounts reclassified into earnings related to derivative instruments, tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical", "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax": { "auth_ref": [ "r60", "r64", "r65" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Actuarial net loss and prior service benefit reclassified, before tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "auth_ref": [ "r60", "r64", "r65", "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "negatedTerseLabel": "Actuarial net loss" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "auth_ref": [ "r60", "r64", "r65", "r257" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Actuarial net loss and prior service benefit reclassified, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r61", "r329" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax (expense) benefit for reclassification adjustment from accumulated other comprehensive (income) loss of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax", "terseLabel": "Tax on actuarial net loss and prior service benefit reclassified" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r61", "r303", "r305" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]", "terseLabel": "Other comprehensive income (loss), tax, parenthetical disclosures" } } }, "localname": "OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r56", "r60", "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Gain (loss) recognized in accumulated other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r56", "r60", "r366" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "verboseLabel": "Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $0 and $(2)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax": { "auth_ref": [ "r56", "r61" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax", "verboseLabel": "Unrealized gain on derivative instruments, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r345", "r363" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesFairValueOfDerivativeInstrumentsAndConsolidatedBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash expense, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesEffectOfDerivativeInstrumentsOnConsolidatedStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r240", "r260", "r261", "r273" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits Plan" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherShortTermBorrowings": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.", "label": "Other Short-term Borrowings", "terseLabel": "Other Short-term Borrowings" } } }, "localname": "OtherShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r108", "r294", "r300" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "verboseLabel": "Discrete tax expense (benefit)" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other than Temporary Impairment Losses, Investments [Abstract]", "terseLabel": "Investments" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Stockholder's Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r90" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Treasury stock repurchases" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payments of Dividends [Abstract]", "terseLabel": "Dividends Paid" } } }, "localname": "PaymentsOfDividendsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "verboseLabel": "Aggregate amount of cash dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityDividendsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfOrdinaryDividends": { "auth_ref": [ "r90" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.", "label": "Payments of Ordinary Dividends", "negatedLabel": "Payment of dividends" } } }, "localname": "PaymentsOfOrdinaryDividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payment of taxes related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r85" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments to Acquire Additional Interest in Subsidiaries", "negatedTerseLabel": "Purchase of non-controlling interest" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r85", "r324" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash Payment to Acquire Businesses" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r85" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions of businesses and intangible assets, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r87" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payment to acquire fair value investment" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r84" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payments to Acquire Notes Receivable", "negatedLabel": "Payments in exchange for convertible note" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r86" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Investments in property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payment for Pension and Other Postretirement Benefits [Abstract]", "terseLabel": "Defined Benefit Plans Contributions" } } }, "localname": "PensionAndOtherPostretirementBenefitContributionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r16", "r241", "r242", "r246" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "verboseLabel": "Retirement and post-retirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r239", "r260", "r261", "r273" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, issued and outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r88", "r287" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuance of common stock under employee stock plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r89", "r106" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from Lines of Credit", "verboseLabel": "Proceeds from revolving credit facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Additions", "negatedTerseLabel": "NASD site costs" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r193", "r446" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.agilent.com/role/ShareBasedCompensationCapitalizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r63", "r66", "r73" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "terseLabel": "Amounts reclassified out of accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityReclassificationsOutOfAccumulatedComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]", "terseLabel": "Reconciliation of Operating Profit from Segments to Consolidated" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r149", "r151" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "verboseLabel": "Reconciliation of segment results to total enterprise results" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r91" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Repayment of revolving credit facility" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r91", "r106" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "terseLabel": "Repayments of revolving credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r293", "r460" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r102", "r425", "r443" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restricted Cash [Abstract]" } } }, "localname": "RestrictedCashAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r217", "r444" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r261", "r263" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r261", "r263" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r239", "r240", "r260", "r261", "r273" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r239", "r240", "r260", "r261", "r273" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r231", "r232" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails", "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "http://www.agilent.com/role/RevenueRevenueByTypeDetails", "http://www.agilent.com/role/SegmentInformationProfitabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contract with Customer" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue, Performance Obligation [Abstract]", "terseLabel": "Transaction Price Allocated to Remaining Performance Obligation" } } }, "localname": "RevenuePerformanceObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Majority of Remaining Performance Obligation Expected Timing of Satisfaction, Period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Net revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r408", "r413" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Non-Cash Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesSupplementalCashFlowsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeLeaseLeaseReceivable": { "auth_ref": [ "r414" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease.", "label": "Sales-type Lease, Lease Receivable", "terseLabel": "Sales-type Lease, Lease Receivable" } } }, "localname": "SalesTypeLeaseLeaseReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r311", "r312" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsAssetsAndLiabilitiesAssumedDetails", "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails", "http://www.agilent.com/role/AcquisitionsProformaOperatingResultsDetails", "http://www.agilent.com/role/AcquisitionsTextDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r40", "r105", "r213", "r214", "r215", "r216", "r390", "r391", "r393", "r438" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of Senior Notes and Related Interest Rate Swaps" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r260", "r261", "r262", "r263", "r272" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansDetailsTextual", "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansJwpilDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "auth_ref": [ "r260", "r261", "r262", "r263", "r272" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "terseLabel": "Schedule of net pension and post-retirement benefit costs" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r346", "r353", "r359" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r110", "r335", "r337", "r338", "r342", "r344", "r351", "r353", "r361", "r362" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Aggregated notional amounts by currency and designation" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Reconciliation of the numerators and denominators of the basic and diluted net income per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r277", "r284", "r288" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r277", "r284", "r288" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "verboseLabel": "Allocated share-based compensation expense disclosure" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r370", "r371" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r179", "r183" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r179", "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "verboseLabel": "Components of other intangible assets during the period" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r174", "r176" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r174", "r176" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Goodwill balances and movements for each reportable segment during the period" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r27", "r28", "r29" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "INVENTORY" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r112", "r114", "r130", "r131", "r132" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Summary of New Accounting Pronouncements" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NewAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "verboseLabel": "Standard warranty" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the comparison between amounts disclosed under previous guidance and new guidance.", "label": "Schedule of Prospective Adoption of New Accounting Pronouncements [Table Text Block]", "terseLabel": "Schedule of Prospective Adoption of New Accounting Pronouncements" } } }, "localname": "ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/NewAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r8", "r102", "r425", "r443" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restrictions on Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOverviewBasisOfPresentationAndSummaryOfAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r141", "r147", "r148", "r150", "r174" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r141", "r147", "r148", "r150", "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Segment Profitability and Segment Assets" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r279", "r286" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationCapitalizedDetails", "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization expense of finite-lived intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails", "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]", "terseLabel": "Segment Reporting Information" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationProfitabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r80", "r163" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r83" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceOtherMember": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other.", "label": "Service, Other [Member]", "terseLabel": "Service, Other" } } }, "localname": "ServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "ESPP plan purchase price (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions", "terseLabel": "Discount for post-vesting restrictions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility of Agilent shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationCapitalizedDetails", "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r276", "r280" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.agilent.com/role/ShareBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r284" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShareBasedCompensationCapitalizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending Balance (in Shares)", "periodStartLabel": "Beginning Balance (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Sell" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "auth_ref": [ "r33", "r449" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.", "label": "Short-term Bank Loans and Notes Payable", "terseLabel": "Short-term loan facility" } } }, "localname": "ShortTermBankLoansAndNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r11", "r427", "r441" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term Debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermBorrowingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Short-term Debt [Abstract]" } } }, "localname": "ShortTermBorrowingsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Short-term Debt, Other Disclosures [Abstract]", "terseLabel": "Other Short-term loan facilities" } } }, "localname": "ShortTermDebtOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTerms": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Description of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements.", "label": "Short-term Debt, Terms", "terseLabel": "Credit faciity terms (in years)" } } }, "localname": "ShortTermDebtTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "Short-term Debt [Text Block]", "terseLabel": "SHORT-TERM DEBT" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/ShortTermDebtNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r208" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Ending balance at end of period", "periodStartLabel": "Beginning balance as of" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual, Current", "terseLabel": "Accruals for warranties due within one year" } } }, "localname": "StandardProductWarrantyAccrualCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r206" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Settlements made during the period" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Accruals for warranties including change in estimate" } } }, "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Standard Product Warranty Disclosure [Abstract]", "terseLabel": "Standard Product Warranty Disclosure" } } }, "localname": "StandardProductWarrantyDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/WarrantiesAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r147", "r174", "r196", "r198", "r201", "r453" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsGoodwillRollForwardDetails", "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsTextualsDetails", "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "http://www.agilent.com/role/SegmentInformationProfitabilityDetails", "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails", "http://www.agilent.com/role/SegmentInformationSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r17", "r18", "r19", "r212" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r44", "r212" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement Line Items" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails", "http://www.agilent.com/role/RevenueContractBalancesDetails", "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails", "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "http://www.agilent.com/role/RevenueRevenueByTypeDetails", "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails", "http://www.agilent.com/role/StockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RetirementPlansAndPostRetirementPensionPlansComponentsOfNetPeriodicCostsDetails", "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeLossUnauditedParenthetical", "http://www.agilent.com/role/CondensedConsolidatedStatementOfComprehensiveIncomeUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails", "http://www.agilent.com/role/RevenueContractBalancesDetails", "http://www.agilent.com/role/RevenueRevenueByEndMarketsDetails", "http://www.agilent.com/role/RevenueRevenueByRegionDetails", "http://www.agilent.com/role/RevenueRevenueByTypeDetails", "http://www.agilent.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeDetails", "http://www.agilent.com/role/StockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r18", "r19", "r212", "r217" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based awards issued, net of tax (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r18", "r19", "r217", "r278", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based awards issued" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount under share repurchase program" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r18", "r19", "r212", "r217" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "terseLabel": "Stock repurchased and retired during period, (Shares)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r212", "r217" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "terseLabel": "Stock repurchased and retired during period, (Value)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r18", "r19", "r212", "r217" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r212", "r217" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r23", "r24", "r158" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholder's equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r327", "r328", "r331" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/StockholdersEquityNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r406", "r413" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Axis]", "terseLabel": "Subsegments Consolidation Items [Axis]" } } }, "localname": "SubsegmentsConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Domain]", "terseLabel": "Subsegments Consolidation Items [Domain]" } } }, "localname": "SubsegmentsConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SegmentInformationReconciliationOfReportableResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SubsequentEventsDetails", "http://www.agilent.com/role/SubsequentEventsNotes" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SubsequentEventsDetails", "http://www.agilent.com/role/SubsequentEventsNotes" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SubsequentEventsDetails", "http://www.agilent.com/role/SubsequentEventsNotes" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SubsequentEventsDetails", "http://www.agilent.com/role/SubsequentEventsNotes" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/SubsequentEventsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trademarks and Trade Names" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/AcquisitionsIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademark/Tradenames" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/GoodwillAndOtherIntangibleAssetsDisclosuresAndComponentsOfPurchasedOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r433" ], "calculation": { "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Trading securities" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease": { "auth_ref": [ "r60", "r382", "r384", "r385", "r386" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cumulative translation adjustment, after tax, from translating foreign currency financial statements into the reporting currency.", "label": "Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)", "terseLabel": "Currency Translation and Other Adjustment" } } }, "localname": "TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "terseLabel": "Treasury Lock [Member]" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/DerivativesTerminatedInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r45", "r219" ], "lang": { "en-US": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury Stock (in Shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r43", "r219" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "auth_ref": [ "r19", "r212", "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.", "label": "Treasury Stock, Retired, Cost Method, Amount", "negatedLabel": "Retirement of treasury shares" } } }, "localname": "TreasuryStockRetiredCostMethodAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r43", "r219" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "periodEndLabel": "Ending Treasury Stock, Shares", "periodStartLabel": "Beginning Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesRetired": { "auth_ref": [ "r19", "r212", "r217" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common and preferred stock retired from treasury during the period.", "label": "Treasury Stock, Shares, Retired", "negatedLabel": "Retirement of treasury shares (in shares)" } } }, "localname": "TreasuryStockSharesRetired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r43", "r219", "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "periodEndLabel": "Ending Treasury Stock, Value", "periodStartLabel": "Beginning Treasury Stock, Value", "terseLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfEquity", "http://www.agilent.com/role/LongTermDebtDetails", "http://www.agilent.com/role/NewAccountingPronouncementsInitialAdoptionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r97" ], "calculation": { "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized gain on equity securities", "terseLabel": "Unrealized gain on equity securities" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfCashFlowsUnaudited", "http://www.agilent.com/role/FairValueMeasurementsFairValueMeasuresAndImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r133", "r134", "r135", "r136", "r137", "r138", "r139" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/OverviewBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r405", "r413" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable Lease, Cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/LeasesLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r120", "r125" ], "calculation": { "http://www.agilent.com/role/NetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Diluted weighted average shares (in shares)", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares used in computing net income per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r119", "r125" ], "calculation": { "http://www.agilent.com/role/NetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average shares (in shares)", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.agilent.com/role/CondensedConsolidatedStatementOfOperationsUnaudited", "http://www.agilent.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i),(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117415099&loc=d3e34841-113949" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624258-113959" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "35", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=118957181&loc=d3e75592-113984" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32157-110900" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r397": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919379-209981" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r417": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.14)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(a)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r461": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r463": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r464": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r465": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r466": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3),(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" } }, "version": "2.1" } XML 73 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 3 Months Ended
Jan. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill balances and movements for each reportable segment during the period
The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2020:
 
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
(in millions)
Goodwill as of October 31, 2019
$
1,438

 
$
1,594

 
$
561

 
$
3,593

Foreign currency translation impact
—

 
(2
)
 
(2
)
 
(4
)
Goodwill as of January 31, 2020
$
1,438

 
$
1,592

 
$
559

 
$
3,589
Components of other intangible assets during the period
The components of other intangible assets as of January 31, 2020 and October 31, 2019 are shown in the table below:
 
 
Purchased Other Intangible Assets
 
Gross
Carrying
Amount
 
Accumulated
Amortization
and Impairments
 
Net Book
Value
 
(in millions)
As of October 31, 2019
 

 
 

 
 

Purchased technology
$
1,413

 
$
763

 
$
650

Backlog
5

 
5

 
—

Trademark/Tradename
196

 
102

 
94

Customer relationships
329

 
87

 
242

Third-party technology and licenses
28

 
22

 
6

Total amortizable intangible assets
1,971

 
979

 
992

In-Process R&D
115

 
—

 
115

Total
$
2,086

 
$
979

 
$
1,107

As of January 31, 2020
 

 
 

 
 

Purchased technology
$
1,412

 
$
787

 
$
625

Backlog
5

 
5

 
—

Trademark/Tradename
196

 
106

 
90

Customer relationships
329

 
105

 
224

Third-party technology and licenses
28

 
23

 
5

Total amortizable intangible assets
1,970

 
1,026

 
944

In-Process R&D
115

 
—

 
115

Total
$
2,085

 
$
1,026

 
$
1,059
Schedule of estimated future amortization expense of finite-lived intangible assets

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2020 and for each of the five succeeding fiscal years and thereafter is estimated below:
Estimated future amortization expense:
 
(in millions)
 
Remainder of 2020
$
138

2021
$
172

2022
$
150

2023
$
107

2024
$
86

2025
$
68

Thereafter
$
223
XML 74 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE (Notes)
 3 Months Ended
Jan. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer REVENUE


The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
 
Three Months Ended January 31,
 
2020
 
2019
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
Life Sciences and Applied Markets
 
Diagnostics and Genomics
 
Agilent CrossLab
 
Total
 
(in millions)
 
 
 
 
 
 
 
 
Revenue by Region
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Americas
$
209

 
$
118

 
$
167

 
$
494

 
$
168

 
$
109

 
$
156

 
$
433

Europe
167

 
92

 
133

 
392

 
164

 
91

 
128

 
383

Asia Pacific
262

 
39

 
170

 
471

 
275

 
35

 
158

 
468

Total
$
638

 
$
249

 
$
470

 
$
1,357

 
$
607

 
$
235

 
$
442

 
$
1,284

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Revenue by End Markets
 
 
 
Pharmaceutical and Biopharmaceutical
$
423

 
$
391

Chemical and Energy
312

 
308

Diagnostics and Clinical
194

 
187

Food
130

 
129

Academia and Government
141

 
116

Environmental and Forensics
157

 
153

Total
$
1,357

 
$
1,284

 
 
 
 
Revenue by Type
 
 
 
Instrumentation
$
593

 
$
567

Non-instrumentation and other
764

 
717

Total
$
1,357

 
$
1,284



Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.

Contract Balances

Contract Assets

Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheet.

The balance of contract assets as of January 31, 2020 and October 31, 2019 were $131 million and $110 million, respectively. The increase in unbilled receivables during the three months ended January 31, 2020 is a result of recognition of revenue upon the transfer of the control to the customer. In some instances, transfer of control is prior to invoicing the customers and excluding amounts transferred to trade receivables during the period amounted to $21 million.

Contract Liabilities

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2020:

 
 
Contract
Liabilities
 
 
(in millions)
 
 
 
Ending balance as of October 31, 2019
 
$
386

Net revenue deferred in the period
 
180

Revenue recognized that was included in the contract liability balance at the beginning of the period
 
(142
)
Change in deferrals from customer cash advances, net of revenue recognized
 
9

Currency translation and other adjustments
 
(1
)
Ending balance as of January 31, 2020
 
$
432


During the three months ended January 31, 2019 revenue recognized that was included in the contract liability balance at October 31, 2018 was $125 million.

Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Contract Costs

Incremental costs of obtaining a contract with a customer are recognized as an asset if it expects the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the three months ended January 31, 2020 and are included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.

Transaction Price Allocated to the Remaining Performance Obligations

We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.
 
The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of January 31, 2020, was $210 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, and software maintenance contracts and revenue associated with lease arrangements.
XML 75 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Cash flows from operating activities    
Net income $ 197 $ 504
Adjustments to reconcile net income to net cash provided by (used in) operating activities:    
Depreciation and amortization 79 54
Share-based compensation 27 24
Deferred taxes 10 (281)
Excess and obsolete inventory related charges 4 4
Unrealized gain on equity securities (16) 0
Other non-cash expense, net 2 3
Changes in assets and liabilities:    
Accounts receivable (40) (22)
Inventory (32) (12)
Accounts payable (15) (16)
Employee compensation and benefits (80) (71)
Other assets and liabilities (195) 26
Net cash provided by (used in) operating activities (59) 213
Cash flows from Investing activities:    
Investments in property, plant and equipment (34) (39)
Payment to acquire fair value investment (1) (2)
Payments in exchange for convertible note 0 (1)
Acquisitions of businesses and intangible assets, net of cash acquired 0 (248)
Net cash used in investing activities (35) (290)
Cash flows from financing activities:    
Issuance of common stock under employee stock plans 32 22
Payment of taxes related to net share settlement of equity awards (33) (13)
Payment of dividends (56) (52)
Purchase of non-controlling interest 0 (4)
Proceeds from revolving credit facility 432 0
Repayments of revolving credit facility 372 0
Repayment of finance lease (4) 0
Treasury stock repurchases (60) (75)
Net cash used in financing activities (61) (122)
Effect of exchange rate movements (1) 9
Net decrease in cash, cash equivalents and restricted cash (156) (190)
Cash, cash equivalents and restricted cash at beginning of period 1,388 2,254
Cash, cash equivalents and restricted cash at end of period 1,232 2,064
Supplemental cash flow information:    
Income tax paid, net 241 21
Interest payments 17 25
Non-cash changes in investments in property, plant and equipment - increase (decrease) $ (9) $ (13)
XML 76 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Net income $ 197 $ 504
Other comprehensive income (loss):    
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $0 and $(2) 1 (4)
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0 and $(1) 0 (4)
Foreign currency translation, net of tax expense (benefit) of $0 and $(9) (11) 38
Net defined benefit pension cost and post retirement plan costs:    
Change in actuarial net loss, net of tax expense of $3 and $4 6 6
Change in net prior service benefit, net of tax expense of $1 and $0 (3) (2)
Other comprehensive income (loss) (7) 34
Total comprehensive income $ 190 $ 538
XML 77 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
INVENTORY (Notes)
 3 Months Ended
Jan. 31, 2020
Inventory, Net [Abstract]  
INVENTORY INVENTORY
 
 
January 31,
2020
 
October 31,
2019
 
(in millions)
Finished goods
$
423

 
$
416

Purchased parts and fabricated assemblies
283

 
263

Inventory
$
706

 
$
679
XML 78 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives    
Unrealized gain (loss) on derivatives $ 0 $ 5
Unrealized gains and (losses) on derivatives reclassified to cost of products, before tax 0 5
Reclassification of (gains) and losses into earnings related to derivative instruments, tax 0 (1)
Unrealized gains and (losses) on derivatives reclassified to cost of products, net of tax 0 4
Actuarial net loss (14) (10)
Prior service benefit 2 2
Actuarial net loss and prior service benefit reclassified, before tax (12) (8)
Tax on actuarial net loss and prior service benefit reclassified 6 4
Actuarial net loss and prior service benefit reclassified, net of tax (6) (4)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax $ (6) $ 0
XML 79 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($)
$ in Millions
Jan. 31, 2020
Oct. 31, 2019
Derivative Fair Value by Balance Sheet Location    
Derivatives asset fair value $ 6 $ 12
Derivatives liabilities fair value 6 6
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Current Assets    
Derivative Fair Value by Balance Sheet Location    
Derivatives asset fair value 3 3
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Accrued Liabilities    
Derivative Fair Value by Balance Sheet Location    
Derivatives liabilities fair value 2 2
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Current Assets    
Derivative Fair Value by Balance Sheet Location    
Derivatives asset fair value 3 9
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Accrued Liabilities    
Derivative Fair Value by Balance Sheet Location    
Derivatives liabilities fair value $ 4 $ 4
XML 80 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Millions
Jan. 31, 2020
Oct. 31, 2019
Assets Short - term    
Cash equivalents (money market funds) $ 602 $ 784
Derivative instruments (foreign exchange contracts) 6 12
Assets, Long-term    
Trading securities 29 30
Other investments 25 25
Total assets measured at fair value 662 851
Liabilities, Short-term    
Derivative instruments (foreign exchange contracts) 6 6
Liabilities Long-term    
Deferred compensation liability 29 30
Total liabilities measured at fair value 35 36
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets Short - term    
Cash equivalents (money market funds) 602 784
Derivative instruments (foreign exchange contracts) 0 0
Assets, Long-term    
Trading securities 29 30
Other investments 0 0
Total assets measured at fair value 631 814
Liabilities, Short-term    
Derivative instruments (foreign exchange contracts) 0 0
Liabilities Long-term    
Deferred compensation liability 0 0
Total liabilities measured at fair value 0 0
Significant Other Observable Inputs (Level 2)    
Assets Short - term    
Cash equivalents (money market funds) 0 0
Derivative instruments (foreign exchange contracts) 6 12
Assets, Long-term    
Trading securities 0 0
Other investments 25 25
Total assets measured at fair value 31 37
Liabilities, Short-term    
Derivative instruments (foreign exchange contracts) 6 6
Liabilities Long-term    
Deferred compensation liability 29 30
Total liabilities measured at fair value 35 36
Significant Unobservable Inputs (Level 3)    
Assets Short - term    
Cash equivalents (money market funds) 0 0
Derivative instruments (foreign exchange contracts) 0 0
Assets, Long-term    
Trading securities 0 0
Other investments 0 0
Total assets measured at fair value 0 0
Liabilities, Short-term    
Derivative instruments (foreign exchange contracts) 0 0
Liabilities Long-term    
Deferred compensation liability 0 0
Total liabilities measured at fair value $ 0 $ 0
XML 81 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LONG-TERM DEBT (Details) - USD ($)
$ in Millions
Jan. 31, 2020
Oct. 31, 2019
Debt Instrument    
Long-term debt $ 1,787 $ 1,786
Senior Notes 2022    
Debt Instrument    
Long-term debt 399 399
Senior Notes 2023    
Debt Instrument    
Long-term debt 597 597
Senior Notes 2026    
Debt Instrument    
Long-term debt 298 298
Senior Notes 2029    
Debt Instrument    
Long-term debt $ 493 $ 492
XML 83 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
INCOME TAXES (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Income Tax Disclosure    
Provision (benefit) for income taxes $ 22 $ (256)
Effective income tax rate 10.00% (103.20%)
Discrete tax expense (benefit)   $ 299
Excess tax benefit from stock based compensation $ 13 $ 4
XML 84 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
ACQUISITIONS - Proforma Operating Results (Details)
$ / shares in Units, $ in Millions
 3 Months Ended
Jan. 31, 2019
USD ($)
$ / shares
Business Acquisition [Line Items]  
Pro Forma Revenue | $ $ 1,326
Pro Forma Net Income | $ $ 474
Pro Forma Earnings Per Share, Basic | $ / shares $ 1.49
Pro Forma Earnings Per Share, Diluted | $ / shares $ 1.47
XML 85 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE - Contract Balances (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Oct. 31, 2019
Contract Assets      
Contract Assets (Unbilled Accounts Receivable) $ 131   $ 110
Increase in Contract Asset Balance 21    
Contract Liabilities      
Contract liability ending balance as of October 31, 2019 386    
Net revenue deferred in the period 180    
Revenue recognized that was included in the contract liability balance at the beginning of the period (142) $ (125)  
Change in deferrals from customer cash advances, net of revenue recognized 9    
Currency Translation and Other Adjustment (1)    
Contract liability ending balance as of Jan 31, 2020 432    
Transaction Price Allocated to Remaining Performance Obligation      
Remaining Performance Obligation, Amount $ 210    
Majority of Remaining Performance Obligation Expected Timing of Satisfaction, Period 12 months    
XML 86 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Jan. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Assets And Liabilities Measured On Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2020 were as follows:
 
 
 
 
Fair Value Measurement at January 31, 2020 Using
 
January 31,
2020
 
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
 
Significant
 Other
 Observable
 Inputs
 (Level 2)
 
Significant
 Unobservable
 Inputs
 (Level 3)
 
(in millions)
Assets:
 

 
 

 
 

 
 

Short-term
 

 
 

 
 

 
 

Cash equivalents (money market funds)
$
602

 
$
602

 
$
—

 
$
—

Derivative instruments (foreign exchange contracts)
6

 
—

 
6

 
—

Long-term
 
 
 
 
 
 
 
Trading securities
29

 
29

 
—

 
—

Other investments
25

 
—

 
25

 
—

Total assets measured at fair value
$
662

 
$
631

 
$
31

 
$
—

Liabilities:
 

 
 

 
 

 
 

Short-term
 
 
 
 
 
 
 
Derivative instruments (foreign exchange contracts)
$
6

 
$
—

 
$
6

 
$
—

Long-term
 
 
 
 
 
 
 
Deferred compensation liability
29

 
—

 
29

 
—

Total liabilities measured at fair value
$
35

 
$
—

 
$
35

 
$
—


Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows:
 
 
 
 
Fair Value Measurement at October 31, 2019 Using
 
October 31,
2019
 
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
 
Significant
 Other
 Observable
 Inputs
 (Level 2)
 
Significant
 Unobservable
 Inputs
 (Level 3)
 
(in millions)
Assets:
 

 
 

 
 

 
 

Short-term
 

 
 

 
 

 
 

Cash equivalents (money market funds)
$
784

 
$
784

 
$
—

 
$
—

Derivative instruments (foreign exchange contracts)
12

 
—

 
12

 
—

Long-term
 
 
 
 
 
 
 
Trading securities
30

 
30

 
—

 
—

Other investments
25

 
—

 
25

 
—

Total assets measured at fair value
$
851

 
$
814

 
$
37

 
$
—

Liabilities:
 

 
 

 
 

 
 

Short-term
 
 
 
 
 
 
 
Derivative instruments (foreign exchange contracts)
$
6

 
$
—

 
$
6

 
$
—

Long-term
 
 
 
 
 
 
 
Deferred compensation liability
30

 
—

 
30

 
—

Total liabilities measured at fair value
$
36

 
$
—

 
$
36

 
$
—
ZIP 87 0001090872-20-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001090872-20-000004-xbrl.zip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ⅅ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end XML 88 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NET INCOME PER SHARE (Tables)
 3 Months Ended
Jan. 31, 2020
Earnings Per Share [Abstract]  
Reconciliation of the numerators and denominators of the basic and diluted net income per share
The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Numerator:
 

 
 

Net income
$
197

 
$
504

Denominator:
 
 
 
Basic weighted-average shares
310

 
318

Potential common shares— stock options and other employee stock plans
3

 
4

Diluted weighted-average shares
313

 
322
XML 89 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NEW ACCOUNTING PRONOUNCEMENTS (Tables)
 3 Months Ended
Jan. 31, 2020
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
Schedule of Prospective Adoption of New Accounting Pronouncements
Adoption of the new guidance impacted the condensed consolidated balance sheet as follows:

 
October 31, 2019
 
Impact of Adopting
 
November 1, 2019
 
As Reported
 
Lease Guidance
 
As Adopted
 
(in millions)
Other assets
$
611

 
$
192

 
$
803

Other accrued liabilities
$
440

 
$
48

 
$
488

Other long-term liabilities
$
473

 
$
144

 
$
617
XML 90 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
ACQUISITIONS (Notes)
 3 Months Ended
Jan. 31, 2020
Business Combinations [Abstract]  
Acquisitions Disclosure ACQUISITIONS

Acquisition of BioTek and ACEA

On August 23, 2019 we completed the acquisition of privately-owned Lionheart Technologies LLC ("BioTek"), a leader in the design, manufacture and distribution of innovative life science instrumentation for $1.17 billion, under the merger agreement. As a result of the acquisition, BioTek has become a wholly-owned subsidiary of Agilent. Accordingly, the results of BioTek are included in Agilent's condensed consolidated financial statements from the acquisition date. The acquisition of BioTek and its portfolio is another step to expand our position in the cell analysis market.

The consideration paid was $1.17 billion. Agilent funded the acquisition using existing cash of $470 million and debt of $700 million.

The BioTek acquisition was accounted for in accordance with the authoritative accounting guidance. The acquired assets and assumed liabilities were recorded by Agilent at their estimated fair values. Agilent determined the estimated fair values with the assistance of appraisals or valuations performed by third party specialists, discounted cash flow analyses, and estimates made by management. We expect to realize revenue synergies, leverage and expand the existing sales channels and product development resources, and utilize the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of BioTek’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction.
 
Goodwill acquired was allocated to our operating segments and reporting units as a part of the purchase price allocation. All goodwill was allocated to the life sciences and applied markets reporting unit.

Agilent’s acquisition of BioTek is treated as an asset purchase for tax purposes. The tax basis of the acquired assets equals the fair market value on acquisition date.
The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):
Cash and cash equivalents
 
 
$
10

 
Accounts receivable
 
 
28

 
Inventories
 
 
21

 
Other current assets
 
 
2

 
Property, plant and equipment
 
 
8

 
Intangible assets
 
 
641

 
Goodwill
 
 
483

 
Total assets acquired
 
1,193
 

Accounts payable
 
 
(4
)
 
Deferred revenue
 
 
(5
)
 
Employee compensation and benefits
 
 
(7
)
 
Other accrued liabilities
 
 
(2
)
 
Long-term debt
 
 
(4
)
 
Net assets acquired
 
 
$
1,171

 


The fair value of cash and cash equivalents, accounts receivable, other current assets, accounts payable and other accrued liabilities were generally determined using historical carrying values given the short-term nature of these assets and liabilities.
 
The fair values for acquired intangible assets and deferred revenue were determined with the input from third party valuation specialists.
 
The fair values of certain other assets, inventory, property, plant and equipment, investments, long-term debt, and certain other long-term liabilities were determined internally using historical carrying values and estimates made by management.
 
Valuations of intangible assets acquired
 
The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):

 
Fair Value
 
Estimated
Useful Life
Developed product technology
 
$
387

 
 
5-13 years
Customer relationships
 
202

 
 
3-8 years
Backlog
 
5

 
 
2 months
Tradenames and trademarks
 
43

 
 
10 years
Total intangible assets subject to amortization
 
637

 
 
 
In-process research and development
 
4

 
 
 
Total intangible assets
 
$
641

 
 
 


As noted above, the intangible assets, including in-process research and development, were valued with input from valuation specialists. Agilent used variations of the income approach in determining the fair value of intangible assets acquired in the BioTek acquisition. Specifically, the developed product technology and in-process research and development were valued using the multi-period excess earnings method under the income approach by discounting forecasted cash flows directly related to the products expecting to result from the projects, net of returns on contributory assets. The company utilized the incremental cash flow method for determining the fair value of the customer relationships acquired, and the relief from royalty method to determine the fair value of the tradename. Order backlog was valued on a direct cash flow basis.

The primary in-process research and development project acquired relates to a next version of a product which will be released later in 2020. Total costs to complete for all BioTek in-process research and development were estimated at approximately $2 million as of the close date.

Acquisition and integration costs directly related to the BioTek acquisition totaled $4 million for the three months ended
January 31, 2020 and were recorded in selling, general and administrative expenses.

On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for $250 million. The financial results of ACEA have been included in our financial results from the acquisition date.
 
The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's condensed consolidated statements of operations as of the beginning of fiscal 2019 (in millions, except per share amounts):

 
Three Months Ended January 31,
 
2019
Net revenue
$
1,326

Net income
$
474

Net income per share — basic
$
1.49

Net income per share — diluted
$
1.47



The unaudited proforma financial information assumes that the companies were combined as of November 1, 2017 and include business combination accounting effects from the acquisition including amortization charges from acquired intangible assets, the impact on cost of sales due to the respective estimated fair value adjustments to inventory, changes to interest income for cash used in the acquisition, interest expense and currency losses associated with debt paid in connection with the acquisition and acquisition related transaction costs and tax related effects. The proforma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2018.
 
The unaudited proforma financial information for the three months ended January 31, 2019 combines the historical results of Agilent (which includes ACEA after the acquisition date), the first two weeks of the quarter for ACEA and BioTek for the three months ended January 31, 2019.
XML 91 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) - $ / shares
Jan. 31, 2020
Oct. 31, 2019
Stockholders' equity:    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 125,000,000 125,000,000
Preferred stock, issued and outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 2,000,000,000 2,000,000,000
Common stock, issued and outstanding (in shares) 310,000,000 309,000,000
XML 92 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Net revenue:    
Net revenue $ 1,357 $ 1,284
Costs and expenses:    
Cost of revenue 634 577
Research and development 104 102
Selling, general and administrative 404 355
Total costs and expenses 1,142 1,034
Income from operations 215 250
Interest income 3 10
Interest expense (20) (18)
Other income (expense), net 21 6
Income before taxes 219 248
Provision (benefit) for income taxes 22 (256)
Net income $ 197 $ 504
Net income per share    
Basic $ 0.64 $ 1.58
Diluted $ 0.63 $ 1.57
Weighted average shares used in computing net income per share:    
Basic 310 318
Diluted 313 322
Product    
Net revenue:    
Net revenue $ 1,023 $ 980
Costs and expenses:    
Cost of revenue 454 414
Service, Other    
Net revenue:    
Net revenue 334 304
Costs and expenses:    
Cost of revenue $ 180 $ 163
XML 93 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NET INCOME PER SHARE (Notes)
 3 Months Ended
Jan. 31, 2020
Earnings Per Share [Abstract]  
NET INCOME PER SHARE NET INCOME PER SHARE
 
The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:
 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Numerator:
 

 
 

Net income
$
197

 
$
504

Denominator:
 
 
 
Basic weighted-average shares
310

 
318

Potential common shares— stock options and other employee stock plans
3

 
4

Diluted weighted-average shares
313

 
322


 
The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards.

We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive.  

For the three months ended January 31, 2020 and 2019, the impact of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share was not material.
XML 94 R87.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION - Profitability (Details)
$ in Millions
 3 Months Ended
Jan. 31, 2020
USD ($)
Jan. 31, 2019
USD ($)
Segment Reporting Information    
Number of operating segments 3  
Segment Reporting Information    
Net revenue $ 1,357 $ 1,284
Income from operations 215 250
Life Sciences and Applied Markets    
Segment Reporting Information    
Net revenue 638 607
Income from operations 158 159
Diagnostics and Genomics    
Segment Reporting Information    
Net revenue 249 235
Income from operations 34 33
Agilent CrossLab    
Segment Reporting Information    
Net revenue 470 442
Income from operations 119 105
Segment Total    
Segment Reporting Information    
Net revenue 1,357 1,284
Income from operations $ 311 $ 297
XML 95 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Derivative    
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ 0 $ 5
Cash Flow Hedging | Cost of Sales    
Derivative    
Cash flow hedge net gain to be reclassified within next Twelve Months 4  
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Accumulated Other Comprehensive Income (Loss)    
Derivative    
Gain (loss) recognized in accumulated other comprehensive loss 1 (6)
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Cost of Sales    
Derivative    
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales 0 5
Gain (loss) recognized in other income (expense) 0 1
Derivatives Not Designated as Hedging Instruments | Other income (expense)    
Derivative    
Gain (loss) recognized in other income (expense) $ (2) $ (3)
XML 96 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Oct. 31, 2019
Long-Lived Assets      
Impairment of Long-Lived Assets Held-for-use $ 0 $ 0  
Impairment of non-marketable securities 0    
Impairment of long-lived assets held for sale 0 0  
Investments      
Impairment of Investments 0 0  
Non-Marketable Equity Securities without Readily Determinable Fair Value      
Unrealized gain on equity securities 16 $ 0  
Non-marketable equity securities carrying amount $ 63   $ 47
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Nov. 19, 2018
2019 Repurchase Program [Member]      
Share repurchase program      
Share repurchase program authorized amount     $ 1,750
Stock repurchased and retired during period, (Shares) 725,827 1,100,000  
Stock repurchased and retired during period, (Value) $ 60    
Remaining authorized repurchase amount under share repurchase program $ 967    
2015 Repurchase Program      
Share repurchase program      
Stock repurchased and retired during period, (Value)   $ 75  
XML 98 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
ACQUISITIONS - Intangible Assets Acquired (Details) - USD ($)
$ in Millions
Aug. 23, 2019
Jan. 31, 2020
Oct. 31, 2019
Business Acquisition [Line Items]      
Gross Carrying Amount   $ 2,085 $ 2,086
BioTek      
Business Acquisition [Line Items]      
Gross Carrying Amount $ 637    
In-Process R&D 4    
Total Intangible Assets, Gross (Excluding Goodwill) 641    
Developed Product Technology      
Business Acquisition [Line Items]      
Gross Carrying Amount   1,412 1,413
Developed Product Technology | BioTek      
Business Acquisition [Line Items]      
Gross Carrying Amount 387    
Customer Relationships      
Business Acquisition [Line Items]      
Gross Carrying Amount   329 329
Customer Relationships | BioTek      
Business Acquisition [Line Items]      
Gross Carrying Amount 202    
Backlog      
Business Acquisition [Line Items]      
Gross Carrying Amount   $ 5 $ 5
Backlog | BioTek      
Business Acquisition [Line Items]      
Gross Carrying Amount $ 5    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 2 months    
Trademarks and Trade Names | BioTek      
Business Acquisition [Line Items]      
Gross Carrying Amount $ 43    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 10 years    
Minimum | Developed Product Technology | BioTek      
Business Acquisition [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 5 years    
Minimum | Customer Relationships | BioTek      
Business Acquisition [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 3 years    
Maximum | Developed Product Technology | BioTek      
Business Acquisition [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 13 years    
Maximum | Customer Relationships | BioTek      
Business Acquisition [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 8 years    
XML 99 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 100 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE - Revenue by Type (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Net revenue $ 1,357 $ 1,284
Instrumentation    
Net revenue 593 567
Non-Instrumentation and Other    
Net revenue $ 764 $ 717
XML 101 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SHARE-BASED COMPENSATION Capitalized (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jan. 31, 2020
Oct. 31, 2019
Inventory    
Share-based Compensation Arrangement by Share-based Payment Award    
Share-based Payment Arrangement, Expensed and Capitalized, Amount $ 0 $ 0
XML 102 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Future Minimum Lease Payments (Details)
$ in Millions
Oct. 31, 2019
USD ($)
Leases [Abstract]  
2020 $ 52
2021 41
2022 29
2023 21
2024 14
2025 and thereafter 56
Total future minimum lease payments $ 213
XML 103 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Maturities of Lease Liabilities (Details)
$ in Millions
Jan. 31, 2020
USD ($)
Leases [Abstract]  
Operating lease payments due in 2020 $ 41
Operating lease payments due in 2021 45
Operating lease payments due in 2022 33
Operating lease payments due in 2023 22
Operating lease payments due in 2024 14
Operating lease payments due in 2025 and thereafter 57
Total undiscounted future minimum lease payments 212
Amount of lease payments representing interest (20)
Operating lease liability 192
Operating lease liability, Current (51)
Operating lease liability, Noncurrent $ 141
XML 104 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
ACQUISITIONS - Assets and Liabilities Assumed (Details) - BioTek
$ in Millions
Aug. 23, 2019
USD ($)
Business Acquisition [Line Items]  
Cash and Cash and Equivalents acquired $ 10
Accounts Receivable acquired 28
Inventories acquired 21
Other Current Assets acquired 2
Property, Plant, and Equipment acquired 8
Intangible Assets acquired 641
Goodwill arising from acquisitions 483
Total Assets acquired 1,193
Accounts Payable assumed 4
Deferred Revenue assumed 5
Employee compensation and benefits assumed 7
Other Accrued Liabilities assumed 2
Long-term Debt assumed 4
Net Assets Acquired $ 1,171
XML 105 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION (Tables)
 3 Months Ended
Jan. 31, 2020
Segment Reporting [Abstract]  
Segment Profitability and Segment Assets
The profitability of each of the segments is measured after excluding transformational initiatives, acquisition and integration costs, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below:
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Net Revenue:
 
 
 
Life Sciences and Applied Markets
$
638

 
$
607

Diagnostics and Genomics
249

 
235

Agilent CrossLab
470

 
442

Total net revenue
$
1,357

 
$
1,284

 
 
 
 
Segment Income From Operations:


 


Life Sciences and Applied Markets
$
158

 
$
159

Diagnostics and Genomics
34

 
33

Agilent CrossLab
119

 
105

Total segment income from operations
$
311

 
$
297


The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  
 
January 31,
2020
 
October 31,
2019
 
(in millions)
Segment Assets:
 
 
 
Life Sciences and Applied Markets
$
3,187

 
$
3,202

Diagnostics and Genomics
2,612

 
2,620

Agilent CrossLab
1,360

 
1,331

Total segment assets
$
7,159

 
$
7,153
Reconciliation of segment results to total enterprise results
The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: 
 
Three Months Ended
 
January 31,
 
2020
 
2019
 
(in millions)
Total reportable segments’ income from operations
$
311

 
$
297

Transformational initiatives
(13
)
 
(5
)
Amortization of intangible assets related to business combinations
(48
)
 
(28
)
Acquisition and integration costs
(13
)
 
(10
)
NASD site costs
—

 
(2
)
Other(1)
(22
)
 
(2
)
Interest income
3

 
10

Interest expense
(20
)
 
(18
)
Other income (expense), net
21

 
6

Income before taxes, as reported
$
219

 
$
248


(1) The other category primarily includes legal costs related to our pursuing our claim against a third party in addition to other miscellaneous adjustments and settlements.
XML 106 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)
 3 Months Ended
Jan. 31, 2020
Defined Benefit Plan [Abstract]  
Schedule of net pension and post-retirement benefit costs

Components of net periodic costs. For the three months ended January 31, 2020 and 2019, our net pension and post retirement benefit costs were comprised of the following:
 
 
Three Months Ended January 31,
 
U.S.
Pension Plans
 
Non-U.S.
Pension Plans
 
U.S. Post Retirement
Benefit Plans
 
2020
 
2019
 
2020
 
2019
 
2020
 
2019
 
(in millions)
Service cost—benefits earned during the period
$
—

 
$
—

 
$
7

 
$
6

 
$
—

 
$
—

Interest cost on benefit obligation
4

 
5

 
2

 
3

 
1

 
—

Expected return on plan assets
(8
)
 
(7
)
 
(12
)
 
(11
)
 
(1
)
 
(1
)
Amortization:
 
 
 
 
 
 
 
 
 
 
 
Actuarial losses
1

 
—

 
12

 
9

 
1

 
1

Prior service credits
—

 
—

 
—

 
—

 
(2
)
 
(2
)
Total net plan costs
$
(3
)
 
$
(2
)
 
$
9

 
$
7

 
$
(1
)
 
$
(2
)

 
 
 
 
 
 
 
 
 
 
 
 

The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.
XML 107 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FAIR VALUE MEASUREMENTS (Notes)
 3 Months Ended
Jan. 31, 2020
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
 
The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.

Fair Value Hierarchy

The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:

Level 1- applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2- applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.

Level 3- applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.


Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
 
Financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2020 were as follows:
 
 
 
 
Fair Value Measurement at January 31, 2020 Using
 
January 31,
2020
 
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
 
Significant
 Other
 Observable
 Inputs
 (Level 2)
 
Significant
 Unobservable
 Inputs
 (Level 3)
 
(in millions)
Assets:
 

 
 

 
 

 
 

Short-term
 

 
 

 
 

 
 

Cash equivalents (money market funds)
$
602

 
$
602

 
$
—

 
$
—

Derivative instruments (foreign exchange contracts)
6

 
—

 
6

 
—

Long-term
 
 
 
 
 
 
 
Trading securities
29

 
29

 
—

 
—

Other investments
25

 
—

 
25

 
—

Total assets measured at fair value
$
662

 
$
631

 
$
31

 
$
—

Liabilities:
 

 
 

 
 

 
 

Short-term
 
 
 
 
 
 
 
Derivative instruments (foreign exchange contracts)
$
6

 
$
—

 
$
6

 
$
—

Long-term
 
 
 
 
 
 
 
Deferred compensation liability
29

 
—

 
29

 
—

Total liabilities measured at fair value
$
35

 
$
—

 
$
35

 
$
—


Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows:
 
 
 
 
Fair Value Measurement at October 31, 2019 Using
 
October 31,
2019
 
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
 
Significant
 Other
 Observable
 Inputs
 (Level 2)
 
Significant
 Unobservable
 Inputs
 (Level 3)
 
(in millions)
Assets:
 

 
 

 
 

 
 

Short-term
 

 
 

 
 

 
 

Cash equivalents (money market funds)
$
784

 
$
784

 
$
—

 
$
—

Derivative instruments (foreign exchange contracts)
12

 
—

 
12

 
—

Long-term
 
 
 
 
 
 
 
Trading securities
30

 
30

 
—

 
—

Other investments
25

 
—

 
25

 
—

Total assets measured at fair value
$
851

 
$
814

 
$
37

 
$
—

Liabilities:
 

 
 

 
 

 
 

Short-term
 
 
 
 
 
 
 
Derivative instruments (foreign exchange contracts)
$
6

 
$
—

 
$
6

 
$
—

Long-term
 
 
 
 
 
 
 
Deferred compensation liability
30

 
—

 
30

 
—

Total liabilities measured at fair value
$
36

 
$
—

 
$
36

 
$
—


 
Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. It has been classified as level 2
because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself.

Trading securities, which is comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive loss within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income.

Impairment of Investments. There were no impairments of investments for the three months ended January 31, 2020 and 2019.
 
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

For the three months ended January 31, 2020 and 2019, there were no impairments of long-lived assets held and used or long-lived assets held for sale. For the three months ended January 31, 2020 and 2019, there were no impairment of non-marketable securities. For the three months ended January 31, 2020 and 2019, an unrealized gain of $16 million and zero, respectively, were included in net income as adjustments to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. As of January 31, 2020 and October 31, 2019, the carrying amount of non-marketable equity securities without readily determinable fair values was $63 million and $47 million, respectively.

Fair values for the non-marketable securities included in long-term investments on the condensed consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when it occurs.
XML 108 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SHORT-TERM DEBT (Notes)
 3 Months Ended
Jan. 31, 2020
Short-term Debt [Abstract]  
SHORT-TERM DEBT SHORT-TERM DEBT
 
Credit Facilities
 
On March 13, 2019, Agilent entered into a credit agreement with a group of financial institutions which provided for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. For the three months ended January 31, 2020, we borrowed $432 million and repaid $372 million under the credit facility. As of January 31, 2020, the company had borrowings of $175 million outstanding under the credit facility. We were in compliance with the covenants for the credit facility during the three months ended January 31, 2020. On August 7, 2019, we entered into an amendment to the credit agreement, which provided for a $500 million short-term loan facility that was used in full to complete the BioTek acquisition and which is outstanding at January 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental loan facilities as of January 31, 2020.
XML 109 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUBSEQUENT EVENTS (Notes)
 3 Months Ended
Jan. 31, 2020
Subsequent Event [Line Items]  
Subsequent Events SUBSEQUENT EVENT


In February 2020, the company reached a settlement agreement with Twist Bioscience Corporation ("Twist") under which Twist has agreed to pay us $22.5 million to settle our intellectual property claim against Twist. The settlement agreement provides a license to Twist for discrete aspects of Agilent’s oligo-synthesis technology and successfully resolves all outstanding litigation between all parties.